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ABSTRACT 
When rats are administered acute doses of MDMA they produce significantly 
more reference memory errors than working memory errors in the partially baited 
radial arm maze (Kay et al, 2009). The potential role of serotonin and dopamine in this 
effect was examined by administering the serotonin agonist Citalopram and the 
dopamine agonist GBR12909. GBR12909 produced significantly more reference 
memory errors, while Citalopram tended to produce more working memory errors. 
Administration of the D1 agonist A68930 and the D2 agonist Quinpirole predominantly 
produced reference memory errors, but to a lesser extent than acute MDMA 
administration. Low doses of both drugs produced a synergistic effect, more similar to 
that seen with acute MDMA administration. These findings suggest dopamine plays a 
role in the reference memory effect seen with MDMA exposure in the partially baited 
radial maze.  
In the second half of the thesis binge regimes of MDMA (4 x 10mg/kg) were 
administered to rats. When there was a gap of eight weeks between dosing and training 
the ability to acquire the radial arm maze was not significantly impaired. When this 
MDMA regime was repeated with a three-day gap between dosing and training it 
produced a significant but transient deficit in performance. When later challenged with 
acute doses of MDMA (4.0 mg/kg) the binge treated rats were less impaired than 
saline controls indicating drug tolerance. In an additional study that used a three-day 
delay between dosing and training a significant impairment in task acquisition was 
found. This deficit appeared to be long-term as the MDMA treated rats were impaired 
when the rules of task were changed suggesting a deficit in cognitive flexibility. Again 
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when subjects were challenged with acute MDMA there was evidence of drug 
tolerance. The final study examined the effects of repeated MDMA exposure on task 
acquisition by administering acute doses of MDMA or saline once a week after rats 
had previously been treated with either a binge regime of MDMA or saline. MDMA 
exposure significantly impaired task acquisition and produced residual drug effects in 
the binge treated MDMA group the day after acute drug administration. However 
evidence of behavioural tolerance in this study was mixed due to a floor effect where 
performance of the binge MDMA group was so poor at the beginning of the study.  
In conclusion MDMA exposure impaired accuracy with reference memory 
processes were more affected than working memory processes. The underlying nature 
of this impairment remains unclear but it may be due to a long-term memory deficit, an 
impairment in understanding task rules or a perseverative pattern of responding. These 
findings imply human Ecstasy users may show deficits in acquiring information and 
may experience deficits in cognitive flexibility 
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GENERAL INTRODUCTION 
What Is Ecstasy/MDMA? 
Ecstasy or 3,4-methylenedioxymethaphemtamine (MDMA) is a ring 
substituted amphetamine structurally similar to methamphetamine (Farre et al., 2004). 
Its street names include XTC, E, or X (Cottler, Womack, Compton & Ben-Abdallah, 
2001) and it is chemically related to hallucinogens and stimulants (Peroutka, Newman 
& Harris, 1988). It has been described as producing a unique state of euphoria and 
heightened self-awareness (Peroutka et al., 1988). In addition it increases self 
confidence, intimacy, depth of emotion and sensory awareness (Morgan, 2000). 
However, it does not produce the psychotic effects and hallucinations associated with 
other hallucinogenic drugs (Peroutka et al., 1988). MDMA is both a serotonin and 
dopamine agonist and it is unclear which neurotransmitter system is responsible for the 
positive drug effects reported by Ecstasy users (Parrott, 2002). 
The recreational use of Ecstasy increased dramatically during the late 1990s 
(Wilkins, Bhatta, Pledger & Casswell, 2003). This trend has received a lot of media 
attention with reports of severe toxicity and fatalities producing widespread concern 
(Morgan, 1999) and has been recognised as a major public health issue around the 
world (Kish, 2002). There is debate as to whether Ecstasy is a relatively benign 
substance (von Sydow, Lieb, Pfister, Hofler & Wittchen, 2002) and even a valuable 
treatment for a range of psychological conditions (Grob, 2000). Most researchers have 
reported Ecstasy users experiencing a number of unpleasant side effects including 
psychological and cognitive problems (Morgan, 2000; Parrott 2001). Others have 
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suggested it may be a harmful neurotoxin (McCann, Szabo, Scheffel, Dannals & 
Ricaurte, 1998).  
A Brief History: How MDMA Became Ecstasy 
MDMA has been reported as an appetite suppressant; but was never originally 
designed or used for this purpose (Freudenmann, Oxler & Bernschneider-Reif, 2006). 
It was patented in Germany in 1912 by the pharmaceutical company Merck as a 
precursor chemical for other therapeutic compounds (Freudenmann et al., 2006). 
During the 1950s in the USA it was researched for its toxicity and potential as a 
„brainwashing‟ weapon (Eisner, 1994). It resurfaced during the mid 1970s where 
therapists in the USA and Switzerland used it in psychotherapy (Holland, 2001a). 
However by the early 1980s MDMA started to be used recreationally as an illicit 
substance (Hatzidimitrious, McCann & Ricaurte, 1999) and acquired the name Ecstasy 
(Holland, 2001b). As recreational use increased, the USA Drug Enforcement 
Administration (DEA) held emergency hearings arguing MDMA caused brain damage 
(Grob, 2000) based on animal research indicating MDA (a drug related to MDMA) 
produced brain damage in rats (Holland, 2001b). Although therapists argued MDMA 
had clinical uses this was based on anecdotal evidence lacking the necessary double-
blind, placebo controlled studies (Holland, 2001b). Therefore in 1985 MDMA was 
classified as a Schedule 1 drug due to its potential for abuse and lack of medical use. In 
1986 the World Health Organisation and the United National Commission on Narcotic 
Drugs classified MDMA as a Schedule 1 drug internationally and it is illegal in many 
other countries around the world including Australia, Canada, United Kingdom and 
New Zealand (Holland, 2001c). 
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Despite the drug being illegal MDMA consumption has become widespread 
with Ecstasy use increasing over 4000 percent between 1990 and 1995 in the United 
Kingdom alone (Holland, 2001a). There are several studies indicating Ecstasy use is 
still increasing in Europe and the USA (Daumann, Fimm, Willmes, Thron & 
Gouzoulis-Mayfrank, 2003) as well as Australia (Lyvers, 2006). While there have been 
many studies that have found Ecstasy users tend to be young, white and from middle 
class families there are reports that users are becoming more diverse (Bahora, Sterk & 
Elifson, 2009). There is clear evidence that Ecstasy use is increasing and it appears 
there is a range of different demographic, social and psychological variables that 
contribute to Ecstasy use.  
Why Is Ecstasy/MDMA Important To Study? 
Many young people are taking the drug and the medical, social and 
psychological consequences of this are unclear. One issue is the conflicting 
information about Ecstasy found in both the media and the scientific realm. For 
example, Green (2004) proposed there has been a lot of erroneous reporting by the 
media about the dangers of MDMA. Green (2004) argued that the claims made about 
the dangerousness of MDMA are often inaccurate and increased knowledge is 
necessary in both the scientific and popular press. Some claims made by the media 
relating to the dangers of Ecstasy have not been critically evaluated and have been 
reported in order to scare people away from using Ecstasy which may weaken the 
credibility of research findings (Lyvers, 2006). Obtaining accurate information that can 
be delivered to the public is of particular importance to parents. Ecstasy use is the least 
discussed drug between parents and teenagers (Alcoholism and Drug Abuse Weekly, 
2003). A reason for this is that parents do not know the effects of the drug and are 
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unable to recognise whether their children are under the influence of the Ecstasy 
(Alcoholism and Drug Abuse Weekly, 2003). 
Also of concern is the finding Ecstasy use tends to be associated with 
potentially other risky health behaviours such as binge drinking, polydrug use and a 
larger number of sexual partners (Strote et al., 2002; Boyd et al., 2003). However, due 
to the mainly cross sectional nature of prevalence studies it is unclear as to the 
direction and cause of these behaviours. Similarly several studies have found Ecstasy 
use has been associated with elevated impulsivity (Morgan, 1998; McGuire, 2000; 
Morgan, McFie, Fleetwood & Robinson, 2002; Butler & Montgomery, 2004) and 
impairments in the ability to accurately judge reinforcement cues producing impaired 
decision making (Morgan, Impallomeni, Pirona & Rogers, 2006). Morgan et al. (2006) 
argued these impairments may produce problems in everyday functioning and may 
contribute to continued drug use. However, it is difficult to conclude Ecstasy use 
produces increases in impulsivity as drug takers may be naturally more impulsive and 
more likely to take drugs in the first place (Morgan, 1998). Elevated impulsivity and 
risk taking are associated with other drugs of abuse and since Ecstasy users tend to be 
polydrug users it may be these other substances that are contributing to elevated 
impulsivity (Butler & Montgomery, 2004). 
Another important issue is that many Ecstasy users appear to perceive the harm 
of Ecstasy use as low and many believe it to be a safe drug (Green, Cross & Goodwin, 
1995) that produces few health problems (Bahora et al., 2009). Ecstasy users also 
believe the drug is not addictive (Bahora et al., 2009) and has a low potential for abuse 
(Ball, Walsh & Rebec, 2007). A reason for this could be the lack of craving and 
withdrawal effects generally experienced by users (Bahora et al., 2009). However, 
there are reports of tolerance developing to Ecstasy as the positive effects decrease 
over time with repeated ingestion (Parrott, 2001).  
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Is Ecstasy/MDMA Harmful?  
Ecstasy or MDMA has been used as a therapeutic drug by psychotherapists in 
the 1970s and 1980s (Liester, Grob, Bravo & Walsh, 1992). During the 1980s the drug 
was administered to human volunteers and researchers concluded Ecstasy was 
reasonably safe, produced positive changes in mood and did not appear to have 
negative consequences (Downing, 1986). Positive effects reported by Ecstasy users 
include euphoria, enhanced feelings of well-being, an increase in desire for social 
contact and more energy (Hegadoren et al., 1999).  
However, there do seem to be a lot of negative side effects associated with 
Ecstasy use. Some of the commonly reported acute effects of Ecstasy ingestion include 
tachycardia (rapid heart rate), dry mouth, tremors, palpitations, diaphoresis (excessive 
sweating), parasthesias (skin sensation, such as burning, prickling, itching, or tingling) 
(Peroutka et al., 1988). Sub-acute effects that have occurred 24 hours after Ecstasy 
ingestion included drowsiness, aching muscles, fatigue, depression, trismus (jaw 
clenching), difficulty concentrating, headaches, anxiety and irritability (Peroutka, et 
al., 1988). Other commonly reported side effects include mydriasis (dilated pupils), 
photophobia (light sensitivity), decreased appetite, nausea, abdominal cramps, 
diarrhoea, sweating, tachypnea (rapid breathing), bruxism (teeth grinding), and ataxia 
(difficulty walking) (Henry & Rella, 2001). Less reported but more severe side effects 
include hallucinations, severe anxiety, agitation, panic attacks, paranoia, hypertension, 
cardiac arrhythmias, chest pain, severe abdominal cramps and urinary retention (Henry 
& Rella, 2001). There are also more delayed side effects which can include jaundice, 
hepatotoxicity, tooth wear, poor concentration and attention, memory impairment, 
depression, sleep disturbance, weight loss and exhaustion (Henry & Rella, 2001).  
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There have been reports of fatalities related to Ecstasy use. However, most of 
the data relating to Ecstasy fatalities comes from case reports or small case series 
making it difficult to accurately generalise to large populations. Hence estimates of the 
risk of using Ecstasy vary from one death in 2000 to one death in 50000 (Schifano, 
2004). However compared to the number of people who use the drug the number of 
deaths attributed to Ecstasy use is low (Klys et al., 2007). Most of the deaths related to 
Ecstasy use have been attributed to hyperthermia, hyponatremia and 5-HT syndrome. 
A problem with the reported side effects and fatalities is that they have only 
been associated with MDMA use and we cannot infer causality. Many studies 
involving fatalities do not test for the presence of MDMA (Kish, 2002). Another 
problem is Ecstasy tablets are often cut with other psychoactive substances (Green et 
al., 1995). Polydrug use is also an important factor as Ecstasy users often abuse other 
illicit drugs (Morgan, 2000). This makes it difficult to ascertain if these problems are 
due to MDMA, other drugs, or some interaction between different substances. Finally 
there is the issue that Ecstasy users tend to have poor lifestyles and engage in 
behaviours that may affect their health, such as irregular patterns of sleep and food 
intake (Parrott, 2000).  
Ecstasy and Neurotoxicity 
While the evidence regarding potential negative health and behavioural effects 
of MDMA from studies of human users is equivocal evidence has accumulated from 
animal studies since the mid 1980s that MDMA can produce major alterations in the 
serotonergic system in the brain (Grob, 2000). Animal studies suggest MDMA causes 
elevation of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) (Kish, 
2002). Normally 5-HT is tightly regulated within the brain; however MDMA floods 
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the synapse with abnormally high amounts (Marlberg & Bronson, 2001). MDMA is 
unusual pharmacologically as its effects on the serotonergic system are two-fold in that 
it not only releases 5-HT from the pre-synaptic neuron but it also inhibits 5-HT 
reuptake (Marlberg & Bonson, 2001). Within four hours of acute MDMA 
administration there can be an 80% loss of 5-HT within the brain (Green, Cross & 
Goodwin, 1995). In fact three to six hours after ingestion such a large amount of 5-HT 
has been released that it causes temporary 5-HT depletion (Marlberg & Bonson, 2001). 
In addition MDMA temporarily inactivates the enzyme tryptophan hydroxylase that is 
required to make 5-HT resulting in the brain being unable to make enough 5-HT to 
restore levels to normal (Marlberg & Bonson, 2001). Normally the ability to synthesise 
5-HT returns within 24 hours of Ecstasy ingestion (Baumann, Wang & Rothman, 
2007) and therefore normal levels can be restored (Marlberg & Bronson, 2001). 
However prolonged high doses of MDMA have been associated with long-term 5-HT 
depletion (Marlberg & Bonson, 2001). This is of importance as 5-HT plays an 
important role in various bodily functions such as mood modulation (Roiser & 
Sahakian, 2004) and low levels of 5-HT are correlated with depression (Marlberg 
&Bonson, 2001).  
MDMA also releases the neurotransmitters dopamine and norepinephrine but 
to a lesser extent than 5-HT (Kish, 2002). These neurotransmitters tend to be less 
studied in MDMA research (Colado, O‟Shea, & Green, 2004). However, Colado et al. 
(2004) argued the dopamine release found after MDMA administration may play a 
significant role in the behaviours associated with taking MDMA such as alterations in 
mental state. They further argued more attention needs to be focussed on the chronic 
and acute effects of MDMA on dopamine (Colado et al., 2004). Other researchers have 
also reported that it is unclear as to whether some of the effects of Ecstasy use are due 
to the drugs affects on the serotonergic or the dopaminergic systems (Parrott, 2002). 
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One of the most important and as yet unanswered questions is whether MDMA 
produces neurotoxicity within the human brain (Peroutka et al., 1988). Researchers 
examine neurotoxicity by examining the effect of regimes of MDMA that usually 
involve repeated large doses of the drug, in non-human animals (Baggott & 
Mendelson, 2001). Studies using this approach with rats have found these regimes 
produced prolonged reductions in the concentration of brain 5-HT and its metabolite 5-
HIAA, the number of 5-HT uptake sites and the action of tryptophan hydroxylase 
(Ricaurte, 1989). Anatomical studies have also found evidence that indicate damage to 
serotonergic axons (Ricaurte, 1989). These effects have also been found in a number of 
other species including guinea pigs, monkeys and baboons (Ricaurte et al., 2000).  
The serotonergic damage can last for months or even years after exposure to 
the drug (Ricaurte, Yuan, & McCann, 2000) and has been found in several brain 
regions such as the hippocampus, striatum, neocortex and thalamus. Hatzidimitrious et 
al, (1999) found chronic doses of MDMA in squirrel monkeys produced 5-HT damage 
seven years after drug ingestion suggesting damage maybe permanent. Of particular 
concern is primates are 4 to 8 times more sensitive than rodents to the neurotoxic 
effects of MDMA that has led researchers to argue humans may also show greater 
sensitivity (Ricaurte, 1989).  
Unfortunately human studies have been unable to conclusively verify whether 
the brain damage seen in animals occurs in Ecstasy users. One problem is that human 
studies rely on more indirect measures of neurotoxicity. One method involves 
measuring levels of the 5-HT break-down product 5-HIAA in cerebrospinal fluid 
(Reneman, Booij, Majoie, van den Brink & den Heeten, 2001). While some studies 
have found cerebrospinal fluid levels of 5-HIAA were lower in Ecstasy users 
compared to non users there have also been some that have found no differences 
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(Baggott & Mendelson, 2001). In addition there is controversy about the accuracy of 
these measures (Steele, McCann & Ricaurte, 1994). 
Other evidence of neurotoxicity in humans comes from scanning techniques 
such as positron emission tomography (PET). One of the first Ecstasy studies to use 
PET scans was conducted by McCann et al. (1998) who found a reduction in brain 5-
HT transporter binding in previous Ecstasy users compared to the controls and greater 
Ecstasy use produced larger reductions. McCann et al. (1998) argued this was evidence 
Ecstasy users are at risk of 5-HT brain damage. Other studies have also utilised PET 
scan technology and found evidence of altered 5-HT activity in Ecstasy users (Obrocki 
et al., 1999).  
In addition MRI imaging techniques have shown evidence of axonal injury in 
Ecstasy users and this damage was positively correlated with the extent of previous 
Ecstasy use (Reneman et al., 2001). Functional magnetic resonance imaging (fMRI) 
also found a trend for heavy users to have weaker activation in the left frontal and 
temporal areas of the brain. Daumann et al. (2003) suggested this may be indicative of 
subtle differences in brain functioning due to Ecstasy use. 
Again there is controversy as to how well these methods assess damage and 
polydrug use and the purity of Ecstasy are issues that make it difficult to assess 
whether the damage seen is due to MDMA or other substances (Reneman et al., 2001). 
Due to these methodological limitations no one technique has been able to 
conclusively answer whether MDMA causes neurotoxicity in humans. However, there 
is converging evidence suggesting MDMA can damage 5-HT neurons in the human 
brain. Particularly, those who take higher doses and use the drug longer may be 
vulnerable to MDMA induced brain damage. 
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Recently there has been controversy as to whether MDMA can be described as 
a neurotoxin. There is evidence that MDMA does not destroy neurons but rather 
damages the axons leaving the nucleus intact (Baumann et al., 2007) and that 5-HT 
terminals are not destroyed as the damage seen may be eventually reversed (Baumann 
et al., 2007). In addition MDMA exposure may simply deplete 5-HT to levels that are 
undetectable rather than damaging the neurons (Baumann et al., 2007). In fact there 
has been research suggesting MDMA should not be labelled a neurotoxin as there are 
drugs that produce similar effects to MDMA but are not categorised neurotoxic 
(Baumann et al., 2007).  
In addition the validity of animal research has been questioned based on the 
amount of MDMA administered to animals. The doses given to laboratory animals 
tend to comprise of multiple or single doses of 10 to 20 mg/kg whereas the average 
human recreational dose tends to be between 1 to 3 mg/kg (Baumann et al., 2007). The 
route of drug administration used in animal studies has also been questioned as 
animals are often injected with MDMA while humans take the drug orally (McKenna 
& Peroutka, 1990). There has also been debate about the frequency of drug 
administration used in animal research. Animals are often given MDMA twice a day 
for four consecutive days (Ricaurte, Yuan & McCann, 2000). This research may be 
valuable as it suggests Ecstasy users who go on “binges” may be more susceptible to 
damage (Baggott & Mendelson, 2001) but it has been criticised as the majority of 
users tend to take the drug once a week (Morgan, 2000). However, there is evidence 
that patterns of use are changing as users are taking the drug more frequently (Parrott, 
2002). 
Perhaps the most relevant issue is whether the MDMA induced 5-HT damage 
actually produces corresponding behavioural disturbances (Grob, 2000). 5-HT is 
involved in many functions including learning and memory and hence it would be 
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expected that 5-HT depletion should result in deficits in these areas (Grob, 2000). 
However the evidence for this is mixed. An explanation for this is a large amount of 5-
HT depletion may be needed for noticeable physical symptoms to appear. Large doses 
of MDMA produce about 40 to 60% 5-HT depletion in most brain regions (Bauman et 
al., 2007) which may not be sufficient to produce noticeable behavioural symptoms. 
For example visible symptoms in patients with Parkinson‟s disease only occur when 
80-90% of the dopamine neuronal pathway is depleted (Grob, 2000). Therefore a large 
amount of neurotransmitter depletion may be necessary for noticeable behavioural 
changes to be detected. In addition it has been suggested that some cognitive tests have 
not been sensitive enough to detect impairments after MDMA exposure (Baumann et 
al., 2007). 
Recently a study that claimed MDMA produced dopamine neurotoxicity was 
retracted as the rats had accidentally been administered methamphetamine rather than 
MDMA (Ricaurte, Yuan, Hatzidimitrious, Cord & McCann, 2003). Subsequent studies 
revealed no evidence of MDMA producing dopamine neurotoxicity (Ricaurte et al., 
2003). This has brought many of the claims that MDMA produces neurotoxicity into 
question. Indeed Lyvers (2006) argued the haste with which this article was published 
highlights the eagerness of researchers and governments to report findings indicating 
the dangerousness of Ecstasy.  
Cognitive Problems Associated With Ecstasy Users 
Because 5-HT has been implicated in normal learning and memory (Ricaurte et 
al., 1993) a number of studies have examined the effects of Ecstasy use on cognition. 
Of particular concern is some of the brain areas (hippocampus and cerebral cortex) 
found to suffer 5-HT damage due to Ecstasy use are strongly associated with memory 
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function (Parrott, 2000). Therefore, Ecstasy users may suffer various cognitive 
impairments. Indeed Ecstasy use has been associated with general mental confusion 
(Davison & Parrott, 1997) and significant impairments on a variety of cognitive tasks 
(Heffernan, Ling & Scholey, 2001). Within the field of cognition there are many 
different types of memory function. This is important as drugs may impair certain 
memory functions while leaving others intact.  
While Ecstasy users have shown more general memory deficits (Rodgers, 
2000) there are also more specific areas of cognitive function that are impaired with 
Ecstasy use. One area of memory function that seems to be impaired in Ecstasy users 
is the recall of verbal information (Heffernan et al., 2001). Tasks that assess verbal 
learning and recall of verbal stimuli have found Ecstasy users required more trials than 
controls to reach the same level of performance (Fox, Toplis, Turner & Parrott, 2001; 
Gouzoulis-Mayfrank et al., 2000). Other researchers have also found impaired verbal 
learning in Ecstasy users (Reneman et al., 2001; McCardle, Luebbers, Carter & Croft, 
2004). Ecstasy users also show significant deficits in the immediate and delayed recall 
of verbal material indicating they have problems with retrieving verbal information 
(Bolla, McCann & Ricaurte, 1998; Parrott & Lasky, 1998; Reneman et al., 2000; 
Rodgers, 2000; Fox et al., 2001; Verkes et al., 2001; Reneman et al., 2001; Morgan et 
al., 2002; Gouzoulis-Mayfrank et al., 2003; Dafters, Hoshi & Talbot, 2004; McCardle 
et al., 2004; Smith, Tivarus, Campbell, Hillier & Beversdorf, 2006). As Ecstasy users 
produce impaired delayed recall they show impairments in encoding information into 
long-term memory (McCardle et al., 2004) and retrieving learnt information from 
long-term memory (Fox et al., 2001). In addition the degree of memory impairment 
has been correlated with evidence of 5-HT damage in Ecstasy users (Reneman et al., 
2000).  
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One area of the brain affected by MDMA exposure is the forebrain, including 
the frontal cortex (Heffernan, Jarvis, Rodgers, Scholey & Ling, 2001). This brain 
region is thought to be important in executive functioning (Heffernan et al., 2001) 
which involves controlling many higher cognitive functions such as monitoring and 
updating working memory, inhibition, task-shifting, planning, concept formation and 
cognitive flexibility (Roesch-Ely et al., 2005; Dafters, 2006). Zakzanis and Young 
(2001) found impaired executive functioning in abstinent Ecstasy users using an 
extensive battery of tests that assessed time estimation, planning, problem solving and 
rule learning. In addition the more Ecstasy subjects had used, the more prominent these 
impairments were. Wareing, Fisk and Murphy (2000) assessed executive functioning 
in Ecstasy users utilising a random-letter generation task. Ecstasy users found the task 
very difficult and were impaired on several measures of the task with some participants 
failing to complete it.  
Verbal fluency measures have also been impaired in Ecstasy users (Croft, 
Mackay, Mills & Gruzelier, 2001; Gouzoulis-Mayfrank et al., 2000; Montgomery, 
Fisk, Newcombe & Murphy, 2005) suggesting they have executive functioning 
impairments as well as deficits in accessing long-term memory (Montgomery et al., 
2005). Ecstasy users also have produced significant impairments on the Tower of 
London (TOL) suggesting strategic planning deficits (Fox, Parrott & Turner, 2001). 
Interestingly Ecstasy users who did not report problems associated with their drug use 
produced impaired performance implying they were unaware of their impairments 
(Fox et al., 2001).  
Ecstasy users have also been more susceptible to interference effects 
(Gouzoulis-Mayfrank, 2000), associative learning deficits (Croft et al., 2001), 
cognitive flexibility, task switching impairments (Von Geusau, Stalenhoef, Huizinga, 
Snel & Rudderinkhof, 2004; Dafters, 2006) and a tendency to perseverate (Von 
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Geusau et al., 2004; Montgomery et al., 2005). While these studies have examined the 
effects of long-term use, Smith et al. (2006) examined the transient or acute effects of 
Ecstasy. They found 10 to 15 hours after drug ingestion participants were impaired on 
tasks that assessed executive functioning including measures of rule learning, cognitive 
flexibility and problem solving.  
Other researchers have not found such convincing evidence that Ecstasy users 
are impaired at tasks assessing executive functioning. Fox, McLean, Turner, Parrott, 
Rogers and Sahakian (2002) administered an array of tests measuring working 
memory, verbal fluency, attention, associative learning and decision making to Ecstasy 
users. Ecstasy users were only impaired on one task assessing executive functioning 
which measured verbal fluency. They also found Ecstasy users had short-term memory 
deficits. Similarly Gouzoulis-Mayfrank et al., (2003) found no significant deficits on 
tests assessing working memory, executive functioning, impulsivity and planning in 
Ecstasy users. However they did find Ecstasy users had impaired recall. Gouzoulis-
Mayfrank et al. (2003) therefore argued Ecstasy users suffer from memory 
disturbances rather than executive dysfunction and as these deficits are subtle they may 
not be detected resulting in further drug taking exposing users to an increased risk of 
further cognitive deficits (Gouzoulis-Mayfrank et al., 2003).  
One commonly studied executive functioning process is working memory 
which entails the capacity to temporarily store and manipulate information (Howard et 
al., 2003). Gouzoulis-Mayfrank et al. (2000) reported that while the specific cognitive 
deficits associated with Ecstasy use remain ambiguous it appears that working memory 
in particular seems to be affected by Ecstasy consumption. This is supported by the 
large number of studies that found Ecstasy users are impaired on tasks that assess 
working memory processes (Croft et al., 2001; Fox et al., 2001; Verkes et al., 2001; 
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Morgan et al., 2002; Jacobsen, Mencl, Pugh, Skudlarski & Krystal, 2004; Von Geusau 
et al., 2004; Wareing et al., 2004).  
Some researchers have argued that laboratory studies have failed to inform us 
about the memory functioning of Ecstasy users in a more natural context. Therefore, 
other types of memory function have also been examined. Prospective memory 
functioning involves remembering to do something in the future (Heffernan et al., 
2001). Ecstasy users show impairments on tasks assessing prospective memory 
(Heffernan, Ling & Scholey, 2001; Heffernan, Jarvis, Rodgers, Scholey & Ling, 2001) 
and both current and former Ecstasy users have also shown evidence of impaired 
visuospatial memory (Wareing, Murphy & Fisk, 2004). 
One potential confound within the research that examines the cognitive 
impairments found in Ecstasy users is that they tend to be polydrug users and there is 
some debate as to whether it is the Ecstasy that produces the cognitive deficits or other 
drugs they have ingested. For example Croft et al. (2001) found cognitive impairments 
in Ecstasy users who also used cannabis and Ecstasy free cannabis users. There were 
no significant differences between the two groups on the degree of cognitive 
impairment they produced so Croft et al. (2001) argued cannabis use is an important 
confound in Ecstasy research. Rodgers (2000) and Dafters et al. (2004) also found 
Ecstasy and cannabis users and cannabis only users both showed significant memory 
impairments suggesting the deficits found in the Ecstasy users could be due to 
cannabis use rather than Ecstasy use.  
However other researchers that have controlled for polydrug use have found 
supporting evidence that Ecstasy use is the contributing factor to the cognitive 
impairments found in Ecstasy users. Morgan (1999) found Ecstasy users were 
significantly impaired on tests assessing memory compared to Ecstasy free polydrug 
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users and drug free controls. Other researchers have also found that the memory 
impairments found in Ecstasy users remained significant when other drug use, 
including cannabis, were taken into account (Heffernan et al., 2001; McCardle et al., 
2004; Wareing et al., 2004). Gouzoulis-Mayfrank et al. (2000) and Dafters (2006) 
found participants who used Ecstasy and cannabis were significantly impaired on 
several cognitive measures but participants who used only cannabis did not show these 
impairments. Therefore there is evidence that Ecstasy use and not polydrug use is 
associated with cognitive deficits. 
There is also some concern as to whether memory deficits in Ecstasy users 
remain after they have stopped using the drug. Some studies have examined Ecstasy 
users that have abstained from drug use for a short periods, usually one to two weeks, 
and found they still show impairments in cognitive tasks (Bolla et al., 1998; 
Gouzoulis-Mayfrank et al., 2000; Fox et al., 2001; Verkes et al., 2001; Zakzanis & 
Young, 2001; Fox et al., 2002; Gouzoulis-Mayfrank et al., 2003; Dafters et al., 2004; 
Von Geusau et al., 2004; Montgomery et al., 2005). However these studies do not 
inform us about the long-term consequences of Ecstasy use. There has been evidence 
that Ecstasy users who have abstained for longer periods such as two to four months 
(Rodgers, 2000; Reneman et al., 2000; McCardle et al., 2004) and even up to six 
months (Wareing et al., 2000; Wareing et al., 2004) still show significant deficits on a 
number of cognitive tasks. In addition there have been reports of Ecstasy users 
showing cognitive impairments after abstaining from Ecstasy use for several years 
(Reneman et al., 2001; Morgan et al., 2002) suggesting with long-term drug cessation 
the deficits in memory function may not subside.  
In conclusion there is extensive evidence that Ecstasy users experience a wide 
range of impairments on cognitive tasks. Because there has been such a range of 
impairments it is difficult to identify what mechanism might underlie these deficits. 
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There are also some methodological limitations with many of these studies. For 
example human studies are less controlled than animal research due to legal and ethical 
restrictions that only allow the study of the chronic use of the drug by recreational 
users (Curran & Travil, 1997). Therefore, they are unable to utilise traditional double-
blind placebo-controlled drug studies that would help infer causality (Curran & Travil, 
1997). Another problem is Ecstasy users are commonly polydrug users and therefore 
any impairment seen could be the result of ingesting other substances (Morgan, 2000). 
In addition Ecstasy tablets commonly contain substances other than MDMA making it 
difficult to determine if any impairment seen is due to other chemicals found in the 
tablets (Green et al., 1995). Another concern with these studies is they are cross 
sectional in design and do not provide a measure of memory performance before 
participants began using Ecstasy. This is problematic as we do not know if people had 
cognitive problems beforehand. 
There is also a paucity of research on the acute effects of MDMA. It would be 
useful to know what kind of impairments people experience while under the influence 
of the drug. Obviously due to legal and ethical issues acute studies on human 
participants are unlikely. Unfortunately, all of these factors make it difficult to claim 
MDMA actually causes cognitive deficits in humans. Animal models are beneficial as 
they provide a more controlled environment to study the effects of MDMA on 
cognition. Therefore, the current thesis will focus on animal research involving both 
the acute and chronic/binge effects of MDMA on cognition. 
The Current Thesis 
The thesis is divided into two parts that will focus on the acute and 
chronic/binge effects of MDMA on learning and memory in rats. The first part of the 
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thesis will examine the acute effects of Ecstasy on memory performance utilising a 
radial arm maze. It will include a review of the animal literature examining the acute 
effects of Ecstasy on learning and memory. Specifically it will focus on examining 
which neurotransmitter systems may be responsible for the memory deficits produced 
by acute MDMA exposure. The second part of the thesis will focus on the binge 
effects of MDMA on learning in rats. This is an attempt to model some of the long-
term effects of Ecstasy use on memory and learning in humans. By administering a 
binge regime of MDMA to rats the long-term effects of Ecstasy use can be mimicked. 
By comparing the performance of MDMA treated rats with saline controls it can be 
ascertained if MDMA produces learning deficits that will be displayed by an impaired 
ability to acquire a radial arm maze task.  
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PART ONE:  
Acute Effects of MDMA on Non-human Animals 
Acute MDMA Human Studies 
Few studies have examined the acute effects of MDMA on human participants. 
One group of studies was conducted by researchers in Switzerland. Human volunteers 
given MDMA reported alterations in feelings of time and space with participants 
feeling dreamy or lost in thought (Vollenweider, Gamma, Liechti & Huber, 1998). 
Also at higher doses (1.80 mg/kg) MDMA produced thought disturbances including 
impaired decision-making and losing track of one‟s thoughts (Liechti et al., 2001). 
Vollenweider, Liechti, Gamma, Greer and Geyer (2002) summarised a series of 
experiments that examined the acute effects of MDMA on human volunteers in Zurich. 
Drug naive participants in placebo-controlled double blind experiments were 
administered a single oral dose (1.35-1.8 mg/kg) of MDMA. Various physiological 
and psychological measures were used as well as PET scans. They also examined 
information processing by examining pre-pulse inhibition (PPI) which assesses the 
ability to filter out cognitive or sensory stimuli (Vollenweider et al., 2002). MDMA 
exposure produced an increase in positive mood, well-being, emotional sensitivity and 
mild disturbances in thinking such as difficulty concentrating and making decisions. 
However it did not produce hallucinations and PET scans revealed a change in activity 
in cortical, limbic and paralimbic areas of the brain. In conclusion acute administration 
of MDMA in healthy drug naive volunteers produced a number of physiological and 
psychological effects such as mood enhancement and changes in the brain structures 
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associated with emotion as well as altering cognition by affecting the ability to filter 
out stimuli (Vollenweider et al., 2002).  
To date no study has utilised placebo-controlled double blind experiments with 
drug naive participants to specifically examine the acute effects of MDMA on memory 
and learning tasks. Instead previous or current MDMA users have served as 
participants. Kuypers and Ramaekers (2007) investigated the effects of a single dose of 
MDMA on spatial memory with recreational MDMA users. They utilised a double-
blind, placebo controlled design to examine the acute effects of the drug on memory 
1.5 to 2 hours post administration while participants were under the influence of the 
drug. They also assessed participants during the withdrawal phase 25.5 to 26 hours 
after administration. Acute administration of MDMA produced significantly worse 
performance on a less demanding spatial memory task. However, this impairment was 
not present during the withdrawal phase indicating the effect of the drug was short-
term. Performance on a more complex change blindness task was not significantly 
affected during either phase. Therefore, Kuypers and Ramakers (2007) argued acute 
MDMA exposure affects spatial memory while more complex contextual processing is 
spared. Although Kuypers and Ramaekers (2007) tried to control for confounding 
variables by using double blind placebo control measures and using predominantly 
light Ecstasy users this type of study is still problematic in that it did not use naive 
drug users. In fact some of the subjects in the Kuypers et al. (2007) study were 
classified as heavy users that had taken MDMA on 60 to 120 occasions. Therefore, this 
study could not control for the effects of long-term drug use on performance.  
 
 33 
Acute Non-human Animal Studies 
Much of the previous research on the effects of MDMA has focused on chronic 
treatments of MDMA that try to mimic the long-term effects of the drug. However, a 
few studies have tried to assess the effects of acute MDMA exposure on cognition. 
These paradigms generally involve smaller doses of the drug being administered and 
the subjects‟ performance on various tasks is measured while the drug is present in the 
animals system. Studies that have examined the acute effects of MDMA on memory 
have produced mixed results with some finding evidence of MDMA producing 
cognitive deficits while others have not. 
For example Byrne, Baker and Poling (2000) examined the chronic and acute 
effects of MDMA on acquisition of a lever pressing task. Water deprived Sprague-
Dawley rats were administered intraperitoneal injections of 0.0 (saline), 1.0, 3.2 or 5.6 
mg/kg of MDMA. The task involved placing rats in an operant chamber with two 
levers, one lever produced reinforcement (water delivery) and the other if pressed 
cancelled the schedule reinforcer. MDMA exposure increased the latency of the rats to 
start responding but MDMA did not reduce the overall number of reinforcer responses 
or produce any impairment in discrimination learning between the reinforcer and 
cancellation levers.  
DMTS/DNMTS Tasks 
Rather than examining learning by studying task acquisition, more commonly 
research has focussed on what the effects of MDMA exposure are on tasks that assess 
memory. One of the most commonly used tasks to assess memory function in non-
human animals are delayed matching to sample tasks (DMTS) (Edhouse & White, 
1988). These are conditional discrimination procedures where subjects have to match 
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various stimuli that are separated in time by a range of delays (Edhouse & White, 
1988). The procedure begins with the presentation of a sample stimulus which is 
removed for a delay period after which various stimuli are presented concurrently 
(White, Ruske & Colombo, 1996). In a DMTS task the correct response would be to 
pick the stimulus that was identical to the sample stimulus (White et al., 1996). There 
are variations of this paradigm called delayed non matching-to-sample tasks (DNMTS) 
and in these tasks the correct response would be to pick the stimulus that was different 
to the sample stimulus (Dudchenko, 2004). The terms delayed matching-to-position 
(DMTP) and delayed nonmatching-to-position (DNMTP) are sometimes used when 
the task involves stimuli that vary in terms of their location rather than stimuli that 
differ in visual characteristics. DMTS tasks have been argued to assess memory by 
modelling human episodic recognition tasks (Harper et al., 2005) and are commonly 
used to assess short-term or working memory (White et al., 1996).  
Using these tasks two different patterns of impairment can be found. The first is 
referred to as delay independent as overall performance is disrupted across all delays 
(Harper et al., 2005). This type of impairment has been argued to be the result of 
attention or encoding deficits (Harper et al., 2005). Delay dependent impairments 
occur when performance is worse at longer delays than shorter delays (Herremans, 
Hijzen, Olivier & Slangen, 1995). This type of impairment indicates an impairment in 
working memory (Herremans et al., 1995) or an increase in the rate of forgetting 
(White et al., 1996). 
LeSage, Clark and Poling (1993) examined the effects of acute doses of MDMA 
in pigeons using a DMTS task with three different delays (0, 3 & 6 seconds). Doses 
ranged from 0 to 5.6 mg/kg of MDMA. MDMA decreased accuracy and response rate 
in a dose dependent fashion at all delays. Harper, Wisnewski, Hunt and Schenk (2005) 
also examined the effect of MDMA on DMTS performance in rats. They administered 
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acute doses of MDMA (0.3 to 3.0 mg/kg) and found it produced a delay-independent 
decrease in performance that increased with drug dose. Hence acute MDMA appears to 
produce deficits in encoding or attention (Harper et al., 2005). Utilising a DNMTS task 
Marston, Reid, Lawrence, Oliverman and Butcher (1999) examined the effects of 
administering large ascending doses (10, 15 & 20 mg/kg) of MDMA to rats. MDMA 
exposure disrupted performance in trials using longer delays and also produced 
significantly more bias (Marston et al., 1999). These delay-dependent impairments in 
performance were attributed to the acute MDMA administration disturbing short-term 
memory (Marston et al., 1999). 
However, not all studies that have examined the effects of acute MDMA 
exposure on DMTS tasks have found evidence of impairment. For example Frederick, 
Gillam, Allen and Paule (1995) and Frederick and Paule (1997) both utilised a battery 
of operant tasks that included a DMTS task to examine the acute effects of MDMA 
administration on Rhesus monkey. Both studies found no significant differences in 
performance between saline and MDMA (0.1-1.0 mg/kg) administration. Of note both 
Frederick et al. (1995) and Frederick and Paule (1997) used smaller doses of MDMA 
than most other studies which may account for the lack of deficit.  
There is some debate about which cognitive processes DMTS and DNMTS tasks 
actually assess. These tasks have typically been used as evidence of working memory 
deficits. Working memory is a temporary memory that is trial dependent as it is only 
relevant for one trial (Santin et al., 2003). It involves the rat being able to hold in 
memory where it has been and where it has yet to go within a trial. Harper et al. (2005) 
found acute MDMA exposure produced an overall delay independent impairment in 
accuracy that is usually considered to represent a deficit in working memory probably 
due to an attentional deficit. However, Harper et al. (2005) offer an alternative 
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explanation in that these tasks actually involve a reference memory component and 
this may be what is disrupted in DMTS tasks.  
Reference memory is trial independent as the information available for 
performing tasks requiring reference memory is constant from trial to trial (Santin et 
al., 2003). Reference memory is used to learn the general rules or strategies required to 
solve the task and refers to the stable elements of stimulus control related to the task 
(Harper et al., 2005). It is trial independent as it does not matter what trial you are in as 
the rules of the task remain the same. In terms of the DMTS task the reference memory 
component could involve responding to a sample and then choosing to respond to the 
comparison stimuli that matched the sample. Therefore, Harper et al. (2005) argued 
there are other elements of stimulus control at work in DMTS tasks and it is possible a 
rat could become impaired or confused as to the rules of task.  
Instead of simply looking at discrimination or accuracy Harper et al. (2005) 
performed further analyses on their data examining the influence of previous response 
type on performance. This was to assess the effects of proactive interference on 
performance as it has been found that a subject‟s response on the current trial can be 
influenced by the type of response made on the previous trial (Harper et al., 2005). 
They revealed that as delay and drug dose increased rats were more likely to be 
influenced by the previous response type. For example if in the previous trial the rat 
had responded on the left lever and then in the current trial the correct response was to 
also respond on the left, then the rat was more likely be correct than if the current trial 
required them to switch responding by now pressing the lever on the right. Harper et 
al. (2005) suggested the rats may confuse events between the previous trial and the 
current trial and it is this confusion that produces the decrease in accuracy seen with 
acute MDMA exposure in DMTS tasks. Therefore they argued that it may not be 
working memory or episodic memory per se that is affected by MDMA administration 
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but that it is reference memory that is impaired where subjects mix up events between 
trials (Harper et al., 2005). However, many of the tasks used to assess acute effects of 
MDMA on memory unfortunately do not allow an independent assessment of working 
memory from reference memory.  
The hypothesis that rats become confused about the rules of DMTS tasks was 
investigated further by Harper, Hunt and Schenk (2006). They examined the acute 
effects of MDMA in rats and proactive interference was examined by manipulating the 
inter-trial interval (ITI) during the DMTS task. If rats become confused between the 
response required on the previous and current trials then increasing the ITI should 
decrease this deficit as increasing the time interval between trials should reduce the 
likelihood of them mixing up the previous and current trials (Harper et al., 2006). A 
larger ITI of 15 seconds produced less disruption in performance than a smaller ITI of 
5 seconds supporting their argument that the decrease in accuracy seen with acute 
MDMA exposure results from a form of proactive interference (Harper et al., 2005).  
Therefore DMTS tasks may have a substantial reference memory component 
and it may be this type of memory that is affected by acute MDMA exposure. 
However, this is still only speculative as this paradigm does not specifically 
distinguish between working and reference memory errors. 
Test Battery Studies 
Other studies have utilised a battery of cognitive tasks to examine the effects of 
MDMA on cognition. For example Frederick et al. (1995) and Frederick and Paule 
(1997) examined the acute effects of MDMA administration (0.1 to 1.0 mg/kg) on 
Rhesus monkeys utilising the Operant Test Battery (OTB). This battery includes 
different tasks assessing time estimation, short-term memory, attention, motivation, 
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learning and discrimination. Monkeys were injected intramuscularly with either 
MDMA or saline thirty minutes before completing the various cognitive tests. 
Performance on the time estimation task was severely impaired when they were 
administered a relatively low acute dose of 1mg/kg of MDMA to the extent that no 
monkey was able to perform the task. There was also a significant dose dependent 
decrease in responding on progressive ratio schedules. However acute MDMA 
administration did not significantly affect accuracy on a conditional discrimination 
task that assessed the subjects‟ ability to discriminate between different colours. 
Learning was assessed using a four lever sequence task where the sequence to be 
learned changed each testing session. This task assessed subject‟s ability to change 
their behaviour and acquire the new sequences. MDMA administration significantly 
decreased accuracy without affecting response rate. Interestingly subjects produced 
more acquisition errors (between session errors) than retention errors (within session 
errors) indicating they had more difficulty learning the new sequences rather than 
remembering the acquired ones. This type of impairment suggests a difficulty in 
acquiring task rules that could be interpreted as a reference memory impairment (Kay 
et al., 2009). Frederick and Paule (1997) argued this finding implied MDMA 
administration left short-term memory processes unaffected but impaired the 
acquisition of new information producing a perseverative pattern of responding. In 
conclusion it appears time estimation, motivation and task acquisition are significantly 
impaired with acute MDMA administration (Frederick et al., 1995). However 
performance on other cognitive tests such as a relatively simple discrimination task 
seemed to be spared (Frederick et al., 1995).  
Taffe et al. (2001) also used Rhesus monkeys to study the acute effects of 
MDMA utilising an array of neuropsychological tests. However, unlike the previous 
study of Frederick and Paule (1997) they used very large doses of MDMA (2 x 10 
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mg/kg intramuscularly for 4 days) more similar to those usually administered in 
chronic studies. Tests included a DNMTS task, a self-ordered spatial search task 
(SOSS), a reaction time task, a progressive ratio task and finally a bimanual motor 
task. During the drug treatment week MDMA administration produced significant 
impairments on performance across all cognitive tasks. A potential limitation of the 
Taffe et al. (2001) study was that the subjects had been used in a previous study 
conducted five months earlier that examined the effects of other drugs (scopolamine 
and amphetamine) which may confound the findings. 
Maze Tasks 
Radial arm mazes are used to study spatial memory and involve the animal 
being placed in the middle of the maze and it is allowed to explore the maze (Pearce, 
1999). Each arm is baited and therefore the optimal strategy for performing the task it 
to visit each arm only once. This classic radial arm maze paradigm assesses working 
memory because the subject has to either remember the arms it has visited or those that 
remain to be visited (Pearce, 1999). Braida, Pozzi, Cavallini and Sala‟s (2002) used a 
classic eight-arm radial maze paradigm to assess the acute effects of MDMA on spatial 
memory performance. Rats were administered increasing doses of MDMA (1, 2 or 3 
mg/kg) and the highest dose impaired working memory. In another experiment a two 
hour delay was introduced between the fourth and fifth arm choices. This manipulation 
resulted in a dose dependent deficit in long-term working memory. Acute MDMA 
administration produced a specific memory deficit without disrupting motor activity or 
increasing stereotypy (Braida et al., 2002). The arm entry patterns of rats were also 
disrupted in a dose dependent fashion. Therefore, although Braida et al. (2002) argued 
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their study produced a working memory deficit, because of the disruption of the arm 
entry pattern the deficit could be interpreted as a reference memory deficit.  
One advantage of the radial arm maze is that it can be manipulated to 
specifically differentiate between reference and working memory. Olton and Papas 
(1979) designed a paradigm where a set of arms in the radial maze are always baited 
with reinforcers and the remaining arms are never baited. A rat is placed in the middle 
of the maze and is allowed to visit a certain number of arms (the number usually 
containing reinforcers) in a trial. In order to perform optimally the rat needs to learn to 
go to arms that contain reinforcers and avoid arms that do not. Also as the arms are not 
re-baited within a trial the rat must also avoid re-visiting arms within a trial. Therefore, 
in order to learn this task working memory is required to prevent re-visiting the 
reinforced arms while reference memory is required to avoid visiting arms that are 
never baited with reinforcers (Olton & Papas, 1979). In this paradigm a working 
memory error occurs when a rat re-visits an arm during a trial and a reference memory 
error occurs when a rat visits an arm that was never reinforced (Olton & Papas, 1979). 
This paradigm has been used to examine the effects of several drugs on 
behaviour in the radial arm maze. For example, Wirsching, Beninger, Jhamandas, 
Boegman and El-Defrawy (1984) used this paradigm to assess the effects of 
Scopolamine, an acetylcholine receptor antagonist, on rats using an eight arm radial 
maze. Wirsching et al. (1984) found the mean number of working memory errors 
significantly increased during the drug phase. However, the mean number of reference 
memory errors did not. Therefore, Scopolamine selectively impaired working memory 
and this effect has been found in other studies examining the effects of Scopolamine 
(Wang & Tang, 1998 and Pilcher, Sessions & McBride, 1997). Researchers have also 
found using this paradigm and found the same pattern of more working memory errors 
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than reference memory errors in studies utilising other drugs (e.g. Levy, Kluge & 
Elsmore, 1983 with the cholinergic antagonist atropine sulphate). 
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Figure 1: Average error percentage of working memory (WM) and reference memory 
(RM) errors across all rats for all drug doses replicated from Kay, Harper and Hunt 
(2009). The values given above each bar are the mean number of total working 
memory or reference errors made in each condition across rats. 
 
Kay, Harper and Hunt (2009) utilised an eight arm radial to assess the effects of 
MDMA and Scopolamine on reference and working memory. Fifteen rats were each 
assigned a set of four arms that were always reinforced and four maze arms that were 
never reinforced. Each rat was allowed to visit four arms per trial and received three 
trials per day. As previous studies had found that Scopolamine produced an increase in 
working memory errors, this drug was used to compare the performance of rats 
receiving acute doses of MDMA and a saline control. Figure 1 presents findings from 
Kay et al. (2009) showing the data from working and reference memory errors. It 
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shows that MDMA produced significantly more reference memory errors than working 
memory errors while scopolamine produced significantly more working memory errors 
than reference memory errors.  
Conclusion 
In summary there seems to be some evidence that acute exposure to MDMA 
may disrupt reference memory. This is of interest as it seems to be a rather uncommon 
finding in that many other drugs seem to disrupt working memory instead. This finding 
therefore warrants further investigation. However, Ecstasy is a complicated drug as it 
is both a dopamine and serotonin agonist and this makes it difficult to know which 
neurotransmitter system produces the drug effects seen with MDMA administration 
(Parrott, 2002).  
Many studies have focussed on the effects of MDMA on the serotonin system. 
In particular there has been a lot of focus on the possible neurotoxic effects of MDMA 
on serotonin neurons (see General Introduction for a review). However, these studies 
examine the chronic effects of MDMA exposure that may produce serotonin depletion. 
Whereas acute exposure produces an increase in serotonin release and the effects of 
this have not been thoroughly examined. Also dopamine may produce important 
effects and has largely been under examined in MDMA research (Colado et al., 2004). 
Therefore, the first section of this thesis aims to partially replicate and extend the work 
of Kay et al. (2009) by examining which neurotransmitter systems may be responsible 
for producing the reference memory effect seen with acute exposure to MDMA in the 
partially baited radial arm maze.
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General Acute MDMA Method 
Apparatus/Materials 
The maze consisted of an aluminium central hub with eight arms radiating from 
it (see Figure 2). It was secured to an MDF wooden base. The maze arms were 60.5 
centimetres (cm) in length, with outer arm walls 9 cm high, inner arm walls 18 cm 
high and 9.5 cm wide. The centre well of the maze was 30cm in diameter and the maze 
was situated 81 cm from the ground. At the ends of each arm of the maze there were 
food wells. These consisted of a small piece of wood, 3 cm high, 2 cm thick and 9 cm 
wide. A hole 1 cm in diameter and approximately ½ cm deep was drilled out in the top 
centre of the block to form the well.  
Chocolate chips were used as reinforcers and circular plastic Petri dishes that 
were 5 cm in diameter were attached to the ends of the maze arms to house the 
chocolate chip reinforcers. Circular velcro dots, 2.3 cm in diameter, were used to 
attach the dishes to the end of the arms of the maze. During training four open Petri 
dishes were used without lids to house the obtainable chocolate chips in the reinforced 
arms. In the non-reinforced arms four other plastic dishes were used that had chocolate 
chips sealed inside of them. These non-reinforcer dishes were sealed with lids that had 
several small holes drilled in them. This manipulation allowed the odour of the 
chocolate chips to permeate from the dishes without allowing the rats to obtain them. 
This was done to prevent the rats from solving the task using the smell of the 
chocolate. A digital stopwatch was used to record the amount of time it took a rat to 
complete a trial. Microsoft Excel for Windows was used to analyse and graph the data. 
SPSS for Windows, version 11.5, was used to analyse the data.  
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Procedure 
Pretraining: In an attempt to habituate the rats to the new environment of the 
maze, they were individually placed inside the centre hub of the maze and were 
allowed to move around freely. On the first day chocolate chips were placed in the 
centre of the maze and three chips were placed in each of the arms. One chocolate chip 
was placed near the opening of the arm, another half way down the arm and one in an 
open Petri dish at the end of the arm. Rats were given ten minutes (or until all chips 
were consumed) to explore the maze. 
 
Figure 2: Radial arm maze with rat facing arm number one, the starting position. 
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On the second day of habituation rats were again placed in the centre of the 
maze and allowed to explore for seven and a half minutes (or until all chips were 
consumed). This time chocolate chips were placed in the middle of the maze and one 
chip was placed in the centre of each arm while another was placed in the Petri dish at 
the end of each arm.  
Finally on the third day of habituation the rats were placed in the maze for five 
minutes (or until all the chips were eaten). This time there was one chocolate chip 
placed in the middle of the maze and one chip in the Petri dish at the end of each arm. 
On all days of pretraining the arms the rats visited were recorded. This was done to 
determine if the rats were visiting all arms. 
 
Training: Four reinforcer arms were selected for each rat using a ten-sided die. 
No more than two consecutive arms were used for each rat and each arm was used 
approximately the same number of times between rats. Petri dishes without lids were 
placed in the reinforcer arms and two chocolate chips were placed in the bottom of the 
dish. Petri dishes with lids, that contained two chocolate chips sealed inside it, were 
placed in the four remaining non-reinforced arms.  
At the beginning of a trial rats were placed in the centre of the maze with their 
head facing in the direction of arm number one, see Figure 2. The rats were then 
allowed to enter four arms after which time they were removed from the maze. A 
choice or arm entry was defined as all four feet passing the line formed between the 
wood of the centre of the maze and the metal at the beginning of the arm of the maze. 
These four arm entries constituted a single trial. After a trial was completed and the rat 
was removed the maze was then re-baited and the rat was placed back in the maze. A 
set inter-trial interval was not used it was simply the time taken to rebait the maze and 
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retrieve the rat from the cage which took approximately 15-20 seconds. Each rat 
received three trials in succession per day. 
Arm entries were recorded in the order in which they occurred and error type 
was also recorded. A working memory error was defined as re-entering an arm already 
visited during a trial and a reference memory error was defined as entering an arm that 
had never contained reinforcers. If during a trial a rat re-entered a non-reinforced arm, 
the first instance was recorded as a reference memory error, while the second visit was 
recorded as a working memory error. The time it took to complete a trial in seconds 
was also recorded. Timing commenced from letting the rat go in the centre of the 
maze, till when all four feet had passed over the entrance of the fourth arm the rat 
entered. Trial completion time was included as a measure to pick up more sensitive 
differences in patterns of responding if there were no discernable differences in error 
type. Chocolate chips in the Petri dishes with lids were replaced daily. The maze was 
also wiped out each day to remove sawdust and other debris.  
 
Pharmacological Procedure: The acute studies used a within-subjects 
experimental design with each rat receiving all drug types and doses. The maze 
running procedure was identical to the training phase during the drug sessions. All 
drugs (including saline) were administered via an intraperitoneal (i. p.) injection 
twenty minutes before the rat was placed in the maze.  
 
Statistical Analyses: All inferential statistics were calculated using an alpha 
level of 0.05. All p-values are given to two decimal places. 
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Study 1: 5-HT and Dopamine Agonists in the Radial Arm Maze 
Serotonin (5-HT) 
5-HT is a common chemical found in animals and plants (Sirek & Sirek, 1970) 
discovered in the late 1940s (Ogren, et al., 2008). Several years later it was detected in 
the human brain and identified as a neurotransmitter (Ogren et al., 2008). Within the 
forebrain there are several areas where there are serotonergic axons including the 
hypothalamus, cortex, hippocampus, amygdala and striatum (Lucki, 1998). 5-HT plays 
a role in functions such as temperature regulation, pain perception, food consumption, 
sleep cycles, motor activity, mood, cardiovascular regulation, circadian rhythms, 
aggression, sexual behaviour and learning (Ruotsalainen et al., 1997; Lucki, 1998).  
The study of 5-HT is important in MDMA research because MDMA 
administration produces changes to the serotonergic system. Acute exposure to 
MDMA increases 5-HT release (Kish, 2002) while chronic exposure to MDMA has 
been associated with long-term 5-HT depletion (Marlberg & Bonson, 2001). Studies 
have examined the effects of MDMA use on serotonergic function using brain imaging 
techniques such as PET scans have found potentially harmful alterations to the 5-HT 
system that correlate with Ecstasy use (McCann et al., 1998). Therefore there is 
evidence suggesting long-term Ecstasy use can lead to alterations in the serotonergic 
system. However, there has been less research on the acute effects of MDMA on 
serotonergic function. 
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5-HT and Cognition 
Animal research has found 5-HT plays an important function in various 
cognitive behaviours with activation of 5-HT receptors producing impairments in 
learning and working memory in a variety of tasks (Buhot, 1997). A recent review 
article by Meneses (1999) examined the evidence for 5-HT‟s importance in cognition 
and concluded there was support for the hypothesis that 5-HT pathways and receptors 
are present in brain areas commonly associated with memory and learning. There is 
also evidence from human research that 5-HT may play an important role in cognition. 
For instance serotonergic cells in patients with Alzheimer‟s show damage suggesting 
5-HT may play a role in age-related cognitive disorders (Santucci et al., 1996). 
Research utilising human participants has found memory impairments 
correlated with Ecstasy use. These impairments in cognitive function have been 
correlated with evidence of serotonergic damage where the amount of Ecstasy used 
tends to be positively related to damage to the serotonergic system and the degree of 
cognitive impairment (Bolla et al., 1998; McCann et al., 1999). In addition deficits in 
verbal memory functioning have been found in Ecstasy users and these have also been 
associated with changes in 5-HT functioning (Reneman et al., 2001). While some 
studies have found evidence of serotonergic manipulation impairing cognitive 
performance, some have found it to improve performance while others have found it 
had no effect (Santucci et al., 1996). Ogren et al. (2008) also point out that confusingly 
depleting and increasing 5-HT activity have both been shown to impair cognition. 
Hence the exact nature of 5-HT‟s role in cognition is still unclear (Meneses, 1999). 
It should be noted that studies reporting 5-HT stimulation enhancing cognitive 
performance often involve participants from clinical populations. For example people 
suffering from depression (Levkovitz et al., 2002) and schizophrenia (Meltzer & 
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Sumiyoshi, 2008) have shown improved cognitive functioning after treatment with 5-
HT agonists. However in these cases participants may have abnormal brain functioning 
that may impair cognitive functioning in the first place. Studies reporting improved 
cognitive functioning after 5-HT stimulation in normal populations are rare. Hence 
increasing 5-HT activity in healthy participants may not be beneficial to cognition 
(Barch, 2004). Therefore the focus of this research review, summarised in Table 1, will 
focus on 5-HT manipulation producing cognitive impairments. 
A lot of research has focused on the effects of 5-HT found after chronic MDMA 
exposure. Several hours after MDMA administration there is a temporary depletion of 
5-HT and chronic use of MDMA has been associated with long-term 5-HT depletion 
(Marlberg & Bonson, 2001) and damage to serotonergic axons (Ricaurte, 1989). 
Therefore, this research tends to focus on 5-HT depletion and damage to the 
serotonergic system. Acute administration of MDMA produces an increase in 5-HT 
activity (Marlberg & Bronson, 2001). This effect has not been studied as extensively 
as 5-HT depletion but there is evidence that increasing 5-HT release may also produce 
cognitive impairments (Santucci et al, 1996). For example Santucci et al. (1996) 
investigated the effects of p-chloroamphetamine to rats. Performance on a passive 
avoidance task and a radial arm maze task were significantly impaired during the 5-HT 
release phase of the drug but not during the depletion phase suggesting 5-HT release 
impaired cognitive performance. 
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Table 1: Summary of research on the effects of serotonin (5-HT) agonists on cognition. 
Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Lader et al. 
(1986) 
Citalopram – SSRI 
(20 & 40 mg/kg) 
5-HT 
Agonist 
Orally Healthy Human 
Volunteers 
Battery of cognitive tasks Significantly impaired immediate recall & 
coding skills. 
Did not effect reaction time or delayed 
memory performance 
Winter & Petri 
(1987) 
LSD 
(0.1 to 1.0 mg/kg) 
5-HT 
Agonist 
I.P. injections 
15 minutes 
before testing 
Fischer 344 
Rats 
Standard 8 arm radial maze task 
(all arms were baited) – 
assessed spatial working 
memory 
LSD - significant decrease in performance. 
 TFMPP 
(0.3 to 1.0 mg/kg) 
5-HT2C 
Agonist 
 TFMPP – no significant effect. 
 8-OH-DPAT 
(0.1 t0 3.0 mg/kg) 
5-HT1A 
Agonist 
 8-OH-DPAT – significantly impaired 
performance. 
 RU 24969 
(0.3 to 3.0 mg/kg) 
5-HT1A & 1B 
Agonist 
 RU 24969 – significantly impaired 
performance. 
Rowan et al. 
(1990) 
Buspirone 
(0.5 to 2.0 mg/kg) 
5-HT1A 
Agonist 
I.P. injection 
30 mins before 
testing 
Albino Wistar 
rats 
Passive avoidance task 
(retention tested24 hours later) 
Significantly impaired performance on 
retention test of passive learning. 
    Morris Water Maze task – 
assessed spatial memory 
Significantly impaired acquisition (increased 
time to find platform & impaired probe 
trials). 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Carli & 
Samanin 
(1992) 
8-OH-DPAT 
(30, 100 & 300 µg/kg) 
5-HT1A 
Agonist 
S.C. injection 
30 mins before 
testing 
Albino Rats Morris Water Maze – assessed 
spatial memory. 
Accuracy significantly reduced with no 
effect on latency – spatial memory impaired. 
Ohno et al. 
(1993) 
8-OH-DPAT 
(0.32 & 1.0 mg/kg IP) 
5-HT1A 
Agonist 
I.P. injection Rats Three panel runway task - 
assessed spatial memory & 
differentiated between working 
and reference memory. 
Both intraperitoneal & intra-hippocampal 
administration of 8-OH-DPAT produced 
more working memory errors than reference 
memory errors.   8-OH-DPAT 
(1.0, 3.2 & 10.0 µg/side 
IH) 
 IH injection  
Jansen & 
Andrews 
(1994) 
Fluoxetine – SSRI 
(0.625 to 10 mg/kg) 
5-HT 
Agonist 
S.C. injections 
30 minutes 
before testing 
Long Evans 
Rats 
Delayed (5 to 45 seconds) 
matching to position task – 
assessed spatial memory  
Fluoxetine - no significant effect on both 
tasks 
Fenfluramine – SSRI 
(0.313 to 5 mg/kg) 
5-HT 
Agonist 
 Delayed (5 to 45 seconds) 
nonmatching to position task – 
assessed spatial memory 
Fenfluramine - largest dose significant 
deficit in performance on both tasks 
 Ipsapirone 
(2.5 to 10 mg/kg) 
5-HT1A 
Agonist 
  Ipsapirone - no significant effect on accuracy 
on either tasks but did effect reaction time 
Buhot et al. 
(1995) 
8-OH-DPAT 
(5µg/µl) 
5-HT1A 
Agonist 
I.H. injections 
15 mins before 
testing 
Long-Evans 
Black-hooded 
Rats 
8 arm radial maze task (4 arms 
baited and 4 unbaited)  
8-OH-DPAT – no significant effect. 
 CP-93,129 
(5, 10 & 16 µg/µl) 
5-HT1B 
Agonist 
 CP-93,129 - significantly more RM errors 
than WM errors. 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Carli et al. 
(1995) 
8-OH-DPAT 
(100 µg/kg) 
5-HT1A 
Agonist 
S.C. injection 
15 mins before 
testing 
Albino Rats Morris Water Maze task that 
differentiated between visual & 
spatial memory  
Produced impairment on spatial task but not 
visual task – stimulation of 5-HT1A receptors 
impaired spatial learning 
Herremans et 
al. (1995) 
Fluvoxamine – SSRI 
to 10 mg/kg) 
5-HT 
Agonist 
I.P. injection 
20 mins before 
testing 
Wistar Rats Delayed (1 to 20 seconds) 
conditional discrimination task 
(assessing working memory) 
First 3 drugs - significant dose dependent but 
delay independent  impairment in 
performance (attention/encoding deficit 
rather than working memory impairment) 
Flesinoxan - significant delay dependent 
impairment indicative of a working memory 
deficit (rate of forgetting) 
 Ipsapirone 
(0.3 to 10 mg/kg) 
5-HT1A 
Agonist 
 
 TFMPP 
(0.03 to 0.3 mg/kg) 
5-HT1B 
/1D/2C 
Agonist 
  
 Flesinoxan 
(0.3 to 3 mg/kg) 
5-HT1A 
Agonist 
   
Robbe & 
O‟Hanlon 
(1995) 
Paroxetine – SSRI 
(20 & 40 mg/kg) 
5-HT 
Agonist 
Orally Healthy human 
volunteers 
Driving & cognitive 
performance (including 
tracking, attention visual 
discrimination, recognition & 
memory)  
Lower dose – no effect on performance. 
Larger dose - significant impairments on 
tracking, divided attention & recognition 
tasks as well as subjective ratings of memory 
disturbances. 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Santucci et al. 
(1996) 
p-chloroamphetamine  
(0.5 to 2.5 mg/kg) 
Increases 5-
HT release 
& then 5-HT 
depletion 
I.P. injection 
30 mins prior 
to testing  
Sprague-
Dawley Rats 
Passive avoidance task – 
assessed learning & long-term 
retention. 
Impaired performance on avoidance task 
during 5-HT release not depletion phase. 
   8 arm radial maze (4 arms 
baited & 4 arms unbaited). 
Significant increase in working & reference 
memory errors during 5-HT release not 
depletion phase. 
Kant et al. 
(1996) 
8-OH-DPAT 
(0.25, 0.5 & 1.0 mg/kg) 
5-HT1A 
Agonist 
I.P. injection 
30 mins before 
testing 
Sprague-
Dawley Rats 
Modified Morris Water Maze -
rats swam through alleyways & 
doors to find a platform 
5-HT1A agonist - significantly more errors & 
an increase in latency. 
 TFMPP 
(0.25, 0.5 & 1.0 mg/kg) 
5-HT2C 
Agonist 
 5-HT2C agonist - increase in latency (no 
effect on accuracy). 
Warburton et 
al.  
(1997) 
8-OH-DPAT 
(0.05 to 1.0 mg/kg) 
5-HT1A 
Agonist 
I.P. injection 
30 mins before 
testing 
Listar-Hooded 
rats 
Delayed non-matching-to-
position task using operant 
chambers (delays of 0, 8, 16 & 
32 seconds) – assessed spatial 
working memory 
Highest dose – significant delay-independent 
impairment (increase in premature 
responding & bias).  
8-OH-DPAT 
(10, 30, 100 ng) 
 I.H. 10 mins 
before testing 
 Administration into hippocampus - 
significant delay independent impairment 
 8-OH-DPAT 
(10, 30, 100 ng) 
 I.R.N. 10 mins 
before testing 
 Highest dose into median raphe nucleus - 
delay independent improvement in 
performance. Lower doses - no effect. 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Kant et al. 
(1998) 
8-OH-DPAT 
(0.1, 0.25 & 0.5 mg/kg) 
5-HT1A 
Agonist 
I.P. injection 
30 mins before 
testing 
Sprague-
Dawley Rats 
Modified Morris Water Maze as 
used above. 
Rats were given 25 trials on a 
maze configuration before drug 
administration then maze layout 
was changed & they assessed 
how subjects learnt the new 
maze configuration. 
8-OH-DPAT - no effect on learnt maze. New 
maze - significantly more errors & increased 
swim times. 
 Buspirone 
(2.5, 5.0 & 10 mg/kg) 
5-HT1A 
Agonist 
 Buspirone - no effect on learnt maze. New 
maze - lower doses significantly more errors 
& increased swim times. Highest dose 
completely blocked learning of new maze. 
 DOI 
(0.1 & 0.25 mg/kg) 
5-HT2 
Agonist 
 DOI - significantly slower swim times on 
well learned & new maze. No effect on 
errors.   
Luciana et al. 
(1998) 
Fenfluramine – SSRI 
(60 mg/kg) 
5-HT 
Agonist 
Orally Healthy human 
volunteers 
Delayed spatial location task 
(assessed spatial working 
memory) 
Fenfluramine - significant impairment in 
spatial memory – especially with longer 
delays. 
     Spatial location task (assessed 
motor function) 
Biletter cancelation task 
(assessed visual scanning & 
motor function) 
Other 2 tasks that assessed motor function 
not significantly affected – therefore 
fenfluramine produced spatial working 
memory deficits. 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Naghdi & 
Majlessi 
(2000) 
Citalopram – SSRI 
(1, 2, 4, 8 & 16 mg/kg) 
5-HT 
Agonist 
I.P. injection 
30 mins before 
testing 
Albino Wistar 
Rats & N.MRI 
Mice 
Morris water maze task – 
assessed spatial memory 
Significantly impaired performance (increase 
in time taken & distance travelled platform). 
 Alternating T-maze task, 
assessed spatial memory 
No effect on T-maze task. 
Majlessi & 
Naghdi (2002) 
Citalopram – SSRI 
(1, 2, 4 & 8 mg/kg) 
5-HT 
Agonist 
I.P. injection 
30 mins before 
testing 
Albino Wistar 
Rats 
Morris Water Maze task – 
assessed spatial memory 
Both SSRIs - spatial learning impairment 
(significant increase in latency & distance 
travelled to platform without change in 
swimming speed)  Fluoxetine – SSRI 
(1, 2, 4, 8, & 16 mg/kg) 
5-HT 
Agonist 
  
Ahlander-
Luttgen et al. 
(2003) 
Anpirtoline 
(1 to 1.0 mg/kg) 
5-HT1B 
Agonist 
S.C. injection 
30 mins before 
testing 
Sprague-
Dawley Rats 
Morris Water Maze – assessed 
spatial memory 
Anpirtoline - significant impairment in both 
tasks. 
NAS-181 
(1.0 to 10 mg/kg) 
5-HT1B 
Antagonist 
 Passive avoidance task 
(retention tested 24 hours later). 
NAS-181 – higher doses significantly altered 
performance on water maze task. NAS-181 
pre-treatment attenuated the impairments 
produced in both tasks. 
Luttgen et al. 
(2005) 
8-OH-DPAT 
(0.03 to 0.3 mg/kg) 
5-HT1A 
Agonist 
S.C. injection 
15 mins prior 
to testing 
Sprague-
Dawley Rats 
Morris Water Maze – assessed 
spatial memory 
Significantly impaired water maze 
performance 
 NAD-299 
(0.05 & 0.5 mg/kg) 
5-HT1A 
Antagonist 
 Passive avoidance task 
(retention tested 24 hours later).  
Improved passive avoidance performance at 
low doses & impaired it at high doses. 
     Pre-treatment with NAD-299 blocked 8-OH-
DPAT impairments in both tasks. 
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Author 
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Cognitive Effects 
Egashira et al. 
(2006) 
8-OH-DPAT 
(1 mg/kg) 
5-HT1A 
Agonist 
I.P. injections 
15 mins before 
testing 
Wistar Rats Standard 8 arm radial maze task 
(all arms were baited) – 
assessed spatial working 
memory 
8-OH-DPAT - significant dose dependent 
impairment in performance. 
 WAY-100635 
(0.001 to 0.1 mg/kg) 
5-HT1A 
Antagonist 
 WAY-100635 - significantly attenuated 8-
OH-DPAT impairment. 
 NAN-190 
(0.3 to 3.0 mg/kg) 
5-HT1A 
Antagonist 
 NAN-190 - significantly attenuated 8-OH-
DPAT impairment. 
 8-OH-DPAT 
(4μg/side) 
5-HT1A 
Agonist 
Micro-
injections into 
various brain 
regions 
 8-OH-DPAT into dorsal hippocampus 
significantly impaired performance that was 
attenuated by administration of NAN-190. 
Wadsworth et 
al. (2005) 
Selective serotonin 
reuptake inhibitors 
(SSRI) 
5-HT 
Agonist  
Orally  Human 
participants 
taking SSRIs & 
drug free 
controls 
Battery of cognitive tasks 
assessed reaction time, attention 
& memory. 
SSRI treatment - significant effect on 
episodic memory, recognition memory & 
delayed recall.  
No effect on working & semantic memory. 
 
I.P. – intraperitoneal  S.C. – subcutaneous I.H – intra-hippocampal infusions I.R.N. - intra-raphe nucleus infusions 
To better understand the role of 5-HT in cognitive function other studies have 
investigated the effects of various 5-HT agonists on cognitive performance. 
Administration of the 5-HT1A agonist 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT) has significantly spatial learning spatial learning (Carli & Samanin, 1992; 
Carli, Luschi & Samanin, 1995; Luttgen, Elvander, Madjid & Ogren, 2005; Kant et al., 
1996; Kant, Wylie, Chu & Ghosh, 1998). Learning of a passive avoidance task has 
also shown impairment with higher doses of 8-OH-DPAT (Luttgen et al., 2005). The 
5-HT1A agonist Buspirone has also impaired water maze performance (Kant et al., 
1998) and impaired passive avoidance learning (Rowan, Cullen and Moulton, 1990). 
In particular it would appear 8-OH-DPAT impairs working memory in the radial arm 
maze (Winter & Petti, 1987; Egashira et al., 2006), DNMP performance (Warburton, 
Harrison, Robbins & Everitt, 1997) and in delayed conditional discrimination 
performance (Herremans et al., 1995).  
The role of 5-HT1B receptors in cognition has also been examined where 
administration of various 5-HT1B receptor agonists has been found to impair 
performance on a passive avoidance task, a water maze task (Ahlander-Luttgen, Madjid, 
Schott, Sandin & Ogren, 2003) and a radial arm maze task (Winter & Petti, 1987). 
However not all 5-HT receptors appear to play an important role in cognition. For 
example 5-HT2C agonists have not impaired performance on a radial arm maze task 
(Winter & Petti, 1987) and have not affected accuracy in water maze tasks (Kant et al., 
1996; Kant, Wylie, Chu & Ghosh, 1998). 
Ohno, Yamamoto and Watanabe (1993) utilised a three panel runway task and 
found 8-OH-DPAT produced more working memory errors than reference memory 
errors. Ohno et al. (1993) concluded 8-OH-DPAT impairs spatial memory, specifically 
working memory. With relevance to the current thesis there are also studies that have 
used the partially baited radial arm maze to examine the effects of 5-HT stimulation on 
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reference and working memory errors in rats. Buhot, Patra and Naili (1995) trained rats 
at this task prior to administration of intra-hippocampal injections of 8-OH-DPAT and 
CP-93,129. However unlike previous research they found 8-OH-DPAT had no effect on 
performance. Also contrary to previous research Buhot et al. found CP-93,129 produced 
significantly more reference memory errors rather than working memory errors. 
Therefore, the serotonergic effects on working and reference memory are not clear. 
The research summarised above clearly supports the view that various 5-HT 
receptors may be involved in learning and memory. However more research is needed 
to clarify the different effects of various 5-HT agonists on cognition, especially 
working and reference memory processes. However on balance there does seem more 
evidence that stimulating 5-HT1A receptors, impairs working memory more than 
reference memory processes. Therefore while acute MDMA exposure increases 5-HT 
release it would appear unlikely that this increase in 5-HT activity produced the 
reference memory impairments seen with acute MDMA exposure in Kay et al. (2009). 
Selective Serotonin Reuptake Inhibitors (SSRIs) 
Rather than examining the role of the individual 5-HT receptors on learning and 
memory other researchers have focussed on more general 5-HT agonists. Common 
forms of 5-HT agonists are SSRIs which are indirect agonists as they alter the 
serotonergic system by selectively inhibiting 5-HT reuptake into the pre-synaptic 
neuron (Majlessi & Naghdi, 2002). This increases 5-HT by leaving more 5-HT in the 
synapse and therefore increasing extracellular concentrations of 5-HT and serotonergic 
transmission (Naghdi & Majlessi, 2000). This drug action is relevant as MDMA also 
inhibits 5-HT reuptake (Marlberg & Bonson, 2001) and there have been accounts of 
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cognitive impairments in relation with taking SSRIs (Wadsworth, Moss, Simpson & 
Smith, 2005).  
Administering SSRIs to human participants has resulted in impaired 
performance on immediate recall memory and coding tasks (Lader, Melhuish, Grcka, 
Overo & Christensen, 1986) as well as impairments in attention and recognition tasks 
(Robbe & O‟Hanlon, 1995). Also subjectively participants have reported side effects 
including memory disturbances (Robbe & O‟Hanlon, 1995). Luciana, Collins and 
Depue (1998) found Fenfluarmine (quickly releases 5-HT from pre-synaptic terminals 
& inhibits reuptake) impaired spatial working memory.  
Utilising animal subjects Jansen and Andrews (1994) examined the effects of 5-
HT activity on spatial memory in rats using a DMTP and a DNMTP task. Once 
performance had stabilised they administered various 5-HT agonists. The SSRI 
Fluoxetine failed to significantly impair performance in either task whereas the 5-HT 
release enhancer and SSRI Fenfluramine produced a significant impairment on both 
tasks. Jansen and Andrews (1994) argued these findings suggest more of a general 
disruption in behaviour rather than a specific effect on cognition and further highlight 
the difficulty in identifying the effects that 5-HT has on cognition as drugs that have 
very similar effects on 5-HT produced different effects (Jansen & Andrews, 1994). 
The SSRI Fluvoxamine has produced delay independent impairments on a 
delayed conditional discrimination task suggesting it impaired attention or encoding 
(Herremans et al., 1995). More recently Naghdi and Majlessi (2000) found the SSRI 
Citalopram did not significantly affect performance on a T-maze task but did produce a 
significant dose-dependent deficit on performance in the Morris water maze. In a 
similar study Majlessi and Naghdi (2002) examined the acute effects of Citalopram 
and Fluoxetine on acquisition of the Morris water maze. Both SSRIs produced 
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significant dose dependent impairments on performance. However, neither drugs 
produced a change in the swimming speed of the rats indicating motor activity was not 
impaired. Therefore, Majlessi and Naghdi (2002) argued the learning deficit was due 
to an impairment in spatial learning produced by the 5-HT agonists.  
In conclusion there does seem to be strong evidence that an increase in 5-HT 
levels, either by stimulating specific 5-HT receptors or increasing 5-HT levels by 
inhibiting reuptake is associated with deficits or impairments in cognitive function. 
While not conclusive the majority of studies seems to implicate a role of 5-HT in 
working memory. However, very few studies have specifically tried to differentiate the 
acute effects of drugs that act as 5-HT agonists on working and reference memory. 
Clearly further research in this area of study would be valuable considering the number 
of people who take SSRIs and the number of people who are taking Ecstasy. 
Dopamine 
Dopamine was first discovered in the central nervous system in the late 1950s 
(Beninger, 1983). It is a neurotransmitter that plays an important role in many 
functions including locomotor activity, emotion, cognition and neuroendocrine 
secretion (Jaber et al., 1996). Dopamine has also been shown to play a role in 
reinforcement or motivation (Nieoullon, 2002) as well as being associated with various 
forms of learning (Beninger, 1983). Disruptions of dopaminergic function have been 
associated with several diseases and conditions such as Parkinson‟s disease (PD), 
schizophrenia, Tourette‟s syndrome, attention deficit hyperactive disorder (ADHD), 
pituitary tumours (Vallone et al., 2000), Alzheimer‟s disease, Huntingdon‟s chorea, 
autism and bipolar disorders (Nieoullon, 2002). In addition disruptions to 
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dopaminergic function have been associated with drugs of abuse such as cocaine and 
amphetamine that increase dopamine activity in the brain (Beninger, 1983).  
The reason dopamine is important in regards to MDMA research is that 
MDMA exposure produces a rapid increase in dopamine release (Colado et al., 2004). 
In some areas of the brain MDMA exposure produces a larger increase in extracellular 
dopamine than that of 5-HT (Colado et al., 2004). MDMA increases dopamine release 
in two ways. Firstly by reversing the dopamine uptake carrier and secondly by 
stimulating the 5-HT2A receptors (Liechti & Vollenweider, 2001). In animal research a 
number of studies have found repeated exposure to MDMA produces changes in the 
dopaminergic system in experimental animals with acute administration of the drug 
producing an increase in dopamine release (Gerra et al., 2002).  
However unlike the substantial amount of research that has produced evidence 
that MDMA‟s action on the serotonergic system produces neurotoxic brain damage, 
there is little indication that MDMA produces any permanent impairment to the 
dopaminergic system (Colado et al., 2004). In fact there is very little evidence that 
long-term use of MDMA produces damage to dopamine neurons in humans or rats 
(Colado et al., 2004). 
Dopamine and Cognition 
The dopaminergic system may be vital in short-term or working memory 
(Gouzoulis-Mayfrank et al., 2003) and has also been associated with some forms of 
learning (Beninger, 1983). Evidence from studies support the notion that dopamine 
functioning plays an important role in a range of cognitive processes (Cropley, Fujita, 
Innis & Nathan, 2006) including working memory (Watanabe, Kodama & Hikosaka, 
1997). In addition a variety of experimental studies using animals have suggested 
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repeated exposure to MDMA induces dysfunction in the dopaminergic system that 
may affect learning and memory (Gerra et al., 2002). In rats MDMA administration 
has produced changes in dopamine neurotransmission in the nucleus accumbens(Gerra 
et al., 2002), the hippocampus (Shankaran & Gudelsky, 1998; Gerra et al., 2002) and 
the striatum (Shankaran & Gudelsky, 1998) which are areas that are in important in 
memory and learning (Meneses, 1999; Jay & Dunnett, 2007).  
There is also evidence from imaging and lesioning studies that the striatum 
plays an important role in procedural learning and the learning of new skills (Jay & 
Dunnett, 2007) that involve reference memory processes. As the striatum has reliably 
been found to release dopamine following MDMA administration (Shankaran & 
Gudelsky, 1998) the MDMA induced reference memory impairments seen in Kay et 
al. (2009) may be the result of changes to dopamine activity. 
A more common method of examining the role of the dopaminergic system on 
cognition and memory has been to administer dopamine agonists to examine the effect 
they have on cognitive tasks. Commonly used dopamine agonists are drugs that treat 
various psychological disorders associated with dopaminergic function. While some 
studies have found that manipulating dopamine impairs performance, some have found 
that low doses of dopamine may improve cognitive performance (Barch, 2004). 
However many of the studies have used abnormal clinical populations that may have 
abnormal brain functioning in the first place which makes it difficult to ascertain 
whether dopamine stimulation would actually improve memory function in normal 
subjects.  
In fact the relationship between dopamine function and cognition is complicated 
and has been described as having an inverted U shaped function where either an 
increase or decrease in dopamine activity seems to disrupt cognitive performance 
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(Floresco & Magyar, 2006). Therefore administering dopamine agonists to healthy 
subjects would be less likely to improve memory function than administering them to 
subjects that have decreased dopamine functioning (Barch, 2004). Many dopamine 
agonists are stimulants and hence in low doses they have been shown to improve 
reaction time (Barch & Carter, 2005). However this does not necessarily mean they 
alter memory processes per se. Therefore the focus of this research will be on studies 
that have found evidence of dopamine manipulation producing cognitive impairment 
and this research is summarised in Table 2. 
As seen in Table 2 Shohamy et al.‟s (2006) work examining learning in PD 
patients showed patients on L-dopa were impaired at acquiring an associative learning 
task. Shohamy et al. (2006) concluded dopamine functioning is involved in reward and 
feedback based learning. In addition this form of impairment suggests an impairment 
in the ability to learn task rules which may indicate a reference memory deficit. Further 
evidence that dopamine may play a role in reference memory processes also comes 
from PD patients. Procedural memory is a term used in human cognition research that 
relates to the gradual acquisition of fixed rules and procedures of cognition, perception 
or motor activity (Thomas-Ollivier, Reymann, Moal, Schuck, Lieury & Allain, 1999). 
This definition of procedural memory has some common features with reference 
memory learning used in animal research. Procedural memory is assessed by having 
participants perform two tasks simultaneously. After an initial learning phase on one 
task a secondary one is introduced. If the first task has been automated (learnt to a 
procedural level) then there should be minimal interference when another task is 
introduced (Thomas, Reymann, Lieury & Allain, 1996). Studies using PD patients 
have shown evidence of impaired procedural memory (Thomas et al., 1996; Thomas-
Ollivier et al., 1999). PD patients who showed impaired procedural memory also 
performed badly on the Wisconsin Card Sorting Task (Thomas-Ollivier et al., 1999). 
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This suggests they were impaired in their ability to acquire task rules which is also 
indicative of a reference memory type impairment.  
However, one difficulty in examining PD patients is that they have abnormal 
brain functioning as their condition reduces dopamine levels and the dopamine 
stimulating medication is administered in an attempt to return their levels to normal. In 
the current study healthy rats, presumably with normal dopamine functioning, were 
administered dopaminergic stimulating drugs to increase their dopamine levels beyond 
normal. Therefore, it may be problematic in extending these findings to the current 
paradigm. However these findings may reveal that there is an ideal level of dopamine 
activity required for effective procedural or reference memory performance. 
There have been researchers that have administered dopamine agonists to 
healthy human volunteers. Dopamine agonists have been found to significantly impair 
the acquisition of an associate learning, learning transference and long-term retention 
(Breitenstein et al., 2006). They have also significantly impaired performance on tasks 
that assessed source recognition, item recognition and proactive memory interference 
(Montoya et al., 2008). Therefore dopamine manipulation produced deficits in learning 
task rules and confusion or interference on cognitive tasks which may indicate 
reference memory deficits. 
Animal research also provides evidence that administering dopamine agonists 
can impair cognition such as deficits in long-term memory (Zarrindast et al., 1992), 
memory formation (Chuhan & Taukulis, 2006), DMTS performance (Kesner et al., 
1981; Branch & Dearing, 1982; Baron & Wenger, 2001; Wright & White, 2003; 
Harper et al., 2005), DNTMS performance (Kesner et al., 1981) time estimation, 
progressive ratio performance, conditioned position and sequence learning (Mayorga 
et al., 2000). 
Table 2: Summary of research on the effects of dopamine agonists on cognition. 
Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Kesner et al. 
(1981) 
d-amphetamine 
(0.33, 1.0, 2.0  & 
3.0 mg/kg) 
DA 
Agonist 
I.P. injection 
30 mins before 
testing 
Long-Evans rats DNMTS task using an operant 
chamber (delays of 0, 5, 15, 30 & 40 
seconds) 
Larger doses - significant decreases in accuracy & 
as dose increased the impairment was evident at 
earlier delays. 
   Spatial delayed matching-to-sample 
task using an 8 arm radial maze 
(delays of 1 minute or 30 minutes) 
2 highest doses - significant increase in errors 
with the 1 minute delay. But with the 30 minute 
delay only 3mg/kg dose significantly reduced 
accuracy. 
Branch & 
Dearing 
(1982) 
Cocaine 
(0.56 to 10 mg/kg) 
DA 
Agonist 
I.M. injection Pigeons DMTS task using operant chambers 
(delays of 0.05 - 4.0 seconds) 
Cocaine - dose related significant decrease in 
accuracy. 
Buresova & 
Bures (1982) 
Amphetamine 
(1 mg/kg) 
DA 
Agonist 
I.P. injections 
10 mins before 
testing 
Hooded rats Radial arm maze (12 and 24 arm 
versions - standard paradigm where 
all arms were baited.) 
Neither drug significantly impaired performance 
on the standard 12 or 24 arm maze performance. 
 Apomorphine 
(0.05 mg/kg) 
DA 
Agonist 
 Also involved a condition where a 5 
minute delay was introduced between 
the 6
th
 & 7
th
 arm choice for the 12 
arm maze. 
Amphetamine (but not apomorphine) produced a 
significant impairment when the delay was 
introduced into the maze paradigm. 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Beatty et al. 
(1984) 
Amphetamine 
(0.5, 1.0 & 2.0 
mg/kg) 
DA 
Agonist 
I.P. injection Albino rats 12 arm radial maze task (6 arms 
baited & 6 arms not baited). 
Amphetamine – no increase in either error type 
compared to saline controls. 
    12 arm radial maze task (6 arms 
baited & 6 arms not baited). Rat 
removed for a delay (0 or 5 minutes) 
after they had visited 3 arms & then 
put back in maze. 
Significant increase in both WM & RM errors 
with the 2.0 mg/kg dose of amphetamine but only 
with the 5 minute delay – DA agonist only 
produced memory deficit when a delay was 
introduced. 
Zarrindast et 
al. (1992) 
Apomorphine  
(0.06 to 0.5 mg/kg) 
DA 
Agonist 
S.C. injection 
30 mins before 
testing 
Albino mice Active avoidance learning task using 
mild foot shock. Tested 24 hours later 
to measure retention (assessed long-
term retrieval) 
Apomorphine – low doses improved performance.  
Higher doses - significant impairment in 
performance (over-stimulating dopamine impairs 
long-term retention). 
Thomas et al. 
(1996) 
PD patients – 
abnormal 
dopamine function 
  Parkinson‟s 
disease patients 
and elderly and 
student controls 
Tactile maze task: 
First phase was acquiring the maze 
task. 
Second phase they had to memorise 
visual items while concurrently 
performing the maze task. 
PD patients - significant impairment in acquiring 
the maze task compared to controls.  
During second phase PD patients also showed 
significant impairment suggesting  procedural 
memory impairment. 
     Arithmetic/alphabet task: 
First phase involved having to learn a 
numerical and alphabetical code and 
solving problems using the code. 
Second phase completing longer & 
harder problems. 
PD patients - significantly impaired compared to 
student controls but not age matched controls.  
In second phase PD patients failed to automate 
the initial task into long-term memory suggesting 
a procedural memory deficit. 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Thomas-
Ollivier et al. 
(1999) 
PD patients – 
abnormal 
dopamine function 
  Parkinson‟s 
disease patients 
and age matched 
controls 
Verbal material task:  
First phase involved memorising a 
poem. 
Second phase introduced a secondary 
concurrent finger tapping task 
PD patients - significantly more errors than 
controls when learning the poem.  
During second phase of the task PD patients were 
significantly impaired compared to controls - had 
more difficulty in performing two tasks at once 
(impaired procedural memory).  
     Visuo-motor task: 
First phase involved learning & 
memorising sequence of key presses 
on a keyboard 
Second phase introduced a secondary 
concurrent task that required them to 
keep track of alphabetical stimuli 
PD patients - significant impairment in acquiring 
the visuo-motor task compared to controls.  
During second phase PD patients did not score 
differently from controls suggesting they were 
able to perform these two tasks concurrently as 
well as controls. 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Mayorga et al. 
(2000) 
Methylphenidate 
(MPH) 
(1.12 to 18 mg/kg) 
Amphetamine 
(0.1 to 6 mg/kg) 
DA 
Agonist 
I.P. injection 
15 mins before 
testing 
Sprague-Dawley 
rats 
Battery of operant tasks consisting of:  
A conditional position task (having to 
learn to discriminate between tones 
and lights)  
Lower doses - both drugs produced an increase in 
response rate. Higher doses - both decreased 
response rate. Both MPH & amphetamine at 
higher doses produced a significant decrease in 
accuracy.  
    An incremental repeated acquisition 
task (learning lever sequences) 
Both drugs increased response rates at lower 
doses but at higher doses decreased response 
rates. Both drugs significantly decreased accuracy 
at higher doses. 
     Temporal response task (assesses 
sensitivity to the passage of time) 
Significantly impaired performance at lower 
doses than the other cognitive tasks – 
performance easily disrupted. 
     Motivation task (using a progressive 
ratio schedule) 
At higher doses rats were less inclined to work for 
reinforcement - however effect only significant 
for amphetamine. 
Baron & 
Wenger 
(2001) 
d-amphetamine 
(0.01 to 1.0 mg/kg) 
DA 
Agonist 
I.M. injections 
into the upper 
leg 
Squirrel monkeys DMTS task using operant chambers 
with a fixed delay for three seconds. 
Both drugs produced a significant reduction in 
accuracy compared to saline. 
Cocaine 
(0.1 to 3.2 mg/kg) 
DA 
Agonist 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Wright & 
White (2003) 
Methylphenidate 
(MPH/Ritalin) 
(0.25, 2.5 & 10 
mg/kg) 
DA 
Agonist 
I.P. injection 
30 mins before 
testing 
Pigeons DMTS task using operant chambers 
(delays of 0.2, 1, 3, 6 & 12 seconds).  
Highest dose significantly reduced accuracy in 
both the FR1 & FR5 conditions indicating 
manipulating attention did not alter performance.  
   In sample phase used FR1 & FR5 
schedules to manipulate 
attention/encoding 
MPH affected accuracy in a delay-independent 
fashion – suggesting encoding deficit rather than 
a memory deficit per se. 
Harper et al. 
(2005) 
Cocaine 
(0.3, 1.0, 2.0 & 3.0 
mg/kg) 
DA 
Agonist 
I.P. injections 
ten mins 
before testing 
Sprague-Dawley 
rats 
DMTS task using operant chambers 
with delays of 0.1, 3.0, 9.0 & 18.0 
seconds. 
Both drugs - dose dependent impairment in 
performance (significant decrease in accuracy) 
but in a delay independent manner - attention or 
encoding deficit. 
 Amphetamine 
(0.1, 0.3, 0.6 & 1.0 
mg/kg 
DA 
Agonist 
 Analysed data for evidence of 
proactive interference 
Both drugs - proactive interference effect where 
rats were more likely to be influenced by the 
response on the previous trial (confusion between 
trials/task rules implying reference memory 
deficit) 
Breitenstein et 
al. (2006) 
Pergolide 
(0.1 mg) 
DA 
Agonist 
Orally 2 hours 
before testing 
Healthy human 
volunteers 
Acquisition of associative learning 
task  
Significant acquisition impairment.  
Transfer of learning task Significantly impaired transfer of learning. 
 Long-term retention assessed a week 
& a month later 
Significant impairment on both retention tests. 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Chuhan & 
Taukulis 
(2006) 
Methylphenidate 
(MPH) 
(10 mg/kg) 
DA  
Agonist 
Orally Long-Evans rats Object recognition task with 24 hour 
delay (non-spatial episodic memory) 
Significantly less time exploring novel object – 
impaired memory formation. 
Shohmay et al. 
(2006) 
L-dopa 
(normal medical 
dosage) 
DA 
Agonist 
Orally PD patients taking 
L-dopa & PD 
patients who 
ceased medication 
& PD free 
controls 
Acquisition of an associative learning 
task  
L-dopa patients - significant impairment on task 
acquisition.  
   Transfer phase - generalise set of 
response rules 
No effect on transfer learning. 
   Error-correcting feedback learning 
task (shaping condition) 
L-dopa patients - did not differ significantly from 
controls with shaping condition. 
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Author  
(date) 
Drug  
(dose) 
Drug 
Action 
Method of 
Delivery 
Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Montoya et al. 
(2008) 
Apomorphine 
(5 μg/kg) 
DA 
Agonist 
S.C. injections 
10 mins before 
testing 
Healthy human 
volunteers 
Battery of cognitive tasks: 
Source & item recognition test 
Memory interference test 
(assessed proactive interference) 
Categorised words tests 
(immediate recall task) 
Apomorphine administration significantly 
reduced accuracy (compared to controls) on the 
source & item recognition test.  
Suggesting participants given the dopamine 
agonist were impaired at a recognition task & also 
impaired about where they had seen the stimuli. 
Apomorphine administration also significantly 
reduced accuracy on the memory interference 
test.  
Suggesting dopamine manipulation produced 
impairment or confusion on a task measuring 
interference. 
     Go/no-Go test 
(measured inhibitory control) 
Stroop test 
(measures attention & inhibitory 
processes) 
Trail making test 
(assessed visuomotor coordination & 
executive function) 
Verbal fluency test 
(generating words beginning with a 
particular letter or semantic category) 
Accuracy was not significantly reduced on the 
remaining tasks. 
I.M. – intra-muscular I.P. – intraperitoneal S.C. - subcutaneous 
The dopamine agonist amphetamine has also impaired working memory in a 
standard radial maze task but only when a 5 minute delay was introduced into the task 
(Buresova & Bures, 1982). To specifically examine working and reference memory 
processes, Beatty, Bierley and Boyd (1984) utilised the partially baited radial arm 
maze to assess the performance of rats administered amphetamine. Amphetamine 
administration produced a significant increase in both working and reference memory 
errors but only when the paradigm was altered by introducing a delay in between arm 
visits. It thus appears that amphetamine can disrupt memory processes providing there 
is a delay between the to-be-remembered event and testing (Beatty et al., 1984). 
Harper et al. (2005) examined performance on a DMTS task for evidence of 
proactive interference and found for all drugs (amphetamine, cocaine & MDMA) the 
same pattern emerged: as drug dose increased rats were more likely to be influenced 
by the previous response type. Therefore, although previous researchers have 
interpreted this impairment as affecting attention or encoding Harper et al. (2005) 
argued rats did not have impaired attention because this would imply that rats were not 
attending to previous trial events. Instead Harper et al. (2005) argued the rats may 
confuse events between the previous trial and the current trial. This confusion is what 
produced the decrease in accuracy seen with acute MDMA, cocaine and amphetamine 
exposure in DMTS tasks. Thus MDMA and the dopamine agonists actually impair 
reference memory processes as subjects mix up events between trials and become 
confused as to the rules of the DMTS task (Harper et al., 2005). 
In conclusion the finding that drugs and psychological conditions that increase 
dopamine activity as well as those that block or decrease dopamine activity both have 
produced deficits in cognitive performance. This has led researchers to argue that there 
is an optimal level of dopamine required to adequately perform various cognitive tasks 
(Wright & White, 2003). There is substantial evidence that administration of various 
 73 
dopamine agonists disrupt cognitive performance on a number of tasks. However, the 
exact nature of the cognitive impairment produced by drugs that stimulate or mimic 
dopaminergic activity are still unclear. There is some evidence that dopamine plays a 
role in working memory with stimulation of the dopaminergic system disrupting short-
term memory. However, there is also evidence that stimulating the dopaminergic 
system may disrupt procedural and reference memory process as well.  
The Current Investigation 
While there is ample evidence that MDMA administration produces memory 
impairments, to date no one has been able to say whether the memory deficits seen 
when MDMA is administered are due to 5-HT or dopamine release. Identifying the 
role of these two neurotransmitters is important when considering ways of treating or 
ameliorating the drugs effect on cognitive processes. For example it has been 
suggested that administering 5-HT2 antagonists may prevent damage produced by 
large doses of MDMA (Marlberg & Bonson, 2001) but the validity of this depends on 
the extent to which cognitive impairments relate to 5-HT as opposed to dopamine. To 
further examine the effects that neurotransmitters and receptors have on cognition may 
also be helpful in developing pharmacological treatments for learning and memory 
impairments (Meneses, 1999).  
The current study examined whether the reference memory deficit Kay et al. 
(2009) observed in the radial arm maze was due to dopaminergic or serotonergic 
activity within the brain. The review of previous research suggests that 5-HT may play 
a stronger role in working memory processes than reference memory processes. The 
current study utilised the 5-HT and dopamine agonists, Citalopram and GBR12909 to 
examine what effect these drugs have on performance in the radial arm maze. 
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Citalopram is a potent serotonin agonist that works by selectively inhibiting 5-HT 
reuptake thus increasing levels of extracellular serotonin (Majlessi & Naghdi, 2002). It 
is a selective inhibitor of 5-HT and has been described as a useful instrument in 
examining the function of the serotonergic system (Naghdi & Majlessi, 2000).  
GBR12909 is an indirect dopamine receptor agonist (Ellinwood, Davidson,Yu, 
King & Lee, 2002) as it is a dopamine reuptake inhibitor (Baumann, Charr, Goodman, 
Ayestas & Rothman, 1995) which is long lasting (Elmer et al., 1996) and has been 
described as an excellent pharmacological means by which to study the specific role of 
dopamine in psychostimulant effects and reinforcement (Roberts, 1993). 
Based on the literature review it was hypothesised that the acute administration 
of the 5-HT agonist Citalopram would produce a significant increase in working 
memory errors compared to reference memory errors in the radial arm maze. It was 
also hypothesised that due to the role that dopamine function appears to play in 
procedural and reference memory that the acute administration of the dopamine 
agonist GBR12909 would produce significantly more reference memory errors than 
working memory errors.  
 
Method 
Subjects 
The subjects were fourteen white male Sprague-Dawley rats that were twelve to 
thirteen months old at the beginning of the study. These rats had been used previously 
in an Honours research project where they had experienced the training outlined in the 
General Acute MDMA Method. The rats were kept at approximately 85-90% (between 
233 and 281 grams) of their free feeding body weight and began re-training around a 
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week after reaching this weight. They had continuous access to water and were kept on 
a 12:12-hour light:dark cycle and were run during the dark phase of this cycle. 
Apparatus/Materials 
The experiment was carried out in the aluminium maze previously described in 
the general method section and chocolate chips were used as reinforcers. A digital 
stopwatch was used to record the amount of time it took a rat to complete a trial.   
Drugs used were GBR 12909 (10, 20 & 30 mg/kg), Citalopram (15 & 30 
mg/kg), saline (0.9 %) and MDMA (4.0 mg/kg). The Citalopram and MDMA were 
dissolved in saline to the required dose in 0.9 % of saline solution. The GBR 12909 
was also dissolved in the same saline solution. However this drug was more difficult to 
get into solution and was therefore given the additional treatment of gentle heating and 
agitation.  
Procedure 
Subjects completed twelve retraining sessions to bring their performance on the 
task to the criterion of 80% accuracy. The study was a within-subjects experimental 
design with each rat receiving all drug types and doses. All drugs were administered 
via an intraperitoneal (i.p.) injection twenty minutes before running. 
Rats were run in groups where the first four rats were injected and then twenty 
minutes after the first rat was injected all four rats were run in the experiment. Once 
this group had completed running the maze the second group was run and then the 
third group of three rats was run and then the final group of three rats were run. There 
were at least three days between drug sessions. 
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Table 3: Counterbalancing schedule of drug administration 
  Drug Session 
Rat 1 2 3 4 5 6 7 8 9 
C1 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C3 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C4 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C6 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C7 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C8 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C9 Saline Low GBR Hi GBR Saline Low Cital Hi Cital Saline MDMA  GBR 30 mg/kg 
C10 Saline Hi Cital Low Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C11 Saline Hi Cital Low Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C12 Saline Hi Cital Low Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C13 Saline Hi Cital Low Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C14 Saline Low Cital Hi Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C15 Saline Low Cital Hi Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
C16 Saline Low Cital Hi Cital Saline Hi GBR Low GBR Saline MDMA  GBR 30 mg/kg 
          
* Low GBR - GBR12909 10 mg/kg  * Low Cital - Citalopram 15 mg/kg  * Saline - 0.9 mg/kg 
* Hi GBR - GBR12909 20 mg/kg  * Hi Cital - Citalopram 30 mg/kg  * MDMA - MDMA 4.0 mg/kg 
 
 
The maze running procedure was identical to the training phase (outlined in the 
General Acute MDMA Method section) during the drug sessions. Saline 0.9 % was 
used to obtain a baseline measure to compare the other drug doses with. The rats also 
received a dose of 4.0 mg/kg of MDMA to examine if Kay et al.‟s (2009) findings 
would be replicated and to compare session performance with the dopamine and 
serotonin agonists. This dose was chosen as it produced the largest effect in Kay et 
al.‟s (2009) study. 
A complete counterbalance of drug type and dose was not feasible because of 
the difficulties in mixing GBR12909 such that only one dose could be used per testing 
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day. Thus rats were exposed to the drug type and dosage conditions according to a 
modified counterbalancing scheme as shown in Table 1. Following these conditions a 
larger dose of GBR12909 (30 mg/kg) was administered. This condition was included 
as data from the lower doses indicated a pattern of errors consistent with a pattern of 
errors resulting from reference memory impairment albeit less severe, seen with 
administration of MDMA.  
 
Results 
In all figures error bars show standard error of the mean. Data from the three test 
days for each condition were combined. Percent correct figures were calculated by 
averaging across the three daily trials to obtain an average level of performance for the 
session for each rat. The data for the three saline sessions were averaged together as 
visual inspection of the data showed no obvious differences or trends in the data. These 
data are presented in Figure 3 and show that percent correct values decreased in a dose 
dependent fashion for both GBR12909 and Citalopram. However, this figure clearly 
shows that neither of these drugs produced the degree of impairment that MDMA 4.0 
mg/kg produced. 
A one-way repeated measures ANOVA comparing percent correct for saline and 
GBR12909 was conducted. There was a significant effect for dose, F (3, 39) = 6.69, p 
< 0.05 (p = 0.00). A one-way repeated measures ANOVA was also conducted to 
compare percent correct for saline with Citalopram and a significant effect for dose 
was found, F (2, 26) = 5.40, p < 0.05 (p = 0.01). Finally a repeated measures t-test 
revealed a significant effect between saline and MDMA, t (13) = 7.78, p < 0.05 (p = 
 78 
0.00). Therefore, our findings showed that as drug dose increased for all drugs 
accuracy significantly decreased. 
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Figure 3: Average percent correct across all rats for each drug and dose. 
 
 
Mean daily/session trial completion times, in seconds, were calculated for each 
rat by averaging the three trial completion times from each trial for each drug dose. 
Again, the three saline doses were averaged together. Figure 4 indicates that generally 
trial completion times increased as drug dose increased for all drug types, with the 
exception that the highest dose of GBR12909 (30 mg/kg) produced a faster trial 
completion time than the immediately smaller dose. As indicated from the error bars 
some rats were more affected by some doses of the drugs than others. 
A one-way repeated measures ANOVA comparing trial completion times for 
saline and Citalopram revealed a significant effect, F (2, 26) = 5.94, p < 0.05 (p = 
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0.01). A one-way repeated measures ANOVA was also calculated to compare the trial 
completion times for saline with GBR12909 and it also produced a significant effect, F 
(3, 39) = 3.67, p < 0.05 (p = 0.02). Finally a paired samples t-test showed that there 
was a significant effect for trial completion time between saline and MDMA, t (13) = -
5.68, p < 0.05 (p = 0.00). Therefore, as drug dose increased trial completion time was 
significantly affected. 
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Figure 4: Average trial completion time in seconds across all rats for each drug and 
dose. 
 
 
To examine the difference between drugs in terms of the error type the number 
of working memory errors made per session/day for each rat was obtained by adding 
together the number of working memory errors made in the three trials. These figures 
were then converted into percentage error values by taking the mean number of 
working memory errors and dividing by nine, the total number of working memory 
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errors possible. Reference memory errors per session/day for each rat were also 
calculated by summing the number of reference memory errors made across the three 
trials. These figures were then divided by twelve, as this was the maximum number of 
reference memory errors possible. This manipulation was done to take into account 
that a rat could not make as many working memory errors as reference memory errors 
and therefore proportional figures were more representative.  
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Figure 5: Average error percentage of working and reference memory errors across all 
rats for all drug doses. The values given above each bar are the mean number of total 
working or reference memory errors made in each condition across rats. 
 
Group means for these data are presented in Figure 5 and show that saline 
produced very few errors of either type, while the 4.0 mg/kg dose of MDMA produced 
the most errors of both types. Also evident from Figure 5 both MDMA and GBR12909 
produced more reference memory errors than working memory errors, however 
GBR12909 produced less reference memory errors than that seen with MDMA 
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administration. Citalopram in contrast, and as expected tended to produce more 
working memory errors than reference memory errors and the level of working 
memory errors was similar to that seen with MDMA administration.  
Two 2-way repeated measures ANOVAs comparing error type and drug dose 
were used to analyse the data for GBR12909 and Citalopram. GBR12909 
administration produced a significant main effect for error type, F (1, 13) = 65.68, p < 
0.05 (p = 0.00) and a main effect for dose, F (3, 39) = 6.79, p < 0.05 (p = 0.00). There 
was also a significant interaction between error type and dose, F (3, 39) = 6.01, p < 
0.05 (p = 0.00), showing that acute exposure to GBR12909 produced significantly 
more reference memory errors than working memory errors. 
Citalopram administration failed to produce a main effect for error type, F (1, 
13) = 3.25, p > 0.05, (p = 0.10). However, it did produce a significant main effect for 
drug dose, F (2, 26) = 6.31, p < 0.05 (p = 0.01). There was no interaction between error 
type and drug dose, F (2, 26) = 1.12, p > 0.05 (p = 0.34), hence Citalopram 
administration did not result in a significant difference in the type of error made. 
Finally a 2-way repeated measures ANOVA comparing error type with MDMA 
and saline administration was conducted. A main effect for error type was found, F (1, 
13) = 23.70, p < 0.05 (p = 0.00) as well as a main effect for dose, F (1, 13) = 67.37, p < 
0.05 (p = 0.00). There was also a significant interaction between error type and dose, F 
(1, 13) = 24.69, p < 0.05 (p = 0.00) indicating MDMA administration produced 
significantly more reference memory errors than working memory errors. 
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Discussion 
Kay et al. (2009) found acute MDMA administration produced more reference 
memory errors than working memory errors in the radial arm maze. To reiterate, the 
aim of this study was to replicate the acute effects of MDMA on performance in the 
radial arm maze and examine which neurotransmitter system plays a role in producing 
the MDMA induced reference memory effect seen in the radial arm maze. As acute 
MDMA administration produces an increase in both 5-HT and dopamine activity this 
study administered acute doses of both a 5-HT agonist (Citalopram) and a dopamine 
agonist (GBR12909) to examine which neurotransmitter system may be responsible 
for the reference memory effect seen with MDMA exposure. The current study found 
administration of MDMA significantly reduced accuracy and increased trial 
completion time in the radial arm maze. Therefore MDMA significantly disrupted 
performance in a task used to assess memory function. In addition both Citalopram and 
GBR12909 significantly affected accuracy where as the dose of both drugs was 
increased there was a significant decrease in the percent of correct arm choices in the 
maze. Therefore both 5-HT and dopamine stimulation reduced accuracy in the maze 
task. All drugs had an effect on trial completion time with drug administration 
generally increasing the amount of time it took to complete a trial. Once again both 5-
HT and dopamine stimulation produced a significant effect on this measure of 
performance in the maze task. 
The current findings concur with the reviewed animal literature that found that 
5-HT manipulation has impaired performance in terms of accuracy and or the amount 
of time it took subjects to perform tasks that assess memory function such as radial 
arm maze tasks, (Santucci et al., 1996; Winter & Petri, 1987; Egashira et al., 2006; 
Buhot et al., 1995; ) passive avoidance tasks (Santucci et al, 1996; Luttgen et al., 2005; 
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Ahlander-Luttgen et al., 2003; Rowan et al., 1990), DMTS/DNMTS tasks (Warburton 
et al., 1997; Jansen & Andrews, 1994, Herremans et al., 1995), water maze tasks (Carli 
& Samanin, 1992; Carli et al., 1995; Luttgen et al., 2005; Ahlander-Luttgen et al., 
2003; Kant et al., 1996; Rowan et al., 1990; Naghdi & Majlessi, 2000; Majlessi & 
Naghdi, 2002) and a three-way panel task (Ohno et al., 1993). Also our findings are in 
agreement with the reviewed human research that has shown 5-HT manipulation has 
produced deficits in an array of cognitive tasks (Wadsworth et al., 2005; Robbe & 
O‟Hanlon, 1995; Lader et al., 1986; Luciana et al., 1998). 
The current findings also correspond with the reviewed dopamine animal 
literature that indicates that dopamine manipulation produces impairments in accuracy 
and or the amount of time it takes subjects to perform various cognitive tasks such as 
radial arm maze tasks (Buresova & Bures, 1982; Beatty et al., 1984), avoidance tasks 
(Zarrindast et al., 1992), object recognition tasks (Chuhan & Taukulis, 2006), 
DMTS/DNMTS tasks (Wright & White, 2003; Branch & Dearing, 1982; Kesner et al., 
1981; Baron & Wenger, 2001; Harper et al., 2005) as well as conditional position, 
incremental learning task, time sensitivity and motivation (Moyorga et al., 2000).In 
addition these findings concur with human studies that have found that altering 
dopamine function reduces performance on cognitive tasks (Breitenstein et al., 2006; 
Shohmay et al., 2006; Montoya et al., 2008).  
Possibly the most notable finding from the current study was that 
administration of the dopamine agonist GBR12909 produced significantly more 
reference memory errors than working memory errors. Also when MDMA was 
administered in the current study it produced this same pattern of more reference 
memory errors than working memory errors.  
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When MDMA was administered to rats in Kay et al. (2009) they found a 
significant increase in working memory errors in the radial arm maze. However, the 
increase in reference memory errors was significantly greater than that of the working 
memory errors. Therefore as GBR12909 produced significantly more reference 
memory errors in the current study it suggests that the stimulation of the dopaminergic 
system produces the reference memory effect seen in the radial arm maze. While the 
increase in working memory errors with acute exposure to the 5-HT agonist 
Citalopram failed to reach significance it still may be indicative that 5-HT may be 
responsible for the increase in working memory errors seen with the Kay et al. (2009) 
study. However, the conclusion that MDMA induced dopamine stimulation is 
responsible for the reference memory impairments seen with acute MDMA 
administration is tentative and would need to be further examined by pre-treating 
subjects with dopamine and 5-HT antagonists before they were administered MDMA. 
If the stimulation of dopamine levels produced by administering acute MDMA was 
blocked by administering a dopamine antagonist and reference memory errors were 
significantly diminished this would provide additional support that the reference 
memory effect is due to an increase in dopamine levels.  
Many of the reviewed studies failed to differentiate between working and 
reference memory, however of those that did make this distinction, the current findings 
are in agreement with Harper et al. (2005) who found that MDMA administration 
significantly reduced accuracy in a fashion that may be due to a reference memory. 
Harper et al. (2005) also found that several dopamine agonists produced the same 
pattern of impairment in the DMTS task as that of MDMA. This is consistent with our 
finding that the dopamine agonist GBR12909 reduced accuracy in the radial arm maze 
in a similar manner of impairment to that seen with MDMA administration.  
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Beatty et al. (1984) found that the dopamine agonist d-amphetamine produced 
an increase in both working and reference memory errors in the radial arm maze but 
only if a delay was introduced into the paradigm. While our study also found that a 
dopamine agonist did produce an increase in reference memory errors it did not 
produce a significant increase in working memory errors. Also unlike their study we 
did not have to introduce a delay into our procedure to obtain a significant decrease in 
accuracy in the maze. However it could be that the increase in trial completion time 
seen with drug administration may act like introducing a delay into the paradigm. 
The finding that dopamine agonists may produce reference memory 
impairments concur with studies that have examined human performance in tasks that 
involve dopamine such as assessing source recognition and proactive interference 
(Montoya et al., 2008) and procedural memory tasks (Thomas et al., 1996; Thomas-
Ollivier et al., 1999). However our findings conflict with those of Buhot et al. (1995) 
who found that a 5-HT agonist produced significantly more reference memory errors 
than working memory errors in the radial arm maze and Santucci et al. (1996) who 
found that there was a significant increase in both working and reference memory 
errors in the radial arm maze during the 5-HT release phase of p-chloroamphetamine. 
Of the studies that specifically differentiated between working and reference 
memory and 5-HT function our findings are conflict with those that found that 5-HT 
stimulation produced a significant increase in working memory errors (Santucci et al., 
1996; Ohno et al., 1993). Although the administration of the 5-HT agonist Citalopram 
failed to produce a significant increase in working memory errors we did find evidence 
that suggests that 5-HT did significantly disrupt accuracy in the radial arm maze and 
this to a certain extent may involve working memory.  
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While the findings of the current study provide evidence that the dopaminergic 
system may be responsible for producing the reference memory effect seen in the 
radial arm maze, it is important to note that the effect that we witnessed with acute 
exposure to GBR12909 was clearly not as strong as that seen with MDMA exposure. 
There may be several reasons as to why this occurred. One possible explanation is that 
in order to produce the same level of impairment as that seen with acute MDMA 
administration it is necessary to activate both serotonin and dopamine activity. It may 
be that there is an additive or synergistic effect to the dopaminergic and the 
serotonergic system when MDMA is administered.  
In addition it has been found that there is a relationship between serotonin and 
dopamine release. For example the serotonin receptor 5-HT2C seems to play a role in 
the control of dopaminergic functioning within the brain (DiMatteo, Cacchio, DiGiulio 
& Esposito, 2002). Colado et al. (2006) also reported that 5-HT2 receptors enhance the 
dopamine release found with acute exposure to MDMA. Therefore, it may be that the 
effects of acute MDMA on each neurotransmitter system may be very difficult to 
differentiate as the two appear to interact. 
Another explanation for the smaller reference memory effect with acute 
administration of GBR12909 compared to MDMA was that we did not use a large 
enough dose of GBR12909. It may be that a larger dose of GBR12909 could have 
produced more comparable results with that of MDMA. However, this was not 
performed due to the difficulties in getting the GBR12909 into solution. Also the 
GBR12909 did produce a significant effect on trial completion time indicating that the 
drug was affecting performance in the radial arm maze.  
It could also be useful to examine whether a larger dose of Citalopram would 
produce a stronger effect on working memory errors in the radial arm maze. We only 
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examined the effects of two doses of this drug whereas we used three different doses of 
GBR129009. However, with the two doses of Citalopram that we did use we obtained 
a significant effect on trial completion time that was comparable with that of the acute 
MDMA treatment. Therefore it could be argued that the drug was definitely having 
some pharmacological effect which was evident on performance in the maze.  
There are many different 5-HT receptors. 5-HT receptors have been divided into 
families and subtypes which are 5-HT1A/1B/1D/1E/1F, 5-HT2A/2B/2C, 5-HT3A/3B, 5-
HT4A/4B/4C/4D, 5-HT5A/5B, 5-HT6 and 5-HT7A/7B/7C/7D (Meneses, 1999). Therefore there 
are seven classes of 5-HT receptors each with its own distribution and function in the 
brain. This makes research challenging because there are several different ways to 
increase or decrease serotonin levels in the brain and therefore it can be difficult to tell 
which drugs act on which 5-HT receptors. It also is problematic in that it is difficult to 
ascertain which 5-HT receptors are involved in which behavioural functions. There is 
the possibility that Citalopram may be too general in its pharmacological agonist 
effects as there is a reasonable amount of evidence suggesting that it may specifically 
be the 5-HT1A receptor that plays a pivotal role in memory processes. 
For example the serotonin agonist 8-OH-DPAT impaired performance on the 
Morris Water Maze indicating that it affects spatial learning (Carli & Samanin, 1992). 
Similarly Carli et al. (1995) found acute administration of 8-OH-DPAT significantly 
impaired performance on a spatial memory task using the water maze paradigm. Kant 
et al. (1996) also examined the effects of serotonin agonists 8-OH-DPAT on 
performance using a modified Morris water maze. Stimulation of the 5-HT1A receptors 
impaired performance leading Kant et al. (1996) to argue that serotonin and 5-HT1A 
receptors in particular, seem to play an important role in memory and learning. In 
particular relevance to the current study Winter and Petti (1987) found 8-OH-DPAT 
produced significant decreases in efficiency in the radial arm maze. This may be of 
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importance as this drug is a 5-HT1A agonist which may play a role in memory function 
due to the large number of receptors found in the hippocampus, an area which has been 
found to play a role particularly in spatial memory (Winter & Petti, 1987). Therefore 
one possible reason why Citalopram did not produce a significant effect on working 
memory errors is that Citalopram may not be specific enough in its action on 5-HT1A 
receptors.  
Serotonin may also play a role in reference memory to a certain extent as Buhot 
et al. (1995) found that administration of the 5-HT1B agonist CP-93,129 produced more 
reference memory errors than working memory errors in the radial arm maze. 
Therefore, reference memory errors may not have been produced due to Citalopram 
not acting specifically on 5-HT1B receptors. Buhot (1997) also argues that 
manipulating serotonin non-specifically is problematic because serotonin has so many 
functions that it may alter other processes and behaviours that will affect performance 
rather than affecting memory per se. She further argued that manipulating the whole 
serotonergic system in a global manner is also not ideal as it can produce interactions 
with other neurotransmitter systems. Buhot (1997) suggested activating specific 
serotonin receptors to produce more comprehensive knowledge of the relationship 
between brain structures and cognitive processes. Therefore, it may not be ideal using 
a general serotonin agonist such as Citalopram when examining the cognitive effects 
of serotonin activation in the radial arm maze.  
It may be useful for future research to examine the effects of other dopamine and 
serotonin agonists. Both agonist drugs used in the current study were reuptake 
inhibitors that work by preventing the neurotransmitters being taken back up into the 
pre-synaptic membrane and hence allowing the neurotransmitter to stay active in the 
synapse longer (Meneses & Hong, 1995). Therefore, these drugs are termed indirect 
agonists as they do not directly affect the release of the neurotransmitters. It may be 
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that different results would be produced by using different types of agonists that 
operate differently for example although MDMA does work by inhibiting reuptake of 
serotonin it also produces serotonin release from the pre-synaptic membrane (Malberg 
& Bonson, 2001). Similarly in rats MDMA produces the release of dopamine from 
cerebral tissue (Colado et al., 2004).Therefore, MDMA does not necessarily function 
the same way as Citalopram and GBR12909 and may not be able to encompass all the 
pharmacological effects that acute administration of MDMA produces. It could be 
useful to use agonists that produce dopamine and serotonin release in a more similar 
manner to that of acute MDMA exposure to ascertain whether the same effects on 
working and reference memory would be produced as those seen with administration 
of Citalopram and GBR12909. 
The methodology of the current study had some potential flaws. Unfortunately 
the counterbalancing procedure was not ideal as due to technical difficulties we did not 
observe a very strict counterbalancing regime. This was due to the difficulty in 
dissolving the GBR12909 into solution as well as the impracticality of having to mix 
more than one drug solution up per day. It could also be beneficial to repeat the doses 
of each drug we used to clarify our findings to control for any extraneous variables that 
may have been present in a particular testing session. 
As the current study suggested that stimulating dopamine activity appears to 
impair reference memory performance it may be advantageous to examine this finding 
further as there are several dopamine receptor types. Future study could examine 
whether the reference memory effect in the radial arm maze is due to either D1 or D2 
receptor agonists. It would also be beneficial to further support these findings by 
administering dopamine and serotonin antagonists along with MDMA administration 
to see if blocking the activation of the dopamine and serotonin systems can attenuate 
the reference memory effect seen in the radial arm maze. If indeed the administration 
 90 
of a MDMA and a dopamine antagonist does indeed reduce the amount of reference 
memory errors than MDMA administration alone it could corroborate the role of 
dopamine activity in reference memory.  
In conclusion the current study examined radial arm maze performance in a 
paradigm that differentiates between working and reference memory. This study 
replicated the findings of Kay et al. (2009) that found acute exposure to MDMA 
significantly reduced accuracy in the maze and also produced significantly more 
reference memory errors than working memory errors. In addition the current study 
discovered that acute administration of the serotonin agonist Citalopram significantly 
reduced accuracy. It also found that the acute administration of the dopamine agonist 
GBR12909 significantly reduced accuracy in the maze and specifically produced more 
reference memory errors than working memory errors.  
Therefore the main finding of this study was that it appears that stimulation of 
dopaminergic activity may be responsible for the reference memory effect in the radial 
arm maze seen with acute exposure to MDMA. Therefore dopamine activity seems to 
play an important role in reference memory which involves a long-term form of 
memory that entails the learning of task rules. However it is still unclear as to the 
underlying causes of this reference memory effect. It could be due to a long term 
memory retrieval problem, an impairment or confusion with the rules of the memory 
task or the result of proactive interference. 
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Study 2: D1 and D2 Agonists in the Radial Arm Maze 
While many studies have found evidence that dopamine plays an important role 
in motor function and motivation the actual function that dopamine participates in with 
respect to memory processes is less clear (Bushnell & Levin, 1993). To make matters 
more complicated there are several different subtypes of dopamine receptor which are 
D1, D2, D3, D4 and D5 (Vallone et al., 2000). These five receptor types are divided into 
two main subclasses which are D1-like and D2-like receptors (Jaber et al., 1996). These 
divisions are made on the basis of biochemical and pharmacological properties 
(Vallone et al., 2000). The D1-like family of dopamine receptors include the D1 and D5 
receptors while the D2-like family consists of the D2, D3 and D4 receptors (Vallone et 
al., 2000). The number of dopamine receptors that exist makes it difficult to determine 
what role each dopamine receptor plays in cognition.  
There is some evidence that different behaviours are associated with different 
dopamine receptors. For example the D2-like family have been related to the 
psychological disorder schizophrenia (Farde, 1997) and the emotional high associated 
with the use of stimulant drugs of abuse (Liechti & Vollenweider, 2001). Whereas the 
D1-like family have been associated with locomotion (Jaber et al., 1996) and executive 
function, which involves learning and memory (Roesch-Ely et al., 2005). However 
there is also some evidence that D2 receptors may play an important role in cognition. 
For example while there are a large number of D1 receptors in important cognitive 
areas like the prefrontal cortex (PFC) there are also some D2 receptors in this area 
(Muller, von Cramon & Pollmann, 1998). In addition there are both D1 and D2 
receptors found in the hippocampus which is an area of the brain that is important in 
memory function (Umegaki et al., 2001). It is also thought that D2 receptors may play 
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a role in working memory based on the findings that administering D2 agonists alter 
memory performance possibly via the striatum (Ellis et al., 2005). However, it is not 
fully known whether the different dopamine receptors are involved in different roles of 
cognitive processing (Levin & Bowman, 1986). Also it still remains uncertain as to 
whether stimulation of various dopamine receptors produces improvements or 
impairments in memory performance (Zarrindast et al., 1992). 
It has been argued that some cognitive functions such as working memory 
operate within an optimal level of dopamine activity where either too much or too little 
dopamine activity produces impairment (Williams & Castner, 2006). Thereby it is 
possible to examine dopamine receptor function by utilising either dopamine 
antagonists or agonists. As Study 1 found dopamine manipulation appeared to be 
produce the reference memory impairment seen in the radial arm maze task, the 
current study examined which dopamine receptor type might contribute to this 
reference memory impairment.  
A common method of examining what roles different dopamine receptors play 
in cognition involves administering various dopamine receptor agonists or antagonists 
before subjects are tested on various cognitive tasks. Unfortunately for the purpose of 
the current study many of the tasks that are used to assess memory and cognition are 
confounded as they measure both working and reference memory. Hence to review the 
role of D1 and D2 receptors in cognition is it necessary to look at tasks that claim to 
assess various cognitive functions including working memory as often these paradigms 
assess reference memory as well. The effects of D1 and D2 receptor manipulation on 
cognition are summarised in Table 4. 
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Table 4: Summary of research on the effects of D1 and D2 agonists and antagonists on cognition. 
Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Levin & 
Bowman 
 (1986) 
Quinpirole 
(0.03 to 1.0 
mg/kg) 
D2 Agonist I.P. injection Rats Standard 8 arm radial 
maze (all arms baited) 
Significant impairments in arm entries & 
latencies 
Sawaguchi & 
Goldman-
Rakic (1991) 
SCH23390  
(10 to 80 µg) 
D1 Antagonist Injected  into 
dorsolateral PFC 
Rhesus monkeys Delayed (1.5 to 6 
seconds) working 
memory oculomotor task 
(DMTS using eye 
movement) 
Both D1 antagonists - increase in errors & 
latency 
SCH39166 
(1 to 10 µg) 
D1 Antagonist   
Raclopride 
(100 µg) 
D2 Antagonist   D2 antagonist – no effect on performance 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Zarrindast et 
al. (1992) 
SKF38393 
(2 to 16 mg/kg) 
D1 Agonist I.P. injection 30 
minutes before 
testing except for 
SCH23390 via S.C. 
injection 
Albino mice Active avoidance learning 
task using mild foot 
shock. Testing 24 hours 
later to measure retention 
(assessed long-term 
retrieval) 
SKF38393 improved retention 
performance. 
 Bromocriptine 
(4 to 32 mg/kg)  
D2 Agonist  Low doses of bromocriptine improved 
performance & high doses significantly 
impaired.  
 Quinpirole 
(0.25 to 2 
mg/kg)  
D2 Agonist  Quinpirole no significant effect.  
 SCH23390 
(0.025 to 0.1 
mg/kg)  
D1 Antagonist  
 
  Low doses of SCH23390 significantly 
impaired performance & higher doses had 
no effect.  
 Sulpiride 
(20 to 60 
mg/kg)  
D2 Antagonist  
 
  Low doses of sulpiride significantly 
impaired performance & higher doses had 
no effect.  
SCH23390 pre-treatment reduced the 
improvements seen with SKF38393 but 
sulpiride pre-treatment had no effect. 
Sulpiride pre-treatment reduced the 
impairment produced by bromocriptine. 
Pre-treatment with SKF38393 before 
bromocriptine increased impairment 
suggesting both D1 & D2 receptors involved 
in task performance. 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Bushnell & 
Levin 
 (1993)  
D-amphetamine 
(0.30 to 1.0 
mg/kg)  
General 
Dopamine 
agonist  
I.P. injection  Rats  
 
DNMTS trials (assessing 
spatial working memory)  
Visual discrimination 
trials (like DMTS task 
except correct answer was 
cued by a light – assessed 
reference memory)  
Dopamine agonist - significant impairment 
in working memory  
 SKF38393 
(1.0, to 3.0 
mg/kg)  
D1 Agonist    D1 agonist - no significant impairment in 
either task  
 SCH23390 
(0.010 to 0.024 
mg/kg)  
D1 Antagonist   D1 antagonist - no significant impairment in 
either task  
 Quinpirole 
(0.010 to 0.056 
mg/kg)  
D2 Agonist 
 
  D2 agonist - significant impairment in 
working memory  
 Raclopride 
(0.056 to 1.0 
mg/kg)  
D2 Antagonist  
 
   D2 antagonist - no significant impairment in 
either task  
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Sawaguchi & 
Goldman-
Rakic  
(1994) 
Haloperidol 
(10 to 100 µg) 
General DA 
Antagonist 
Injected into 
dorsolateral PFC 
Rhesus monkeys Delayed (1.5 to 6 
seconds) working 
memory oculomotor task 
(DMTS using eye 
movement) 
Haloperidol - significant decrease in 
accuracy & increase in latency 
SCH23390 
(10 to 80 µg) 
D1 Antagonist   SCH23390 - significant decrease in 
accuracy & increase in latency 
SCH39166 
(1 to 5 µg) 
D1 Antagonist   SCH39166 - significant decrease in 
accuracy & increase in latency 
Raclopride 
(100 µg) 
D2 Antagonist   Raclopride – no significant effect  
Sulpiride 
(50 to 100 µg) 
D2 Antagonist   Sulpiride – no significant effect 
Arnsten et al. 
(1994) 
SKF38393 
(0.001 to 0.5 
mg/kg) 
D1 Agonist I.M. injections Young healthy 
rhesus moneys 
Young 
experimentally 
dopamine 
depleted monkeys 
Elderly monkeys 
(natural dopamine 
depletion) 
Delayed response testing 
(had to remember location 
of reinforcer over various 
delays – working 
memory) 
SKF38393 - low doses produced significant 
improvement. Higher doses - significant 
impairment. 
 Dihydrexidine 
(0.001 to 1.0 
mg/kg) 
D1 Agonist  Dihydrexidine - significant improvement in 
young monkeys but impaired the majority 
of elderly monkeys. 
 SCH23390 
(0.001 to 0.1 
mg/kg) 
D1 Antagonist   SCH23390 impaired performance in young 
monkeys - no effect on elderly monkeys. 
 Pre-treatment with SCH23390 blocked the 
improvements & impairments produced by 
both D1 agonists 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Arnsten et al. 
(1995) 
Quinpirole 
(0.0001 to 1.0 
mg/kg) 
D2 Agonist I.M. injections 1 
hour before testing 
Young healthy 
rhesus monkeys 
Young 
experimentally 
DA depleted 
monkeys 
Elderly monkeys 
(natural DA 
depletion) 
Delayed response testing 
(had to remember location 
of reinforcer over various 
delays – working 
memory) 
Quinpirole - small doses significantly 
impaired young monkeys & higher doses 
improved performance. 
Quinpirole – no overall significant effect in 
elderly monkeys. 
Pretreatment with SCH23390 did not 
reverse impairments produced by low doses 
of quinpirole but did reverse improvements 
seen with high doses. 
Pretreatment with Raclopride reduced the 
impairments & improvements seen with 
quinpirole administration 
 SCH23390 
(0.0065 mg/kg) 
D1 Antagonist 
 
 
 Raclopirde 
(0.001 to 0.2 
mg/kg) 
D2 Antagonist 
 
 
Cai & 
Arnsten 
(1997) 
A77636 
(0.001 to 0.1 
mg/kg) 
D1 Agonist I.M. injections 1 
hour before testing 
Elderly rhesus 
monkeys 
(natural DA 
depletion) 
Delayed response testing 
(had to remember location 
of reinforcer over various 
delays – working 
memory) 
Both D1 agonists - lower doses significantly 
improved & higher doses significantly 
impaired. 
 SKF81297 
(0.001 to 0.1 
mg/kg) 
D1 Agonist  Pre-treatment with D1 antagonist reversed 
the improvements & impairments for both 
agonists. 
 SCH23390 
(10 μg/kg) 
D1 Antagonist   
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Luciana & 
Collins 
(1997) 
Bromocriptine 
(1.25 & 2.5 mg) 
D2 Agonist Orally Healthy human 
volunteers 
Spatial task – delayed 
matching to position task  
Non-spatial task (object 
memory) – delayed 
matching to sample using 
geometric stimuli 
Bromocriptine - improved spatial task 
performance. 
Haloperidol 
(3 mg) 
D2 Antagonist   Haloperidol - impaired spatial task 
performance. 
Neither drug affected performance on non-
spatial task 
Zahrt et al. 
 (1997) 
SKF81297 
(0.01 & 0.1 µg) 
D1 Agonist Cannulae infusion 
into PFC 
Sprague-Dawley 
rats 
Delayed alternation T-
Maze task 
D1 agonist - increase in errors & no increase 
in latency 
SCH23390 
(0.01 & 0.03 
mg/kg) 
D1 Antagonist I.P. injection   Pre-treatment with D1 antagonist before the 
D1 agonist – no impairment 
Seamans et 
al. (1998) 
SCH23390 
(0.05 to 5 µg 
/µl) 
D1 Antagonist Infusion into PFC Rats Delayed win-shift task 
using an 8 arm radial 
maze 
D1 antagonist - significantly more errors 
 Sulpiride 
(0.05 to 5 µg 
/µl) 
D2 Antagonist   D2 antagonist – no significant effect 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Wilkerson & 
Levin  
(1999) 
Quinpirole 
(1.1 to 10 
µg/side) 
D2 Agonist Local infusions into 
ventral 
hippocampus 
Sprague-Dawley 
rats 
Standard 8 arm radial 
maze  (all arms baited) 
Quinpirole – significant improvement 
 Raclopride 
(0.19 to 1.67 
µg/side) 
D2 Antagonist    Raclopride - significant impairment 
 Dihydrexidine 
(1.1 to 10 
µg/side) 
D1 Agonist    Dihydrexidine – no significant effect 
 SCH23390 
(0.19 to 1.67 
µg/side) 
D1 Antagonist    SCH23390 – no significant effect 
Druzin et al. 
(2000)  
PPHT 
(0.004, 0.04 & 
0.4 μg/1μl) 
D2 Agonist Bilateral micro-
infusions into PFC  
Wistar rats U-maze - DMTS task 
with 0 & 3 second delays.  
RE errors – incorrectly 
entering same arm as 
previous trial. 
AE errors – incorrectly 
entering alternate arm as 
previous trial. 
PPHT - significantly impaired delayed trials 
(more RE errors than AE errors - 
perseveration impairment, possibly due to 
impaired executive functioning). 
 Sulpiride  
(0.03, 0.3 & 3 
μg/1μl) 
D2 Antagonist   Sulpiride - significantly improved delayed 
trials (more AE errors than RE errors) 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Mehta et al. 
(2001) 
Bromocriptine 
(1.25 mg) 
D2 Agonist Orally Healthy human 
volunteers 
Reward–responsitivity 
task (assessed motivation) 
No effect on motivation task 
     Pattern recognition  No effect on pattern recognition.  
     Spatial recognition  No effect on spatial recognition.  
     Spatial memory span  Significant improvement in spatial span 
performance.  
     Self-ordered spatial 
working memory task  
No significant effect on spatial working 
memory performance.  
     Tower of London task  No significant effect on planning.  
     Probabilistic reversal task  Significant impairment in probabilistic 
reversal performance.  
     Concurrent reversal task  No significant effect on concurrent reversal 
performance  
Kozlov et al. 
(2001) 
SKF38393  
(1 nmol) 
D1 Agonist Microinjections into 
medial frontal 
cortex 
Wistar rats Delayed alternation Y 
maze take 
D1 Agonist – short delays no effect. Longer 
delays – significant improvement. 
 SCH23390 
(1 nmol) 
D1 Antagonist   Short & long delays D1 antagonist – 
significant impairment. 
Floresco et 
al. (2001) 
SKF81297  
(0.05 to 0.20 µg 
/0.5 µl saline) 
D1 Agonist Cannulae infusion 
into PFC 
Rats Delayed win-shift task 
using an 8 arm radial 
maze  
30 minute delay - significant impairment & 
12 hour delay – significant improvement. 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Umegaki et 
al. (2001) 
Raclopride 
(8 µg/kg) 
D2 Antagonist Cannulae infusion 
into hippocampus 
Fischer-344 rats 14 unit T-maze 
(used aversive foot shock 
to move through maze) 
D2 Antagonist - significantly more errors 
 Quinpirole 
(8 µg/kg) 
D2 Agonist Cannulae infusion 
into hippocampus 
 D2 Agonist - on its own did not produce 
significant impairment 
 Raclopride (8 
µg/kg) & 
Quinpirole  
(0.5 mg/kg) 
 Pretreatment via I.P. 
injection 
 Pretreatment with D2 agonist - ameliorated 
previous impairment 
Liao et al. 
(2002) 
SCH23390 
(0.05 & 0.10 
mg/kg) 
D1 Antagonist I.P. injection 1 hour 
before testing 
Wistar rats Partially baited 8 arm 
radial maze:  
Place task – 4 arms of 
maze consistently baited 
used extra maze cues. 
Assessed spatial memory. 
SCH23390 & Haloperidol - significant 
increase in number of arms entered & time 
taken to complete a trial. 
 Spiperone 
(0.05 & 0.10 
mg/kg) 
Selective D2 
Antagonist 
  Spiperone – no effect on performance 
 Haloperidol 
(0.08 & 0.16 
mg/kg) 
Non-selective 
D2 Antagonist 
  Cue task – 4 arms of maze 
baited that changed each 
trial & signalled using 
within maze cues. 
Assessed non-spatial 
memory. 
Cue task - all drugs had no effect on the 
arms entered. All drugs increased time 
taken to complete a trial (significant motor 
impairment rather than memory deficit.) 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Gibbs & 
D‟Esposito 
(2005) 
Bromocriptine 
(1.25 mg) 
D2 Agonist Orally Healthy Human 
Volunteers 
Spatial working memory 
tasks - delayed matching 
to location, delayed 
nonmatching to location 
& delayed matching to 
object. 
D2 Agonist - significant impairment in all 
tasks 
fMRI scan    fMRI - decrease in brain activity during 
encoding 
Stuchlik & 
Vales  
(2006) 
A77636 
(0.1 to 1.0 
mg/ml) 
D1 Agonist IP injection 20 mins 
before testing 
Long-Evans rats Allothetic place 
avoidance task (placed on 
rotating circular platform 
& had to evade foot 
shock).  
D1 agonist - significantly less errors & 
increase in activity 
SCH23390 
(0.02 & 0.05 
mg/ml) 
D1 Antagonist   D1 antagonist - significantly more errors & 
decrease in activity 
Von Huben 
et al.  
(2006) 
SCH23390 
(3.2 to 5.6 
μg/kg) 
D1 Antagonist IM injections  Rhesus monkeys Progressive ratio schedule 
task  
Both drugs - reduction in responding.  
   Bimanual motor skill task Both drugs – impaired motor ability. 
 Raclopride 
(10 to 56 μg/kg) 
D2 Antagonist   Rotating turntable task 
(motor coordination) 
Both drugs - impaired coordination. 
    Self-ordered spatial 
search task 
Raclopride - impaired performance. 
SCH23390 – no significant effect. 
     Visuo-spatial paired 
associates learning task 
Raclopride – significant impairment. 
SCH23390 – no significant effect. 
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Author 
(date) 
Drug  
(dose) 
Drug Action Method of Delivery Subjects/ 
Participants 
Cognitive Task/s Results/Memory Effects 
Lumme et al. 
(2007) 
PET scan Measuring 
D2/D3 receptor 
activity 
 Healthy human 
volunteers 
Wisconsin card sorting 
task (executive 
functioning & abstract 
reasoning) 
Errors were correlated with high D2/D3 
receptor binding suggesting involvement in 
executive functioning. 
Rinaldi et al. 
(2007) 
SCH23390 
(6.25, 12.5 &  
50 ng) 
D1 Antagonist Bilateral injections 
into PFC 
CDI mice Spatial recognition test  Both drugs – time spent visiting displaced 
& non-displaced objects were not 
significantly different (spatial memory 
impairment). 
 Sulpiride 
(12.5, 50 &  
100 ng) 
D2 Antagonist 
 
  Object recognition test Both drugs – no effect on time spent 
visiting novel object (no object recognition 
impairment) 
Boulougouris 
et al. 
 (2009) 
Quinpirole 
(0.1 & 0.3 
mg/kg) 
D2 Agonist I.P. injection 20 
mins before testing 
Lister Hooded rats 2 lever reversal task – one 
lever reinforced the other 
not. Once criterion 
reached levers were 
switched & ability to 
change behaviour was 
assessed. 
Quinpirole - no significant effect on 
acquisition but significantly impaired 
reversal learning (perseverative errors). 
 Raclopride 
(0.1 & 0.3 
mg/kg) 
D2 Antagonist   Raclopride - significantly impaired 
acquisition but not reversal. 
Pre-treatment with raclopride attenutated 
impairments produced by quinpirole. 
I.M. – intra-muscular injection I.P. – intraperitoneal PFC – prefrontal cortex S.C. – subcutaneous  DA - dopamine 
The Role of D1 Receptors in Cognition: Evidence From Humans and Monkeys 
Within the cortical structures of the primate brain the PFC has the highest 
concentration of dopamine (Sawaguchi & Goldman-Rakic, 1994). PFC dopamine 
depletion produces memory impairments in monkeys suggesting dopamine receptors 
are involved in memory processes (Sawaguchi & Goldman-Rakic, 1991). Within the 
PFC there is an abundance of D1 receptors but low levels of D2 receptors suggesting 
D1 receptors may play a more pivotal role in mnemonic processes (Sawaguchi & 
Goldman-Rakic, 1991). There are no studies examining D1 receptor manipulation in 
humans as there is no selective D1 agonist that can be administered to human 
participants (Barch, 2004). Administering D1 antagonists to Rhesus monkeys 
significantly impairs performance on working memory tasks while D2 antagonists do 
not (Sawaguchi & Goldman-Rakic, 1991; Sawaguchi & Goldman-Rakic, 1994). Thus 
D1 receptors in the PFC may have a more prominent role in working memory than D2 
receptors (Sawaguchi & Goldman-Rakic, 1994). As humans and monkeys age there is 
a noticeable loss of dopamine in the PFC (Arnsten, Cai, Murphy & Goldman-Rakic, 
1994) and this correlates with a marked decrease in PFC cognitive functioning (Cai & 
Arnsten, 1997). Therefore researchers have used elderly monkeys to study the role that 
dopamine receptors play in cognition. Administering D1 agonists has impaired 
cognitive performance in elderly monkeys suggesting D1 activity may be involved in 
cognitive performance (Arnsten et al., 1994; Cai & Arnsten, 1997).  
The Role of D1 Receptors in Cognition: Evidence From Rats 
The reviewed research in Table 4 has found evidence that altering D1 activity 
sometimes improves cognitive performance (Stuchlik & Vales, 2006; Floresco & 
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Phillips, 2001). However the majority of animal research suggests that altering 
dopamine activity by administering D1 agonists and antagonists impairs performance 
on cognitive tasks (Stuchlik & Vales, 2006; Zahrt, Taylor, Mathew & Arnsten, 1997; 
Seamans, Floresco & Phillips, 1998; Floresco & Phillips, 2001; Kozlov, Druzin, 
Kurzina & Malinina, 2001).  
These cognitive impairments include deficits in spatial memory in an 
avoidance task (Stuchlik & Vales, 2006), impairments in spatial memory in the radial 
arm maze (Seamans et al., 1998; Floresco & Phillips, 2001), deficits in spatial working 
memory and the ability to learn an alternation rule in a T-maze (Zahrt et al., 1997) and 
a Y-maze (Kozlov et al., 2001). While T-maze and Y-maze tasks are often used to 
assess working memory they do contain the learning of a fixed rule that subjects need 
to alternate their arm choices and hence these tasks do contain a reference memory 
component (Frick et al., 1995) which appears to be disrupted by D1 receptor 
manipulation. 
Administration of D1 agonists has produced perseverative responding 
indicative of an impairment in PFC functioning (Zahrt et al., 1997). Perseverative 
responding is a pattern of impairment that has also been found with acute MDMA 
exposure in rats (Frederick & Paule, 1997) and may be the result of an impairment in 
understanding task rules indicating a reference memory type impairment. In addition 
manipulation of D1 receptor activity by administering D1 antagonists has produced 
evidence of proactive interference (Kozlov et al., 2001). As it has been argued that the 
impairments produced by MDMA administration, which increases dopamine activity, 
could be the result of proactive interference (Harper et al, 2005 & 2006). It could be 
useful to further examine this phenomenon using dopamine agonists that increase 
dopamine activity rather than antagonists which decrease it. In addition Zahrt et al. 
(1997) found the memory impairment produced by the administration of D1 agonists 
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was attenuated with the pre-treatment of D1 antagonists (Zahrt et al., 1997) suggesting 
the effects were due to D1 receptor manipulation and not general drug effects. In 
conclusion researchers have argued that there is an optimal level of D1 receptor activity 
for successful cognitive functioning where either over stimulation or inadequate 
stimulation of D1 receptors seems to impair cognitive processing (Cai & Arnsten, 
1997). However it is not clear whether working or reference memory processes are 
more affected by manipulating D1 receptor activity. 
The Role of D2 Receptors in Cognition: Evidence From Humans and Monkeys 
Some researchers have argued that the role of D1 receptors in cognitive 
functioning is well established (Lumme, Aalto, Ilonen, Nagren & Hietala, 2007) and 
the role that D2 receptors play in cognition is unclear (Lumme et al., 2007). However 
others have argued D2 receptors may play a key role in cognitive functioning 
(VonHuben et al., 2006) and more research on the role of D2 receptors is needed 
(Luciana et al., 1997). Research using human participants has found manipulating D2 
receptor activity alters performance on spatial memory tasks (Luciana & Collins, 
1997) and probabilistic reversal learning (Mehta, Swainson, Ogilvie, Sahakian & 
Robbins, 2001). This suggests stimulation of D2 receptors may impair the learning of 
task rules indicating a reference memory deficit. Further evidence that dopamine plays 
an important role in cognition comes from imaging studies. Using PET scans Lumme 
et al. (2007) found errors produced while participants performed the Wisconsin Card 
Sorting Task were correlated with high D2/D3 receptor bindings. This indicates these 
receptors may play a role in rule formation suggesting an involvement in reference 
memory processing. In addition Gibbs and D‟Esposito (2005) found a D2 agonist 
significantly impaired spatial working memory performance and fMRI imaging 
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showed a decrease in brain activity during encoding which may account for the 
impairments. Manipulating D2 receptor activity in rhesus monkeys has also impaired 
working memory (Arnsten, Cai, Steere & Goldman-Rakic, 1995; Von Huben et al. 
2006), attention, reinforcer efficacy, motivation and associative memory (Von Huben 
et al., 2006). Therefore, Von Huben et al. (2006) suggested that D2 receptors may play 
a more pivotal role than D1 receptors in these processes. 
The Role of D2 Receptors in Cognition: Evidence From Rats 
Manipulating dopamine activity by altering D2 receptor activity has produced 
mixed results. There are some studies which have found that utilising D2 receptor 
agonists and antagonists have had no affect or improved memory performance 
(Bushnell & Levin, 1993; Wilkerson & Levin, 1999; Druzin, Kurzina, Malinina & 
Kozlov, 2000; Umegaki et al., 2001; Boulougouris, Castane & Robbin, 2009). 
However the majority of research suggests that manipulating D2 receptor activity has 
impaired performance on a variety of cognitive tasks (Levin & Bowman, 1986; 
Bushnell & Levin, 1993; Wilkerson & Levin, 1999; Druzin et al., 2000; Umegaki et 
al., 2001; Boulougouris, et al., 2009) 
These impairments include deficits in several areas of cognition such as 
reversal learning (Boulougouris et al., 2009), spatial learning in a 14 unit T-maze 
(Umegaki et al., 2001) spatial memory and executive functioning in a DMTS U-maze 
task ( Druzin et al., 2000), spatial working memory in the radial arm maze (Levin & 
Bowman, 1986; Wilkerson & Levin, 1999) and working memory in a DNMTS task 
(Bushnell & Levin, 1993). In addition D2 receptor manipulation has also been shown 
to produce a perseverative pattern of responding in a reversal learning task 
(Boulougouris et al., 2009) and in a U-maze task (Druzin et al., 2000). Therefore it 
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would seem increasing D2 receptor activity produces perseveration in rule based tasks 
indicative of a reference memory impairment which has also been found with acute 
MDMA administration (Frederick & Paule, 1997). Therefore manipulation of D2 
activity has been found to alter both reference and working memory processes.  
One study that has examined the effects of dopamine manipulation on 
cognition that has specifically tried to differentiate between working and reference is 
that of Bushnell and Levin (1993). Visual discrimination trials were was used to assess 
reference memory whereas standard DNMTS trials were used to assess working 
memory. Administration of the general dopamine agonist d-amphetamine impaired 
performance on working memory trials. D1 receptor manipulation produced no effect 
on either task whereas administration of the D2 agonist quinpirole significantly 
reduced accuracy on working memory trials. This suggests D2 receptors play a role in 
working memory. While Bushnell and Levin (1993) argued reference memory 
processes were not affected the DNMTS task still involved a reference memory 
component. In addition it could be argued that the visual discrimination trials were 
easier and hence visual discrimination performance would be more difficult to disrupt.  
Pre-treatment with D2 antagonists has attenuated impairments produced by D2 
agonists (Boulougouris et al., 2009). In addition impairments produced by 
administering a D2 antagonist into the hippocampus was ameliorated by pre-treatment 
with a D2 agonist indicating manipulation of hippocampal D2 receptor activity was 
responsible for the observed deficits (Umegaki et al., 2001) and not general drug 
effects. In conclusion there is strong evidence that D2 receptors are involved in 
cognitive functioning. However whether D2 receptors are more involved in working or 
reference memory processes remains unclear. 
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Contradicting Findings for D1 and/or D2 Receptors Producing Cognitive Deficits 
Not all studies that have tried to differentiate between the roles of D1 and D2 
receptors in cognition have found such clear cut results. There are many studies with 
conflicting findings or studies which have suggested both D1 and D2 receptors may be 
important in cognition. For example Rinaldi, Mandilo, Oliverio and Mele (2007) 
examined the effects of dopamine manipulation on memory performance. 
Administering D1 and D2 antagonists impaired performance on a spatial memory task 
while leaving object recognition intact. Therefore, dopamine manipulation did not alter 
object recognition memory and both D1 and D2 receptors may be involved in spatial 
memory. 
Using a partially baited eight arm radial maze Liao, Lai and Lin (2002) 
examined the effects of D1 and D2 receptors on memory. A selective D1 antagonist and 
a non selective D2 antagonist significantly impaired spatial memory. However a 
selective D2 antagonist did not have any significant effect on performance. Therefore 
Liao et al. (2002) argued D1 receptors appeared to play a more crucial role in spatial 
memory. Accuracy on a non-spatial memory task (cued task) was not impaired by any 
drug but did increase reaction time suggesting decreased motor activity rather than a 
memory deficit.  
Zarrindast et al. (1992) conducted an extensive study investigating the effects 
of dopamine manipulation on an active avoidance task. To assess long-term retention 
24 hours after mice were trained on the task they were administered various D1 and D2 
agonists and antagonists. Low doses of the general dopamine agonist apomorphine 
improved performance while the highest dose impaired performance. Pre-treatment 
with the D2 antagonist sulpiride reversed these effects indicating the involvement of D2 
receptor activity in retention functioning. However, pre-treatment with the D1 
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antagonist SCH23390 also reversed the impairment seen with the highest dose of 
apomorphine indicating D1 receptor involvement.  
Administration of the D2 agonist bromocriptine produced a similar pattern 
where low doses improved, and large doses impaired, retention. Pre-treatment with the 
D2 antagonist sulpiride ameliorated the impairment produced by bromocriptine 
indicating the changes in performance were due to D2 receptor activity. Conversely 
administering another D2 agonist quinpirole did not significantly disrupt or improve 
performance at any dose. Also when the mice were pre-treated with the D1 agonist 
SKF38393 and then given bromocriptine it increased the impairment seen with 
bromocriptine indicating both D1 and D2 activity can affect retention.  
The D1 agonist SKF38393 significantly improved retention performance at all 
doses used. Pre-treatment with the D1 antagonist SCH23390 reduced this improvement 
while the pre-treatment with the D2 antagonist sulpiride did not have any significant 
effect. This indicated D1 receptor activity can also influence retention performance. 
Finally administration of low doses of the D1 antagonist SCH23390 and the D2 
antagonist sulpiride on their own both significantly impaired performance suggesting 
that decreasing D1 and D2 receptor activity can disrupt retention. Therefore this study 
produced a rather entangled set of findings suggesting both D1 and D2 receptors may 
be important in retrieving information from long-term memory. 
To try and make sense of the variability of the effects produced by the different 
drugs Zarrindast et al. (1992) suggested the mechanism in which the drugs manipulate 
neurotransmitter activity may be a factor in explaining the conflicting results. They 
argued post-synaptic manipulation of D2 receptor activity appeared to impair 
performance while pre-synaptic D2 or post-synaptic D1 receptor manipulation appeared 
to improve performance. In addition the active avoidance task is used to assess long-
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term retention of a fixed rule (moving into the safe chamber to avoid a foot shock). 
Therefore this paradigm may involve reference memory as the rule does not change 
across trials and by assessing functioning 24 hours later it involved long-term memory 
processes which may also involve reference memory. However this paradigm used 
motor activity to assess learning which is potentially confounding as dopamine 
manipulation can alter motor activity and hence any effect could be due to changes in 
motor activity and not memory per se. 
Therefore the findings of the current literature review are equivocal as there are 
reports of activation of the D1 family of dopamine receptors both improving and 
impairing memory function. Similarly there is evidence that stimulating the D2 family 
of dopamine receptors can both improve and impair performance on memory tasks. In 
addition there is evidence suggesting both D1 and D2 manipulation are important in 
cognitive functioning and reports that neither D1 nor D2 receptors have any effect on 
certain paradigms. Therefore it is difficult to say with any certainty what role the 
different dopamine receptors play in cognition.  
In addition numerous tasks that have been used to assess memory performance 
claim to specifically assess working memory. However many of these paradigms could 
also assess reference memory as they involve the learning of a rule such as alternating 
arm or lever choices, or not entering arms of a maze that do not contain reinforcement, 
or matching to sample. These are long-term rules that do not change across trials and 
hence may involve a reference memory component. In addition the finding that both 
D1 (Kozlov et al., 2001) and D2 (Druzin et al., 2000) receptor manipulation can 
produce proactive interference may suggest that changing dopamine levels can induce 
reference memory impairments in terms of producing deficits in the understanding of 
task rules. 
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The Current Study 
Study 1 found the dopamine agonist GBR12909 produced more reference 
memory errors than working memory errors in a partially baited radial maze. Hence 
the current study further examined the involvement of dopamine in this paradigm by 
administering both D1 and D2 agonists to examine which dopamine receptors 
contribute to reference memory functioning by measuring which type of errors are 
produced by the different agonists. The current study utilised the D1 agonist A68930, a 
full selective and potent D1 agonist (DeNinno et al., 1991). It also used quinpirole a 
selective D2 receptor agonist (Levin & Bowman, 1986).  
Based on previous findings examining the effects of D1 and D2 agonists it is 
difficult to conclude which dopamine receptor plays a more pivotal role in memory 
functioning. There is evidence that cognitive performance can be impaired when either 
D1 or D2 receptor activity is stimulated or reduced. Therefore it is difficult to predict 
which dopamine receptor will play a more important role in reference memory. 
However due to the clear evidence that dopamine manipulation can effect cognitive 
performance we hypothesise that either D1 or D2 stimulation will impair radial arm 
maze performance. In addition due to GBR12909 impairing reference memory in 
Study 1 we hypothesise that administering either the D1 or D2 agonist will produce a 
significant reference memory impairment.  
 
Method 
Subjects 
This study utilised the subjects from Study 1 (14 white male Sprague-Dawley 
rats that were now sixteen to seventeen months old). Half way through this study one 
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rat died and hence only the conditions it produced data for were analysed while the 
remaining conditions involved the thirteen remaining rats.  
As this study was carried out immediately after Study 1 the rats were already at 
criterion and did not receive any extra training. Again they were kept at approximately 
85-90% (between 233 and 281 grams) of their free feeding body weight. They had 
continuous access to water and were kept on a 12:12-hour light:dark cycle and were 
run during the dark phase of this cycle. 
Apparatus/Materials 
The aluminium maze previously described and chocolate chips were used as 
reinforcers contained in the Petri dishes previously described in the general method 
section. A digital stopwatch was used to record the amount of time it took a rat to 
complete a trial. Saline 0.9 % was used to obtain a baseline measure to compare the 
other drug doses with. Drugs used were Quinpirole 0.04, 0.08 and 0.12 mg/kg and 
A68930 0.1, 0.3 and 0.9 mg/kg. Each drug was prepared on the day of use by 
dissolving to the required dose in 0.9 % saline solution.  
Procedure 
This study utilised a within-subjects experimental design with each rat 
receiving all drug types and doses. The maze running procedure was identical to the 
training phase during the drug sessions. All drugs were administered via an 
intraperitoneal (i.p.) injection twenty minutes before running. As in the previous study, 
rats were run in batches where the first four rats were injected and then fifteen minutes 
after the first rat was injected all four rats were run. Once this batch had completed 
running the maze the second batch was run and so on until all the rats were finished. A 
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drug session was conducted within a day and there were at least three days between 
drug sessions to prevent any lasting effects of the drugs from previous days. 
Unfortunately due to the drug A68930 taking such a long time to arrive from 
suppliers this study was unable to be counterbalanced. Therefore, in this study all rats 
received the same dose of the drug being examined during a session. The first drug 
session involved all rats receiving 0.9 % of saline. During the second session all rats 
were administered a 0.04 mg/kg dose of Quinpirole. In the third session all rats 
received 0.08 mg/kg of Quinpirole and in the fourth session they were given the 0.12 
mg/kg dose of Quinpirole. During the fifth session all rats were administered 0.1 
mg/kg of A68930 and on the seventh sixth they were given 0.3 mg/kg of this drug. 
Session seven involved all rats receiving another dose of 0.9 % saline solution. While 
during the eighth session all rats were given 0.9 mg/kg of A68930.  
 Finally on the last day of the study the medium sized doses of both Quinpirole 
(0.08 mg/kg) and A68930 (0.3 mg/kg) were combined to examine if there were 
synergistic or additive drug effects. This was also done to see if both D1 and D2 
receptors were important in producing the reference memory effect seen with acute 
MDMA administration. Another dose of MDMA 4.0 mg/kg was not administered in 
this study therefore the MDMA data from the previous study was added in to the 
analyses to compare the drugs in this study with. 
 
Results 
In all figure error bars show standard error of the mean. Percent correct figures 
were calculated in the same way as Study 1. These data are presented in Figure 6. The 
MDMA data is from the previous study (Study 1) to be used as a comparison to the 
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other drugs. Figure 6 clearly shows that for both Quinpirole and A68930 as drug dose 
increased percent correct decreased indicating that both drugs had a detrimental effect 
on accuracy. It is also clear that neither drug on its own had as large an effect on 
accuracy as MDMA administration. However the combination of the two drugs 
produced a deficit in accuracy which was more similar to that of MDMA 
administration. 
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Figure 6: Average percent correct across all rats for each drug and dose. 
 
 
A one-way repeated measures ANOVA comparing saline performance with 
that of Quinpirole revealed a significant effect for drug dose, F (3, 39) = 19.91, p < 
0.05 (p = 0.00). There was also a significant effect for drug dose when comparing 
saline performance versus administration of A68930, F (3, 36) = 20.22, p < 0.05 (p = 
0.00). Therefore as the drug dose of both the D1 and D2 agonists increased accuracy 
was significantly impaired. Finally a paired difference t-test revealed a significant 
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effect for saline performance versus the combined administration of A68930 0.3 mg/kg 
and Quinpirole 0.08 mg/kg, t (12) = 10.43, p < 0.05 (p = 0.00). Therefore the 
combination of the two drugs produced a significant impairment on accuracy 
compared to saline administration. 
Average session trial completion times, in seconds, were calculated the same 
way as in the previous study. These data are depicted in Figure 7 and show that for 
both drugs mean trial completion times increased as drug dose increased compared to 
saline. Also the highest dose of each drug produced an increase in trial completion 
time similar to that seen with MDMA administration. A one-way ANOVA revealed a 
significant effect for saline performance versus Quinpirole administration, F (3, 39) = 
33.82, p < 0.05 (p = 0.00). 
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Figure 7: Average trial completion time in seconds across all rats for each drug and 
dose. Error bars show standard error of the mean. 
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There was also a significant effect for saline performance versus the 
administration of A68930, F (3, 36) = 23.24, p < 0.05 (p = 0.00). Therefore as the dose 
of both drugs increased the average amount of time it took for rats to complete a trial 
was significantly longer. Finally a paired samples t-test for saline versus the 
combination of Quinpirole 0.08 mg/kg and A68930 0.3 mg/kg revealed a significant 
difference, t (12) = -14.05, p < 0.05 (p = 0.00). Therefore when the two drugs were 
combined rats on average took significantly longer to complete a trial than when 
administered saline. 
To examine the difference between error types the number of working memory 
errors made per session for each rat was obtained by adding together the number of 
working memory errors made in the three trials. Reference memory errors per session 
for each rat were also calculated by summing the number of reference memory errors 
made across the three trials. These figures were then converted into percentage error 
values in the same way as in Study 1. These data are presented in Figure 8 and show 
that the saline condition produced very few errors of either type while both Quinpirole 
and A68930 produced more reference memory errors than working memory errors. It 
should be noted that neither of these drugs, at least in the doses tested in the current 
study, on their own produced the amount of errors seen with MDMA administration. 
However, the combination of the medium sized doses of Quinpirole 0.08 mg/kg and 
A68930 0.3 mg/kg produced more reference memory errors than working memory 
errors and this impairment was similar in magnitude to that of MDMA. 
A 2-way repeated measures ANOVA for error type versus drug dose for 
Quinpirole was conducted. It revealed a significant effect for error type, F (1, 13) = 
74.53, p < 0.05 (p = 0.00) and a main effect for drug dose, F (3, 39) = 19.92, p < 0.05 
(p = 0.00). There was also a significant interaction between error type and drug dose, F 
(3, 39) = 10.21, p < 0.05 (p = 0.00). These analyses were also conducted for A68930 
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and it also produced a main effect for error type, F (1, 12) = 21.56, p < 0.05 (p = 0.00) 
and drug dose, F (3, 36) = 18.90, p < 0.05 (p = 0.00). A68930 also produced a 
significant interaction between error type and drug dose, F (3, 36) = 12.19, p < 0.05 (p 
= 0.00). This indicates that both drugs produced significantly more reference memory 
errors than working memory errors. 
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Figure 8: Average error percentage of working and reference memory errors across all 
rats for all drug doses. The values given above each bar are the mean number of total 
working or reference memory errors made in each condition across rats. 
 
 
 Finally a 2-way repeated measures ANOVA comparing error type and drug 
dose for saline versus the combination of 0.3 mg/kg A68930 and 0.08 mg/kg 
Quinpirole was conducted. It revealed a main effect for error type, F (1, 12) = 75.74, p 
< 0.05 (p = 0.00) and a main effect for drug dose, F (1, 12) = 100.30, p < 0.05 (p = 
0.00). A significant interaction was also found, F (1, 12) = 75.06, p < 0.05 (p = 0.00), 
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indicating that the drug combination produced significantly more reference memory 
errors than working memory errors.  
 
Discussion 
The goal of the current study was to examine which dopamine receptor system 
was responsible for the reference memory effect seen in the previous study that found 
that administering the general dopamine agonist GBR12909 significantly decreased 
accuracy in a partially baited radial maze. Specifically the dopamine agonist produced 
significantly more reference memory errors than working memory errors. Therefore 
the current study administered the D1 agonist A68930 and the D2 agonist quinpirole to 
investigate which dopamine receptor may play a more crucial role in radial maze 
performance. The MDMA data from Study 1 was also presented in the results to allow 
comparisons between the degree of impairment seen with MDMA administration and 
the specific dopamine receptor agonists. 
The current study found the D1 agonist A68930 significantly impaired 
performance in the radial arm maze. As the dose of A68930 was increased accuracy 
significantly decreased and the average amount of time to complete a trial significantly 
increased. These findings are in agreement with Zahrt et al. (1997) who found the D1 
agonist also impaired memory performance using a maze task. However our findings 
contradict some of the previous research that has found that administering D1 agonists 
actually improves memory performance (Stuchlik & Vales, 2006; Kozlov et al., 2001). 
In addition there are studies that have shown a more complicated dose related pattern 
where small doses of D1 agonists have improved performance while larger doses have 
impaired performance on memory tasks (Floresco & Phillips, 2001; Arnsten et al., 
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1994; Cai & Arnsten, 1997). The findings of current study produced a more simple 
dose dependent pattern of impairment where small doses produced small impairments 
while larger doses produced larger impairments.  
The current study also found the D2 agonist quinpirole significantly decreased 
accuracy in the radial arm maze as well as significantly increasing the average amount 
of time it took to complete a trial. These findings were also dose dependent and concur 
with those of Levin and Bowman (1986) who found Quinpirole significantly impaired 
performance in a radial maze task and Bushnell and Levin (1993) who found 
quinpirole produced deficits in a DMTS task. Similarly Druzin et al. (2001) found the 
D2 agonist PPHT impaired memory performance utilising a U-maze paradigm and 
Gibbs and D‟Esposition (2005) who found the D2 agonist bromocriptine impaired 
memory performance in humans. However our findings are incongruent with some 
previous research that has found quinpirole had no effect on a complicated 14 unit T-
maze paradigm (Umegaki et al., 2001) and actually improved performance in a radial 
arm maze task (Wilkerson & Levin, 1999). There is also some previous evidence of 
differing dose related patterns of behaviour with smaller doses of D2 agonists 
improving performance and larger doses impairing performance (Arnsten et al., 1995). 
However in the current study Quinpirole only produced dose dependent impairments.  
One possible explanation for the current study‟s dose dependent impairments 
could be due to high baseline levels of performance. There is evidence that suggests 
that the baseline level of performance is an important factor in the effects of dopamine 
manipulation (Barch, 2004). Administering dopaminergic agents when baseline 
performance levels are high tends to result in impairment, however when baseline 
levels are low dopaminergic agents may improve performance (Floresco & Magyar, 
2006). Therefore as the rats in the current study achieved such a high stable level of 
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near perfect performance before drug administration it would be difficult to show that 
performance improved, resulting in a ceiling-like effect. 
Interestingly the degree of impairment seen in terms of accuracy of arm choices 
with A68930 and quinpirole individually was much less than that seen with acute 
MDMA treatment. However, when two lower doses of the D1 and D2 agonists were co-
administered they produced a more similar level of impairment to that seen with 
MDMA administration. In contrast to the results for accuracy both A68930 and 
quinpirole produced similar increases in trial completion time to that of acute MDMA 
exposure, in fact when the two lower doses of the drugs were combined they produced 
a trial completion time slightly greater than that of MDMA administration.  
These findings are consistent with previous literature such as Rinaldi et al. 
(2007) who found that both D1 and D2 antagonists produced memory impairments 
suggesting that both types of dopamine receptor may play a role in memory function. 
However Rinaldi et al. (2007) administered antagonists which decrease dopamine 
activity whereas the current study used dopamine agonists that increase dopamine 
activity. This difference may produce difficulties in comparing the findings with the 
current study. In addition Rinaldi et al. (2007) did not examine the effects of co-
administering the D1 and D2 antagonists but examined their effects individually which 
did not allow for additive or synergistic drug effects to be investigated. 
 In fact very few studies have co-administered D1 and D2 receptor agonists 
making the current findings of this study an interesting addition to the literature. One 
of the few existing studies that has examined this is Zarrindast et al. (1992) who found 
that co-administering the D1 agonist SKF38393 with the D2 agonist bromocriptine 
increased impairment produced by bromocriptine alone in an active avoidance task. 
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Therefore this finding suggested that both D1 and D2 receptors were involved in task 
performance and may produce an additive drug effect when combined. 
 The current findings conflict with many studies that have used drugs that 
manipulate both D1 and D2 receptor activity and found evidence that only one of the 
dopamine receptor types affect cognitive performance. For example our findings 
disagree with studies that have found that D1 but not D2 receptors are involved in 
cognitive functioning (Sawaguchi & Goldman-Rakic, 1991; Sawaguchi & Goldman-
Rakic, 1994, Sawaguchi, 2001; Seamans et al., 1998; Muller et al., 1998). Our findings 
are also at odds with research that has found that D2 but not D1 receptor activity is 
involved in cognition (Bushnell & Levin, 1993).  
Of most interest the current study found that when the D1 agonist A68930 was 
administered significantly more reference memory errors were produced than working 
memory errors. Also when the D2 agonist Quinpirole was given it also produced 
significantly more reference memory errors than working memory errors. However, 
when A68930 and Quinpirole were administered individually the level of reference 
memory impairment was much lower than produced by the acute dose of MDMA used 
in the previous study. When two lower doses of the D1 and D2 agonists were co-
administered they produced a synergistic effect that resulted in a greater number of 
reference memory errors and so performance was more similar to that observed with 
the acute administration of MDMA. Therefore, it may be that both D1 and D2 receptors 
are involved in reference memory function in the radial arm maze. 
 Very few studies have utilised paradigms that specifically differentiate between 
working and reference memory. Bushnell and Levin (1993) used a task that contained 
visual discrimination (reference memory) and standard DMTS (working memory) 
trials to differentiate between the two types of memory processes. In contrast to the 
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current study they found administrating D1 agonists and antagonists and a D2 
antagonist had no significant effect on either type of trial and a D2 agonist produced a 
significant impairment only on working memory trials. Failure to find a reference 
memory effect in this study may be because the discrimination trials used to assess 
reference memory did not encompass the complexity of reference memory processes. 
During discrimination trials the rat simply had to push the lever with a light above it. 
The task may thus be viewed as more like an object recognition task which has been 
shown to be unaffected by dopamine manipulation (Luciana & Collins, 1997; Rinaldi 
et al., 2007). In addition this task appears much like the radial arm cued task used by 
Liao et al. (2002) that found no significant decrease in accuracy following the 
administration of D1 and D2 antagonists. 
 The finding that D1 and D2 receptors seem to interact where co-administering 
agonists produces either additive or synergistic effects is not a novel finding and has 
been reported in previous research. For example Robertson, Peterson and Worth 
(1992) found combining a D1 agonist and D2 agonist produced a synergistic effect that 
produced significantly more locomotor activity than either drug administered on its 
own. Unfortunately there seems to be a paucity of research on the effects of additive or 
synergistic actions of D1 and D2 receptors on cognitive functioning. However, 
Ichihara, Nabeshima and Kameyama (1992) found the combined administration of D1 
and D2 agonists resulted in a synergistic effect on avoidance learning performance. 
Therefore the current study provides further evidence that D1 and D2 receptors may 
positively interact. 
One difficulty in comparing research on the effects of D1 and D2 receptor 
activity on cognition is the differences in methodology used between studies. There are 
a number of factors that vary between the studies reviewed such as differences in the 
types of memory task used to assess cognition and the type and dosage of the 
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dopaminergic drugs administered. A further major difference in the literature is the 
method of drug administration. In many studies the agonists and antagonists have been 
administered directly into brain regions via cannula infusion but others have injected 
the drugs via intra-muscular, sub-cutaneous or intraperitoneal injections. These 
differences in methodology could produce conflicting findings as they will result in 
varying quantities of drug reaching the brain and therefore may produce different 
behavioural outcomes.  
Another possible explanation for the conflicting findings in dopamine receptor 
research is the mechanisms by which different agonists and antagonists work. For 
example there have been some suggestions that where the drug takes effect within the 
synapse may be of importance. Zarrindast et al. (1992) argued that whether the drugs 
had different effects either via pre-synaptic or post-synaptic action could explain the 
conflicting findings as they found that stimulating post-synaptic D2 receptors impaired 
memory retrieval whereas pre-synaptic D2 stimulation and post-synaptic D1 
stimulation produced an improvement in memory function. However this explanation 
does not seem adequate as other researchers have found opposing findings such as 
Arnsten et al. (1995) who argued their findings suggested that low doses of quinpirole 
produced action at D2 pre-synaptic autoreceptors that resulted in impairments in 
cognitive functioning. Further research into the effects of pre-synaptic and post-
synaptic drug actions could be useful to elucidate the role of D1 and D2 receptors in 
cognition. 
The difficulties experienced in the current study in trying to gain a 
comprehensive understanding of the function of D1 and D2 receptors are not surprising 
due to the complications involved. For instance it has been argued that trying to 
differentiate between the roles that D1 and D2 receptors play in cognition is not an easy 
task and is bound to be complex (Luciana et al., 1992). One possible reason for this is 
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that D1 and D2 receptors may work together and hence trying to differentiate between 
the two may prove difficult. For example Arnsten et al. (1995) argued that memory 
performance may involve interactions between D1 and D2 receptors. Floresco and 
Magyar (2006) argue that while D1 receptors may play an important role in working 
memory it could be that D1 and D2 receptors may work together to influence 
behavioural flexibility such as that seen in paradigms like reversal learning and the 
Wisconsin card sorting task where subjects are required to change their behaviour in 
line with changing environmental conditions. Certainly the current study would 
suggest that both D1 and D2 receptors are involved in reference memory processes 
further highlighting evidence that dopamine activity may not easily be separated into 
clear differences in the roles of the varying receptor types.  
There are also suggestions that that the two types of receptor may interact not 
only with each other but with other neurotransmitter systems (Luciana et al., 1992). 
For example Wilkerson and Levin (1999) argued D2 receptors and acetylcholine may 
interact in the hippocampus to affect memory functioning. In addition the D2 agonist 
Quinpirole produced an increase in acetylcholine release in the hippocampus 
(Umegaki et al., 2001). Moreover Hersi, Rowe, Gaudreau and Quirion (1995) found 
administering the D1 agonist SKF38393 increased acetylcholine release in the 
hippocampus while the D1 antagonist SCH23390 decreased it.  
A possible reason for the reference memory impairment seen in the partially 
baited radial arm maze could be due to a long-term memory problem. It has been 
argued that D1 receptors are crucial in memory retrieval (Liao et al., 2002) therefore it 
may be that administering D1 and D2 agonists impair the subjects ability to retrieve 
previously learnt information (the arms that contain reinforcement) from long-term 
storage. Similarly findings from avoidance procedures that test retention 24 hours after 
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training such as Zarrindast et al. (1992) provide further evidence that D1 and D2 
receptor activity may produce impairments in long-term memory retrieval.   
In addition the evidence from studies that have examined rule based learning 
such as reversal learning (Boulougouris et al., 2009; Mehta et al., 2001) and executive 
functioning card sorting tasks (Lumme et al., 2007) suggest that dopamine receptor 
activity may play a role in the reference memory deficit. Specifically, the impairment 
could be produced by subjects becoming confused as to the long-term rules involved in 
being able to perform various cognitive tasks. 
An alternative explanation for the reference memory impairment seen in the 
radial arm maze could be due to proactive interference. For example Druzin et al. 
(2000) found a D2 agonist produced evidence of proactive interference and 
perseverative responding. In addition Kozlov et al. (2001) also found evidence of 
proactive interference in their study that used both D1 agonists and antagonists. These 
findings are in agreement with Harper et al. (2005) who administered MDMA and 
found evidence suggestive of a reference memory impairment and proactive 
interference. Therefore the reference memory impairment produced by MDMA in the 
radial arm maze may be due to both D1 and D2 receptor activity that produces 
proactive interference. 
It would also be beneficial to examine other drugs that manipulate D1 and D2 
receptor activity to try and gain further insight into the role that they play in cognition. 
Using agonists that operate in a variety of ways to increase D1 and D2 receptor activity 
may be useful in trying to disentangle the conflicting findings in this area of research. 
For example, examining whether direct or indirect agonists produce different findings 
and utilising various drugs that operate on different parts of the synapse may help 
clarify the underlying chemical cause of the reference memory impairments. To verify 
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the effects found in the current study it could be useful to replicate and extend the 
study by utilising various D1 and D2 antagonists.  
Future research could pre–treat the subject with D1 and D2 antagonists and a 
combination of the two to examine whether they would attenuate the reference 
memory deficits produced by MDMA exposure alone. This could further support the 
current findings as if a combination of both D1 and D2 antagonists (blocking the 
increase in dopamine activity that MDMA produces) decreases the number of 
reference memory errors produced by MDMA, this would be further evidence for the 
role of D1 and D2 receptors in reference memory processes. 
In conclusion the current study examined the effects of manipulating different 
dopamine receptors on performance in a partially baited radial arm maze that 
differentiated between working and reference memory. It was discovered that both 
A68930 and Quinpirole produced significant reductions in accuracy and increases in 
the amount of time it took to complete a trial. However these effects on their own were 
not as great as those seen with MDMA administration, but when two smaller doses of 
both D1 and D2 agonists were combined they produced findings similar to that seen 
with MDMA treatment. In addition both dopamine receptor agonists produced more 
reference memory errors than working memory errors and when smaller doses of the 
two drugs were co-administered they produced a synergistic drug effect that resulted in 
an impairment similar to that seen with MDMA administration. Therefore the current 
findings of this study would suggest that both D1 and D2 receptors are involved in 
reference memory. However as in Study 1 of the thesis it remains unclear as to the 
exact underlying nature of the reference memory effect. Further research is needed to 
clarify whether it is due to long-term memory problem, an impairment in terms of the 
long-term rules of the task or a product of proactive interference.  
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Acute MDMA Discussion 
The literature review of the acute administration of MDMA strongly suggests 
MDMA exposure disrupts performance on several paradigms used to assess cognitive 
processes. In particular there are multiple studies indicating MDMA administration 
seems to impair reference memory performance (Kay et al., 2009; Harper et al., 2005; 
Braida et al., 2002). Therefore the first study of this thesis examined the acute effects 
of MDMA on memory performance by replicating the findings of Kay et al. (2009) 
who administered acute doses of MDMA to rats using a partially baited radial arm 
maze paradigm. They found MDMA exposure impaired maze performance producing 
a significant decrease in accuracy and a significant increase in the average amount of 
time taken to complete a trial. MDMA administration also produced a significant 
increase in working memory errors and reference memory errors; however the drug 
produced significantly more reference memory errors compared to working memory 
errors (Kay et al., 2009). 
The first study of the current thesis utilised the same radial arm maze paradigm 
as that of Kay et al. (2009) using the dose of 4 mg/kg of MDMA that had the most 
pronounced effect in their study. The first study in the current thesis produced similar 
findings to Kay et al. (2009) as rats that were administered an acute dose of MDMA 
produced a significant decrease in accuracy as well as a significant increase in the 
average time it took to complete a trial. Study 1 also found that acute administration 
resulted in a significant increase in both working memory and reference memory 
errors. Finally of most interest MDMA exposure produced significantly more reference 
memory errors than working memory errors, thereby replicating Kay et al.‟s (2009) 
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main finding that acute exposure to MDMA impairs reference memory more than 
working memory in the partially baited radial arm maze. 
The finding that acute MDMA exposure produces a deficit in performance 
accuracy is consistent with previous acute MDMA research. For example LeSage et al. 
(1993) found that acute MDMA administration decreased both accuracy and response 
rates in a DMTS task. This impairment was characterised as a dose dependent 
impairment where higher doses of the drug produced more impairment than lower 
doses. Acute MDMA exposure also disrupted performance in a DNTMS task used by 
Marston et al. (1999). Both these tasks explained the impairments produced by 
MDMA exposure as the result of a short-term or working memory deficit. While the 
current findings of this thesis found that working memory processes were generally 
disrupted by MDMA exposure, it clearly showed that reference memory processes 
were more impaired by the drug. However it has been argued that DMTS and DNMTS 
tasks comprise a reference memory component in addition to working memory 
processes (Harper et al., 2005) and this may contribute to the findings that acute 
MDMA administration disrupts performance in these tasks.  
Harper et al. (2005, 2006) also utilised a DMTS task and found MDMA and 
dopaminergic drugs resulted in delay-independent impairments in performance that are 
often attributed to attention or encoding deficits. However, on further analysis of their 
data they found evidence of proactive interference suggesting the deficits found with 
acute MDMA administration may be the result of a reference memory impairment 
whereby subjects become confused as to the rules of the task. This would be consistent 
with the results of the current thesis as it was found that acute MDMA administration 
produced more of a deficit in reference memory processes than working memory 
processes. 
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Using a standard “all-arms-baited” version of the radial maze Braida et al. 
(2002) found acute MDMA exposure significantly disrupted performance in a dose 
dependent manner that was attributed to a deficit in short-term memory. However, 
there was also some evidence of a reference memory impairment in that MDMA 
exposure disrupted arm entry patterns suggesting a rule like disruption in the strategies 
used for solving the task. This would concur with the current studies findings whereby 
MDMA administration produced both reference and working memory impairments. 
Unfortunately the classic radial maze paradigm utilised by Braida et al. (2002) does 
not allow unambiguous differentiation between working and reference memory 
processes as the procedure does not specifically measure both working and reference 
memory errors. 
Taffe et al. (2001) used a number of tasks to assess the effect of acute MDMA 
exposure on cognitive performance. This involved DNMTS, spatial search, reaction 
time, motivation and bimanual motor tasks. Taffe et al. (2001) found acute MDMA 
administration produced significant impairments on performance across all cognitive 
tasks compared to that of the saline controls and attributed these impairments to a 
deficit in short-term memory. Therefore Taffe et al. (2001) found more of a general 
disruption in cognitive performance when subjects were administered acute MDMA 
treatment. These findings could also concur with those of the current thesis as many of 
the tasks that Taffe et al. (2001) utilised would contain both working and reference 
memory components which may account for the deficits found across such a range of 
cognitive tasks.  
The current thesis findings are a little more complicated to compare with 
Frederick and Paule (1997) as they found mixed results when they administered an 
extensive battery of cognitive tasks (OTB) to monkeys who had received acute doses 
of MDMA. It was found that MDMA exposure produced significant disruptions to 
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time estimation, motivation and a sequence lever pressing task that changed each 
session. This sequence task utilised was designed to assess learning of a general task 
rule. It was found that under the influence of MDMA the monkeys made more 
acquisition (between session errors) than retention errors (within session errors). This 
type of deficit tends to suggest more of a reference memory impairment than a 
working memory impairment as they had more trouble learning a new task rule than 
remembering one which they had already acquired. This pattern of impairment is quite 
consistent with the findings from Study 1 in the current thesis.  
However the current findings do not agree with all the previous research that 
has examined the effects of acute MDMA exposure on cognitive performance. Both 
Frederick et al. (1995) and Frederick and Paule (1997) used DMTS tasks and found no 
significant differences in performance when administering MDMA or saline to 
monkeys. A possible explanation for this may be the relatively low doses of MDMA 
used in these studies (0.1 to 1.0 mg/kg) relative to doses used in those that have found 
an effect. 
Byrne et al. (2000) found no overall significant impairment in the acquisition 
of a lever pressing task with acute MDMA exposure. However the drug did 
significantly increase the latency to respond suggesting some degree of impairment or 
disruption in performance. Of note Byrne et al. (2000) examined cognition by 
investigating the effects of MDMA on the ability to acquire or learn a new task while 
the current thesis examined the effects of the drug on previously learnt task 
performance. It may be that acute MDMA administration affects these two cognitive 
processes differently explaining why Byrne et al. (2000) failed to find an effect of 
acute MDMA administration on performance.  
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As well as replicating Kay et al.‟s (2009) findings with acute MDMA 
administration, the first study of this thesis also sought to examine which 
neurotransmitter systems may be responsible for the reference memory effect seen 
with MDMA exposure. As acute MDMA administration produces both an increase in 
5-HT and dopamine activity the first study of this thesis investigated what role each of 
these neurotransmitter systems play in producing the reference memory impairment 
seen in the partially baited radial arm maze. Therefore the first study used the 5-HT 
agonist Citalopram and the dopamine agonist GBR12909 to examine whether either 
neurotransmitter plays a more pivotal role in reference and working memory errors in a 
partially baited radial arm maze. It was found that both agonists significantly reduced 
accuracy and increased the average time it took to complete a trial. Citalopram did not 
significantly affect one error type more than another. Conversely the dopamine agonist 
GBR12909 produced significantly more reference memory errors than working 
memory errors suggesting that alterations in dopamine activity may be more important 
in reference memory processes. 
 The second study of this thesis then examined which dopamine receptors play a 
more pivotal role in the reference memory impairment. Therefore the D1 agonist 
A68930 and the D2 agonist quinpirole were administered to examine their effect on 
performance in the partially baited radial maze. Both agonists produced a significant 
decrease in accuracy and an increase in the average time it took to complete a trial. 
Both agonists also produced significantly more reference memory errors than working 
memory errors. However, when administered individually neither agonist produced the 
level of impairment seen with acute MDMA administration. When the agonists were 
co-administered they produced a synergistic effect producing a deficit more similar to 
that seen with MDMA administration. Therefore it would appear that both D1 and D2 
receptors play an important role in reference memory processes. 
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What Underlying Cognitive Processes Produce the Reference Memory Impairment? 
There are a number of possible explanations for what is underlying the 
reference memory impairments seen with acute MDMA administration. An important 
issue involves trying to discern what sort of impaired cognitive processes are resulting 
in the reference memory errors as measured by the partially baited radial arm maze 
paradigm. One possible reason for the observed reference memory impairment is that 
acute MDMA exposure and acute dopamine manipulation induce a long-term memory 
impairment. This explanation suggests that rats have learnt which arms of the maze 
contain reinforcers, as during baseline and saline trials, performance is near perfect. 
However, after MDMA administration the rat‟s ability to retrieve this information 
from long-term memory becomes impaired. This disruption in long-term memory 
retrieval produces reference memory errors where the rats enter the unbaited arms of 
the maze as they can no longer access the information about which arms of the maze 
do contain reinforcement.  
Support for this explanation may come from avoidance tasks that test long-term 
memory retrieval twenty four hours after initial learning. There is evidence to suggest 
that changes in dopamine activity can impair performance on these tasks (Zarrindast et 
al., 1992) indicating that altering dopamine levels can impair long-term memory 
retrieval which may account for the current findings in the radial arm maze. Also 
within the human Ecstasy literature Montgomery et al. (2005) found Ecstasy users 
were impaired in their ability to retrieve information from long-term memory using a 
word fluency task. Also Laws and Kokkalis (2007) conducted a meta-analysis of 
memory impairments in human Ecstasy research and found a stronger effect for long-
term memory than short-term memory. However, this effect failed to reach 
significance but is suggestive that long-term memory may be slightly more affected by 
MDMA exposure than short-term memory. One possible reason why the rats make 
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more reference memory errors than working memory errors when their long-term 
memory becomes impaired is that when they are unsure of how to respond the rats rely 
on their innate predisposition to alternate rather than repeat arms (Chrobak & Napier, 
1992).  
Another possible explanation for the reference memory impairment in the 
partially baited radial arm maze is that acute MDMA administration and acute 
dopamine manipulation produce a disruption in the rules required to effectively 
perform a task. In other words MDMA exposure and dopamine manipulation produce 
problems in remembering what to do or how to perform when carrying out a task 
(Harper et al., 2005). Therefore the rats are able to remember where they have been 
(which arm they just entered) so do not tend to produce a large number of working 
memory errors. However they have become impaired as to what they should be doing 
within the task and have trouble remembering that they should be entering arms that 
contain reinforcement. Evidence from human Ecstasy use suggests that Ecstasy users 
have more trouble selecting a strategy to solve a cognitive task compared to drug free 
controls (Montgomery et al. 2005) which may be indicative of a reference memory 
type impairment. 
 Another reason for our findings that relates to the possibility of a deficit in task 
rules comes from Harper et al. (2005, 2006) who argued that acute MDMA exposure, 
along with various dopamine agonists, may produce proactive interference. This 
explanation may also account for the results seen in the radial arm maze where rats 
become impaired in entering the reinforced arms of the maze due to a confusion with 
the rules of the task.  
An increase in proactive interference has also been found in studies that have 
manipulated dopamine activity (Harper et al., 2005, Druzin et al., 2000). This theory 
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postulates that due to proactive interference the subjects become confused as to which 
trial they are currently in. During the first two studies in the current thesis all rats 
received three trials a day and therefore if proactive interference occurred we would 
expect that performance should get worse across these trials. This is because the 
information from running the first trials may start to interfere with performance on the 
third trial. To examine this explanation further the data from the first two studies of the 
current thesis were re-analysed in a trial-by-trial basis. This enabled the average 
performance from trial one to be compared with the performance of trial two and 
finally performance on the third and last trial.  
The data from Study 1 of the current thesis that examined performance after 
administration of acute MDMA, the 5-HT agonist Citalopram and the dopamine 
agonist GBR12909 are presented in Figure 9. There is no clear overall pattern to this 
data and there is definitely no evidence that performance worsens over trials. In fact 
for the MDMA data there is a slight tendency for performance to improve across trials 
although this effect is minimal. The data from Study 2 of the current thesis that 
examined the effects of administering the D1 agonist A68930 and the D2 agonist 
quinpirole on performance in the radial maze is presented in Figure 10. Again it clearly 
shows no obvious trends in the data in terms of trial by trial performance and definitely 
no clear evidence that performance worsened over trials.  
Therefore it seems that explaining the current data in terms of a proactive 
interference effect is unlikely as the data from the two figures clearly show no 
evidence of a proactive interference like effect. However the explanation that the 
impairments in previous studies, such as Harper et al. (2005, 2006) that have found 
MDMA disrupts performance cannot be entirely ruled out. It could be argued that the 
three trials used in the current experiments are simply not enough for proactive 
interference to occur.  
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Figure 9: Average percent correct for different doses of GBR12909, Citalopram, saline 
and MDMA compared across the three trials that made up a testing session. 
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Figure 10: Average percent correct for different doses A68930, Quinpirole, saline 
compared across the three trials that made up a testing session. 
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While it is unlikely that proactive interference contributed to the findings of the 
studies within the current thesis it may contribute to research using DMTS and 
DNMTS tasks that use multiple trials within a testing session. It may be useful for 
future research to perform a partially baited radial maze task that utilises multiple trials 
per day to examine whether MDMA may produce proactive interference within the 
radial maze. 
It could also be disputed as to whether a proactive interference explanation 
would be able to explain the reference memory effect seen within the partially baited 
radial maze. This is because if the rats are able to remember which arms contain 
reinforcement (the correct arm to enter), however they become impaired as to which 
trial they are in, then they would be more likely to go back and re-visit arms (at least as 
the start of the trial). A working memory error was classified as a rat re-entering an 
arm of the maze (either a baited one or an unbaited one) within a trial. Therefore if the 
rats remember the reinforced arms, but when given acute MDMA become confused as 
to where they are within the trials, they would be more likely to go back and re-enter 
these arms thus producing more working memory errors. Clearly this explanation then 
cannot account for the data in the current experiments due to the large number of 
reference memory errors made (entering an unbaited arm once within a trial). 
Another possible explanation for the impairments seen in the radial maze may 
be due to perseverative responding. MDMA administration has been shown to produce 
perseveration which is characterised as persisting in a behaviour despite it no longer 
being effective (Head, Kennedy, Rodrigue & Raz, 2009). For example mice given 
MDMA produce perseverative locomotor activity where they engage in repetitive 
movement patterns (Powell et al., 2004). Frederick et al. (1995) and Frederick and 
Paule (1997) found acute MDMA administration produced perseverative responding in 
Rhesus monkeys in a tasks that involved learning sequences of lever pressing. There is 
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also evidence that Ecstasy users are impaired in tasks that assess executive functioning 
and one pattern of responding that has been produced is perseveration (Montgomery et 
al., 2005; Von Geusau et al., 2004). Evidence of perseverative responding has also 
been found in studies that have manipulated dopamine activity (Boulougouris et al., 
2009; Druzin et al., 2000).  
Hence this type of perseveration impairment could explain the current thesis 
findings that both MDMA and dopamine manipulation disrupt reference memory in 
the radial maze. Unfortunately it could also be argued that if the subjects are going to 
produce a perseverative pattern of responding then more working memory errors 
(repeating arms) than reference memory errors would occur. This is because a 
reference memory error is effectively going somewhere new, changing their previously 
learnt behaviour, while a working memory error would be an example of a repetitive 
behaviour. 
 Therefore there are several different explanations for what may produce the 
reference memory errors produced in the partially baited radial maze under the 
influence of MDMA. Unfortunately the findings from the current thesis are unable to 
conclusively verify which one of these particular explanations is most likely to account 
for the reference memory impairment seen with acute MDMA administration. 
Pre-Synaptic Versus Post-Synaptic Receptor Activity and Acute Drug Administration 
One possible explanation for the differences found between studies is the 
different places that a drug can act within the synapse. Different drugs can have either 
a pre-synaptic or a post-synaptic effect. There is research to suggest that where the 
drug has its effect within the synapse may determine the behavioural results. To make 
matters more complicated the same drug at different doses can also have either a pre-
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synaptic or post-synaptic effect. Within the review of the dopamine and 5-HT research 
outlined in the introductions of the first two studies of the current thesis, there are 
some conflicting findings as to what happens to cognitive performance when various 
agonists are administered. One explanation for these differences is that the different 
agonists have different effects within the synapse. 
For example Montoya et al. (2008) examined the effects of dopamine 
manipulation on a battery of cognitive tasks using the dopamine agonist apomorphine. 
They found at doses which primarily produce pre-synaptic effects apomorphine 
impaired performance on a variety of these tasks suggesting the pre-synaptic dopamine 
manipulation had a significant effect on cognitive performance. Further evidence of 
where a drug act on the synapse was found with Buresova and Bures (1982) who 
found that a pre-synaptic dose of the dopamine agonist amphetamine impaired radial 
arm maze performance. However Buresova and Bures (1982) found that a post-
synaptic dose of apomorphine did not significantly affect performance. In addition 
Zarrindast et al. (1992) used many different D1 and D2 agonists and antagonists to 
examine memory retrieval in mice and found differences in the way that pre- and post-
synaptic stimulation affected performance.  
This effect has also been found within the 5-HT literature where Warburton et al. 
(1997) found evidence of a dissociation between the effects of stimulating pre- and 
post-synaptic 5-HT1A receptors. Therefore there is evidence within the literature that 
suggests where a drug has its effect in the synapse may determine its effect on 
cognitive performance and this can vary by dose level. This is a factor that may 
contribute to the conflicting findings within dopamine manipulation research that 
could be used to explain the conflicting findings found with acute MDMA exposure. 
Evidence from the MDMA literature indicates that MDMA primarily works by 
releasing and inhibiting reuptake of 5-HT and dopamine pre-synaptically (Cole & 
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Sumnall, 2003). Further research could be conducted to examine this effect further and 
in particular examine if and how different doses of acute MDMA administration 
effects pre- and post-synaptic 5-HT and dopamine activity. 
Alternative Explanations of the Acute Drug Administration Data 
There are also some alternative explanations for the current thesis findings that 
do not directly relate to underlying memory processes. For example it may be that the 
deficits found in the radial maze after acute MDMA exposure are due to the drugs 
effects on motor function. Accuracy may be impaired not due to a disruption in 
cognitive processes but rather due to the drug producing a deficit in motor activity. In 
general when acute MDMA was administered to the rats in the current thesis a 
significant increase in the amount of time it took to complete a trial was produced. 
This may indicate that the rats had difficulty moving under the influence of MDMA. 
Anecdotally, when observing the rats, this did not seem to be the case as the increase 
in trial completion time seemed to be produced by spending more time circling in the 
middle of the maze. Once they did enter an arm of the maze they were able to run 
freely to the end of it. In other words they did not appear to show movement deficits 
rather an indecisiveness about which arms of the maze to enter. However, as we did 
not directly measure this we cannot exclude that part of the effect we observed may be 
due to motor activity impairments. Future research could use tracking techniques or 
photo beams at the beginning and ends of the maze arms which would enable the 
running speed of the rats to be calculated during saline and MDMA administration 
providing a more direct measure of motor ability.  
In addition acute MDMA administration has been found to produce hyper-
locomotion. For example Spanos and Yakamoto (1989) administered acute doses (2.5, 
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5.0 & 7.5 mg/kg) of MDMA to rats which produced a significant increase in activity 
counts in activity cages. Hence with doses comparable to those used in the current 
thesis MDMA has been shown to increase locomotor activity suggesting that the 
increase in trial completion times seen in the current thesis are unlikely to be the result 
of motor impairments causing the rats to move slower than normal. 
It should also be noted from a theoretical perspective that if a motor impairment 
and hence slowing of trial completion time was producing the impairment in the radial 
maze, we might expect more working memory errors to be made than reference 
memory errors. This is because it has been shown within cognitive research that 
working memory processes are disrupted in a delay dependent manner (Dudchenko, 
2004) in that the longer a subject has to retain information in working memory the 
more likely that information is to be impaired. Therefore, if a subject enters an arm of 
the maze and then has a long delay period it would be more likely to re-visit that arm 
as it would forget that it had already been there. However the current and previous 
research has found that MDMA administration produces more reference memory 
errors rather than working memory errors and therefore, the results of the current study 
may not be attributable to a motor impairment explanation.  
A possible methodological explanation for the current findings is that the 
impairment seen with acute MDMA administration may be due to a disruption in 
motivational processes rather than cognitive processes. Both MDMA (Frederick & 
Paule, 1997; Nader, Hoffman & Barrett, 1989) and dopamine (Chuhan & Taukulis, 
2006) agonists have been found to reduce the reinforcing value of food and reduce 
motivation to work for food reinforcers (Mayorga et al., 2000). Dopamine agonists 
have also been found to suppress the desire to eat (Wellman, Davis, Clifford, Rothman 
& Blough, 2009). Therefore one reason why rats entered non-reinforced arms is that 
they no longer valued the edible reinforcers that were available in the reinforced arms 
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of the maze. With no motivation to solve the task due to the decrease in the value of 
the food reward subjects may simply not care if arms they enter contain reinforcers or 
not. It could also be suggested that subjects produced more reference memory errors 
than working memory errors as again when performance is disrupted in some general 
way they may fall back on their natural disposition to alternate and not repeat 
behaviours (Chrobak & Napier, 1992). However subjects did tend to eat the reinforcers 
at the ends of the arm of the maze. Unfortunately this was not a measure that was 
recorded in the current thesis and therefore we cannot totally discount the reduction in 
the value of food reinforcers as a possible explanation for the current findings. Future 
research could include the number of reinforcers consumed as a useful measure of 
reinforcer value and another condition could involve pre-feeding the rats to examine 
what affect reducing food reinforcer value would have on performance. 
It is also difficult to say with certainty that the impairments in reference memory 
performance seen with acute MDMA administration were the result of a memory 
deficit per se. Another possible explanation for the findings is that acute MDMA 
administration may produce attention deficits where the effects of the drug may have 
caused the subjects to no longer attend to the radial maze task. Although MDMA is 
chemically related to hallucinogens it has been argued that it does not produce the 
psychotic effects or hallucinations that hallucinogens can (Peroutka et al., 1988).  
In human research visual distortions have been reported by Ecstasy users that 
take the form of luminescence of objects and flashes of light or objects in their 
peripheral vision (Peroutka et al., 1988). Thus it cannot be ruled out that non-human 
animals also experience such phenomena and a possible explanation for our findings is 
that the drug may have caused distracting visual distortions that disrupted the ability of 
the rats to attend to the task. This may be particularly important within the radial arm 
maze as there is evidence that subjects rely on extra-maze cues to solve the task (Liao 
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et al., 2002). Therefore acute MDMA administration may impair the rats ability to use 
extra-maze cues. Thus they can perform the task to a high level of accuracy during 
saline administration but when MDMA, 5-HT or dopamine agonists are administered it 
may affect their visual ability and attention processes rather than impairing memory 
processes. The argument that acute drug treatment produces visual impairments that 
impede the use of extra-maze cues is still problematic as there is research that suggests 
that it is the changes in 5-HT activity produced by acute MDMA administration that 
produces visual distortions and not dopamine activity (Liechti & Vollenweider, 2001). 
Therefore this explanation cannot explain the findings from the first two studies of the 
current thesis that suggest that it is the change in dopamine activity produced by acute 
MDMA administration that produces the reference memory effect in the partially 
baited radial maze. 
There is no particular reason why this form of distraction would affect one type 
of memory error more than another and hence cannot fully explain our findings that 
MDMA affected reference memory performance more than working memory 
performance. Also, Harper et al. (2005) argued that MDMA did not produce 
attentional deficits in their study as they found that rats were influenced by how they 
had responded on a previous trial. For them to be influenced by what occurred on a 
previous trial they must have attended to it and this implied acute MDMA treatment 
did not impair attention. Although this task is not directly comparable to the paradigm 
of the current study it does suggest that the current thesis findings may not be due to a 
failure to attend to the task.  
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Future Research 
To extend the current findings regarding acute MDMA, 5-HT and dopamine 
manipulation future research could utilise various antagonists to clarify the role that 5-
HT and dopamine play in the reference memory impairment seen with acute MDMA 
exposure. Administering 5-HT and dopamine antagonists and then administering acute 
doses of MDMA could provide further support for our findings as if 5-HT or dopamine 
activity were blocked by the antagonists and subsequent MDMA exposure produced 
less reference memory errors this would be further evidence for the role of 5-HT or 
dopamine in reference memory processes. 
 It could also be interesting to examine whether acute MDMA administration 
would produce a difference in working memory and reference memory processes using 
a different paradigm to the partially baited radial maze. Unfortunately not many 
memory paradigms are equipped to assess both working and reference memory 
concurrently, however a holeboard task could possibly be used to achieve this. This 
paradigm involves an open field with 16 holes in its floor, a subset of which contain 
food reinforcers (van der Staay, 1999). Like the radial arm maze the holeboard is not 
rebaited within a trial, therefore if the subjects eats the reinforcers from one of the 
holes there is little point re-visiting that hole during a trial (van der Staay, 1999). 
Hence to perform efficiently within the holeboard task a subject has to keep track of 
which holes it has visited and quickly learn which of the holes contain food and which 
do not (van der Staay, 1999). Therefore like the partially baited radial maze it enables 
working and reference memory to be assessed. If a rat re-visits a hole within a trial it 
makes a working memory error and if it goes to a hole that does not contain 
reinforcement it commits a reference memory error (van der Staay, 1999). Thus this 
paradigm could be used to assess the acute effects of MDMA on working and 
reference memory and find further support for the findings of the current thesis. 
 145 
Also as mentioned previously within this chapter it may be beneficial to 
examine the effects of acute MDMA exposure on proactive interference in the radial 
maze. Therefore more trials per training session would need to be conducted and 
possibly the manipulation of the inter-trial intervals could be conducted as that done 
previously by Harper et al. (2006) in a DMTS task. Finally to control for some of the 
potentially confounding variables within the current experiments some measure of 
motor activity and food reinforcer value should be included in future study. 
Conclusion 
 In conclusion there is strong converging evidence that acute MDMA 
administration impairs reference memory processes. In particular using the partially 
baited radial maze paradigm acute MDMA administration produces more reference 
memory errors than working memory errors. In addition it appears that this reference 
memory impairment is due to changes in dopamine levels rather than alterations in 5-
HT activity. More specifically this change in dopamine activity that disrupts reference 
memory processes appears to involve both D1 and D2 dopamine receptors. However, 
these conclusions are tentative as they would require further study where 5-HT and 
dopamine antagonists as well as D1 and D2 dopamine receptor antagonists would need 
to be administered before acute MDMA exposure to examine whether any of these 
manipulations would attenuate the reference memory effect. In addition the underlying 
cognitive mechanisms that produce this form of reference memory impairment are still 
unclear. Future research is required in order to differentiate between several 
explanations of the data including acute MDMA administration producing long-term 
memory deficits, impairments in tasks rules, proactive interference and perseverative 
responding. 
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PART TWO: 
Chronic/Binge Effects of MDMA 
Chronic MDMA and Cognition 
There is considerable evidence that chronic Ecstasy use in humans has been 
associated with a range of cognitive impairments (see General Introduction for a 
review). These findings are confounded by a number of variables such as the purity of 
Ecstasy tablets, the amount used, pre-existing cognitive impairments, the self report 
measures used and polydrug use (Winsauer et al., 2002). These factors make 
determining whether MDMA actually causes cognitive impairments difficult and they 
also make establishing the exact nature of the cognitive impairments seen in Ecstasy 
users difficult to ascertain. Therefore animal studies are an ideal way of resolving 
some of these issues as they provide a much greater degree of experimental control 
(Taffe et al., 2002). However the animal studies that have examined the effects of 
chronic MDMA exposure on cognition have produced mixed results (Able, Gudelsky, 
Vorhees & Williams, 2006) and finding functional or behavioural impairments 
produced by chronic MDMA administration has not been easy (Winsauer et al., 2002).  
Typically studies that utilise non-human animals examine the chronic effects of 
MDMA administration by administering chronic or toxic regimes of MDMA. These 
usually consist of multiple injections of MDMA given over a course of several days 
(Baggott & Mendelson, 2001). Chronic MDMA studies usually involve two main 
study designs. The first involves subjects being trained to perform a cognitive task 
until they reach a stable level of performance. A regime of MDMA is then 
administered and the subjects‟ performance on the previous task is re-assessed to 
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examine whether the MDMA produces disruption of an already learnt task. The other 
type of study examines acquisition where MDMA is administered and then after a 
period of time subjects are given a cognitive task to learn. Their performance is 
compared against that of saline controls to investigate whether there is any long-term 
impairment in their ability to acquire the task. The term chronic usually refers to long-
term drug exposure that occurs over many sessions to examine the long-term effects of 
drug exposure. For example there are developmental MDMA studies such as Skelton 
et al. (2006) that administer MDMA to young rats every day for long periods (up to 10 
days). Although some studies that have examined the effects of MDMA on cognition 
have used the term chronic to describe the regime of MDMA they use, typically these 
studies involve short courses of large doses of the drug. Hence technically they do not 
involve chronic drug exposure. In addition there has been some research that has 
referred to these regimes as toxic regimes. However, this term is now controversial as 
there is debate as to whether MDMA can be considered a neurotoxin (Bauman et al., 
2007).  
Therefore for the purpose of the current thesis the term binge will be used to 
refer to regimes of MDMA that involve typically larger doses than those used in 
research examining the acute effects of the drug, but are administered over either one 
or a few sessions and hence do not fit the definition of chronic drug exposure. In 
addition the term chronic regime will be reserved for studies that exposed subjects to at 
least ten sessions of drug exposure or involved intermittent exposure that lasted over 
several weeks. Many different kinds of tasks have been used to assess the effects of 
chronic/binge MDMA administration on cognition. Therefore this chapter will review 
the findings from studies that have utilised a number of different paradigms to assess 
the effects of chronic and binge MDMA exposure on cognitive functioning and these 
findings are summarised in Table 5. 
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Table 5: Summary of research on the binge and chronic effects of MDMA on cognition. 
Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Slikker et al. 
(1989) 
MDMA 
(1 injection of 5or 10 
mg/kg for 4 days) 
Oral 
gavage 
Sprague-Dawley rats Acquisition of 24-arm complex 
maze (training began 2 weeks 
after drug treatment) 
No effect on performance/acquisition. 
Li et al. 
(1989) 
MDMA 
(2 x 6 mg/kg for 4 days) 
S.C. Sprague-Dawley rats DRL Task 
(72 second inter-response 
interval – task acquired before 
drug treatment) 
Binge regime had no effect on performance 
(subsequent acute challenge resulted in sensitisation). 
LeSage et al. 
(1993) 
MDMA 
(3.2 mg/kg per day for 
20 days) 
Injection 
(type not 
specified) 
Pigeons DMTS Task  
(0, 3, & 6 second delays, task 
acquired before drug treatment) 
No difference in performance before and after chronic 
drug treatment (subsequent acute challenges resulted 
in tolerance).  
Ricaurte et al. 
(1993) 
MDMA 
(2 x 20 mg/kg per day 
for 4 days – repeated 1 
week later). 
S.C. Long-Evans rats Delayed Alteration in T-Maze  
(5 - 180 second delays, training 
began 7 weeks after drug 
treatment) 
No significant effect in learning the task with 0 delay 
& no effect when delays added. 
Robinson et al. 
(1993) 
MDMA 
(8 x 10 mg/kg, 1 
injection every 12 hours) 
I.P. Sprague-Dawley rats Morris water maze acquisition 
(8 trials per day – platform 
shifted to new location each 
day, training began 2 days after 
drug treatment). 
Initial impairment in search strategy when platform in 
new location but once found were able to find it on 
remaining trials – within 4 days of training 
performing at similar level to controls (transient 
impairment). 
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Frederick et al. 
(1995) & 
Frederick & Paule 
(1997) 
MDMA 
(escalating doses of 2 x 
0.10-20.0 mg/kg  – each 
dose given for 14 
consecutive days which 
took approx 4 months) 
I.M. Rhesus monkeys DMTS Task (2 – 48 second 
delays) 
Incremental Repeated 
Acquisition Task 
Colour & Position 
Discrimination Task 
Time Estimation Task 
Progressive Ratio Task 
(All tasks acquired before drug 
treatment) 
No difference in performance before and after chronic 
drug treatment (tolerance developed with repeated 
exposure). 
Frederick et al. 
(1998) 
MDMA 
(2 x 10 mg/kg for 4 days) 
I.M. Rhesus monkeys DMTS Task (2 – 64 second 
delays) 
Incremental repeated acquisition 
task 
Colour & Position 
Discrimination Task 
Time Estimation Task 
Progressive Ratio Task 
(All tasks acquired before drug 
treatment) 
No difference in performance before and after binge 
drug treatment (subsequent acute challenges resulted 
in tolerance). 
Marston et al. 
(1999) 
MDMA 
(2 x 10 mg/kg day 1) 
(2 x 15 mg/kg day 2)  
(2 x 20 mg/kg day 3) 
I.P. Lister Hooded rats DNMTP Task 
(0.3 – 30.0 second delays, task 
acquired before drug treatment) 
Delay dependent impairments during acute treatment 
& still present 16 days post drug-treatment indicating 
long-term working memory impairment (evidence of 
tolerance developing over the 3 days of acute drug 
treatment). 
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Byrne et al. 
(2000) 
MDMA 
(2 x 20 mg/kg for 4 days) 
S.C. Sprague-Dawley rats Acquisition of DRL Task  
(0, 10 & 20 second inter-
response intervals, training 
began 2 weeks after drug 
treatment) 
No effect on group performance – but 25% of 
MDMA treated rats could not learn the task with the 
20 second inter-response interval. 
Broening et al. 
(2001) 
MDMA 
(2 x 5 mg/kg per day 
from P1-10 or P11-20) 
(2 x 10 mg/kg per day 
from P1-10 or P11-20) 
(2 x 15 mg/kg per day 
from P1-10 or P11-20) 
(2 x 20 mg/kg per day 
from P1-10 or P11-20). 
S.C. Sprague-Dawley rats Straight channel swim (P60) 
Cincinnati water maze (P63) 
Morris water maze acquisition 
(P77) 
Morris water maze reversal 
(after acquisition phase) 
Morris water maze 
shifted/reduced platform (after 
reversal phase) 
Morris water maze cued 
learning (P70) 
No effect on swimming speed. 
P1-10 treated rats no effect on performance on 
Cincinnati maze, Morris maze acquisition, Morris 
reversal or shifted/reduced platform. 
P11-20 treated rats significantly impaired on 
performance in Cincinnati maze, Morris maze 
acquisition, Morris maze reversal & shifted/reduced 
platform phase. 
Impaired memory probe trials (conducted at the end 
of each Morris water phase) for P11-20 rats but not 
P1-10 treated rats. 
No effect on cued learning in either group. 
Morley et al. 
(2001) 
MDMA 
(4 x 1 mg/kg for 2 days) 
(4 x 5 mg/kg for 2 days) 
I.P. Albino Wistar rats Object recognition Task  
(15 & 60 minute delays, tested 
14 weeks after drug 
administration) 
Rats treated with higher dose of MDMA spent less 
time exploring novel object with the 15 minute delay 
but not the 60 minute delay (possibly due to floor 
effect) suggesting impaired non-spatial working 
memory. 
Taffe et al.  
(2001) 
MDMA 
(2 x 10 mg/kg for 4 
days). 
I.M. Rhesus monkeys DNMTS (0 – 64 second delays) 
Self Ordered Spatial Search 
(SOSS) 
Progressive Ratio Task 
(All tasks acquired before drug 
treatment) 
Performance impaired on all tasks during drug 
treatment but returned to baseline levels after 1 week 
suggesting binge MDMA treatment had no long-term 
effect on performance. 
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Winsauer et al. 
(2002) 
MDMA 
(2 x 2.5 mg/kg for 4 
days). 
(18 days later 2 x 5 
mg/kg for 4 days). 
I.M. Squirrel monkeys Repeated Acquisition Task  
(Task acquired before drug 
treatment) 
No effect on performance (no difference between 
baseline & either drug treatment) suggests chronic 
MDMA does not impair serial learning. 
Sprague et al. 
(2003) 
MDMA 
(2 x 20 mg/kg given 12 
hours apart) 
S.C. Sprague-Dawley rats Morris water maze acquisition 
followed by probe trials with 
platform removed (Training 
began 7 days post drug 
treatment) 
No effect on learning but impaired performance on 
probe trials. 
Williams et al. 
(2003) 
MDMA 
(2 x 20 mg/kg per day 
from P11-20) 
S.C. Sprague-Dawley rats Straight channel swim (P50) 
Cincinnati water maze (P51) 
Morris water maze acquisition 
(P57) 
Morris water maze reversal 
(P64) 
Morris water maze 
shifted/reduced (P71) 
Morris water maze cued 
learning (P78) 
No effect on swimming speed. 
Impaired Cincinnati maze performance (longer 
latencies, more errors) 
Impaired performance on Morris maze acquisition, 
reversal & shifted/reduced performance phases. 
No effect on cued learning phase of Morris water 
maze. 
Piper & Meyer 
(2004) 
MDMA 
(2 x 10 mg/kg given 
every 5
th
 day from P35-
60). 
S.C. Sprague-Dawley rats Object Recognition Task 
(15 minute delay, tested 5 days 
after drug treatment finished). 
MDMA treated rats spent less time exploring novel 
object, suggests impaired non-spatial working 
memory. 
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Vorhees et al. 
(2004) 
MDMA 
(2 x 5 mg/kg per day 
from P11-20) 
(2 x 10 mg/kg per day 
from P11-20) 
(2 x 20 mg/kg per day 
from P11-20) 
S.C. Sprague-Dawley rats 
(Divided into 2 groups 
to counterbalance order 
of Barnes & Morris 
acquisition tasks). 
Straight channel swim (P61) 
Barnes maze (P62 or P77) 
Morris water maze acquisition 
(P62 or P77) 
Morris water maze cued 
learning (P70) 
Morris water maze working 
memory task (P85) 
No effect on swimming speed. 
No effect on Barnes maze performance – no effect on 
spatial memory. 
Impaired Morris water maze acquisition only in group 
that was tested earlier starting on P62, no effect on 
group who started on P77 – implies transient 
reference memory impairment that recovers over 
time. 
No effect on cued Morris water maze task. 
No effect on working memory Morris water maze 
task. 
Moyano et al. 
(2005) 
MDMA 
(2 x 10 mg/kg for 4 
days) 
I.P. Wistar rats Passive Avoidance Task 
(retention tested 24 hours later, 
training started 7 days post drug 
treatment) 
Binge regime produced no effect on performance 
suggesting no effect on long-term memory 
consolidation (subsequent acute challenge resulted in 
sensitisation). 
Piper et al.  
(2005) 
MDMA 
4 x 5 mg/kg per day, 1 
injection per hour, given 
every 5
th
 day from P35-
60). 
S.C. Sprague-Dawley rats Object Recognition Task  
(15 & 30 minute delays, tested 4 
days after drug treatment 
finished). 
Reduced attention (visited it less & spent less time 
near it) to novel object with the 30 minute delay. 
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Able et al.   
(2006) 
MDMA 
(4 x 15 mg/kg in 1 day) 
S.C. Sprague-Dawley rats Straight channel swim (3 days 
post drug treatment) 
Cincinnati water maze (4 days 
post drug treatment) 
Morris water maze acquisition 
(12 days post drug treatment) 
Morris water maze reversal (19 
days post drug treatment) 
Object recognition (26 days post 
drug treatment, used 1 hour 
delay) 
No effect on swimming speed. 
Impaired Cincinnati performance. 
No effect on Morris water maze acquisition. 
No effect on Morris water maze reversal. 
Impaired on Morris water maze probe trials 
conducted after each phase where platform was 
removed. 
No effect on object recognition performance. 
Skelton et al. 
(2006) 
MDMA 
(2 x 20 mg/kg per day 
from P11 to P20). 
S.C. Sprague-Dawley rats 
Group 1 (tested P30 - 
40) 
Group 2 (tested P180 – 
360) 
Straight channel swim 
Cincinnati water maze 
Morris water maze acquisition  
Morris water maze reversal 
Morris water maze 
shifted/reduced platform 
No effect on swimming speed – no difference 
between the 2 age groups. 
Impaired Cincinnati performance (significantly 
longer latencies, more errors) in younger animals but 
not in the older group. 
Impaired performance in Morris acquisition, probe 
trials, reversal phase & shifted/reduced phase 
(significantly longer latencies, greater distance 
travelled, greater cumulative distance) – both age 
groups impaired.  
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Author 
(date) 
Drug regime 
(dose) 
Method of 
Delivery 
Subjects Cognitive Task (s) Results/Memory Effects 
Skelton et al. 
(2008) 
MDMA 
Group 1- 4 x 15 mg/kg 
over a single day. 
Group 2 - 4 x 15 mg/kg 
over 4 weeks (1 
injection per week) 
S.C. Sprague-Dawley rats Straight channel swim (6 days 
post drug) 
Cincinnati water maze (7-12 
days post drug) 
Morris water maze acquisition 
(14-19  days post drug) 
Morris water maze reversal (21-
26 days post drug) 
Morris water maze 
shifted/reduced platform (28-33 
days post drug) 
Novel object recognition (35-39 
days post drug) 
Novel place recognition (40 
days post drug) 
No effect on swimming time in straight channel. 
Impaired Cincinnati performance (significantly 
longer latencies, more errors) – no difference between 
the two MDMA groups. 
No effect on Morris acquisition & reversal phase. 
Both MDMA groups impaired (significantly longer 
path to reach platform) on Morris shifted & reduced 
phase. 
No effect on object recognition. 
No effect on place recognition. 
 
Skelton et al. 
(2009) 
MDMA 
(4 x 10 mg/kg per day 
from P11 to P20). 
S.C. Sprague-Dawley rats Straight channel swim (9 days 
post drug) 
Morris water maze acquisition 
(10-16 days post drug) 
Morris water maze reversal 1 
(17-23 days post drug)  
Morris water maze reversal 2 
(24-30 days post drug) 
Cincinnati water maze (31-40 
days post drug) 
No effect on swimming speed 
Impaired Morris acquisition, reversal 1, reversal 2 & 
probe trials (significantly longer latencies, greater 
path length & cumulative distance travelled). 
Impaired Cincinnati performance (significantly 
increased latency & errors). 
P - postnatal day I.M. – intramuscular injection S.C. – subcutaneous injection I.P. – intraperitoneal injection 
 
DMTS and DNMTS Tasks 
One of the earliest studies to examine both the acute and chronic effects of 
MDMA exposure on cognitive functioning using a DMTS task was that of LeSage et 
al. (1993). After completion of the acute phase of the study where pigeons had been 
trained to perform a DMTS task they were administered repeated injections MDMA. 
There was no difference in performance before and after chronic MDMA treatment 
suggesting no lasting deficits in performance. However there was evidence of drug 
tolerance when acute challenges of MDMA were administered. Therefore LeSage et al. 
(1993) found that while acute MDMA exposure impaired memory performance 
chronic MDMA treatment did not produce long-term memory impairments. Using a 
similar task Marston et al. (1999) found a binge regime of MDMA impaired DNMTP 
performance during drug administration days and this deficit did not improve 16 days 
post drug treatment. Marston et al. (1999) argued these delay-dependent impairments 
suggested binge MDMA exposure produced harmful long-term effects on memory. 
Using rhesus monkeys the effects of binge MDMA exposure on cognitive 
performance was assessed by Taffe et al. (2001). They utilised a DNMTS task, a 
progressive ratio task and a self-ordered spatial search (SOSS) task. After performance 
had stabilised, a binge regime of MDMA was administered. During the week of drug 
treatment performance was significantly impaired on all tasks but these deficits were 
transient with performance returning to normal the week after drug administration. 
Taffe et al. (2001) concluded that acute MDMA administration impairs cognitive 
performance but binge MDMA treatment does not produce long-term deficits. 
Using a battery of cognitive tasks Frederick et al. (1995) and Frederick and 
Paule (1997) examined the effects of acute and chronic regimes of MDMA on Rhesus 
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monkeys. An operant test battery (OTB) was used that comprised of cognitive tasks 
including a time estimation task, a DMTS task, a progressive ratio task, a lever 
pressing sequence task that assessed learning and a conditional discrimination task. 
Subjects received training on the various cognitive tasks and an acute phase of the 
experiment was conducted two weeks before the chronic regime began. Performance 
was significantly affected by acute MDMA exposure but the chronic regime produced 
no long-term effects. It was also noted that performance on all the cognitive tasks 
showed evidence of drug tolerance (Frederick et al., 1995).  In a later study Frederick 
et al. (1998) administered a binge regime of MDMA to Rhesus monkeys. OTB 
performance was negatively affected by acute MDMA administration but there were 
no long-term effects of binge MDMA treatment. There was also evidence of drug 
tolerance on OTB performance with subsequent acute MDMA challenges. 
In conclusion the evidence for chronic or binge MDMA exposure producing 
memory deficits in DMTS type tasks is mixed, with the majority of studies failing to 
produce evidence of impairments. It would definitely appear that acute MDMA 
exposure disrupts DMTS performance however; it remains unclear as to whether 
chronic or binge regimes of MDMA produce long lasting impairments in these tasks. 
Object Recognition Tasks 
Performance in tasks utilising nonspatial stimuli have also shown impairments 
following binge MDMA administration. For example Morley, Gallate, Hunt, Mallet 
and McGregor (2001) found binge MDMA treated rats were impaired on an object 
recognition task using a 15 minute delay but not a 60 minute delay (possibly due to a 
floor effect where all rats performed poorly in this condition). Therefore Morley et al. 
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(2001) found evidence of a memory impairment after a high dose binge regime of 
MDMA. 
MDMA research has been criticised for using adult rats whereas MDMA use 
often begins in adolescence (Piper & Meyer, 2004). Therefore some researchers have 
administered regimes of MDMA to younger rats to investigate the developmental 
effects on cognition. Chronic research has also been criticised for not representing the 
patterns of use reported in human studies that typically involve intermittent use and 
occurs over longer time periods than that used in animal research (Piper & Meyer, 
2004). To try and more closely resemble human MDMA use, Piper and Meyer (2004) 
administered a chronic regime of MDMA to adolescent rats. When tested in adulthood 
they were impaired on an object recognition task with a delay of 15 minutes. 
Therefore, Piper and Meyer (2004) argued that using an intermittent MDMA regime, 
closer to that found in human MDMA use, impaired non-spatial working memory. In 
an extension of this study Piper, Fraiman and Meyer (2005) used a different regime of 
MDMA and found MDMA treated animals showed impaired object recognition 
performance with a 30 minute delay but not with a 15 minute delay.  
Using a short course binge regime of MDMA Able et al. (2006) found no 
significant impairments on an object recognition task with an hour delay. Skelton et al. 
(2008) also found MDMA treatments did not affect object or place recognition 
performance using an hour delay. 
In conclusion, despite conflicting findings as to which delay period produces 
impairment, in object recognition tasks it is clear that chronic and binge MDMA 
exposure can affect performance in this paradigm. Therefore, chronic and binge 
MDMA regimes do seem to produce impairments in non-spatial memory.  
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Maze Tasks 
Various maze tasks have also been used to assess the effects of chronic and 
binge doses of MDMA on cognition. The earliest study to examine the effects of binge 
MDMA exposure on maze performance was conducted by Slikker et al. (1989) who 
utilised a complex 24 arm maze to assess memory performance. Even though binge 
MDMA treatment produced a fifty percent reduction in 5-HT concentration in the 
frontal cortex and hippocampus of the rats there was no significant effect on maze 
performance. Therefore, Slikker et al. (1989) found binge MDMA treatment did not 
impair spatial memory performance. 
One of the simplest maze layouts is that of the T-maze which consists of a long 
runway that splits at the top where the rat can go either left or right. This task assesses 
spatial memory whereby the rat has to alternate which direction it goes at the top of the 
maze. Therefore it must remember which direction it went on the previous trial. 
Ricaurte et al. (1993) used this procedure to assess the effects of a chronic regime of 
MDMA. While rats showed a significant reduction of brain 5-HT their performance on 
the cognitive task did not significantly differ from drug free controls. Therefore, 
Ricaurte et al. (1993) suggested chronic MDMA treatment did not impair memory as 
assessed by performance in a simple spatial alternation task.  
To assess spatial memory one of the most commonly used mazes is the Morris 
water maze (MWM) (D‟Hooge & De Deyn, 2001). This paradigm involves a large 
circular pool filled with opaque fluid (Morris, 1984). Subjects (typically rats and mice) 
are placed in the maze at a starting point and are trained to swim to a submerged 
escape platform that is placed within the maze (D‟Hooge & De Deyn, 2001). This 
platform is not visible to the rats and therefore requires them to use spatial cues to 
remember its location (Morris, 1984). The standard Morris water maze procedure is 
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used to assess reference memory as the location of the platform remains the same 
between trials (Lindner, Balch & VanderMaelen, 1993) and hence involves trial 
independent long-term stable task rules (Frick, Baxter, Markowska, Olton & Price, 
1995). The time taken to reach the platform (latency), the length of the path to reach 
the platform and cumulative distance from the platform are often used as performance 
measures (D‟Hooge & De Deyn, 2001). After acquisition has occurred probe trials are 
usually conducted where the platform is removed and the time that the rat spends in the 
old platform position, referred to as the target site or target quadrant is measured 
(D‟Hooge & De Deyn, 2001). To assess a subject‟s ability to change their behavior 
and learn a new location a reversal phase is often conducted where the platform is 
shifted to a different quadrant within the maze (Morris, 1984). The amount of time the 
subject spends in the old location and how quickly they learn the new location is 
usually examined.  
The Morris water maze can also assess working memory using a delayed 
matching to place (DMP) task (Morris, 1984) or matching-to-sample procedure 
(Vorhees, Reed, Skelton & Williams, 2004). The platform is shifted to a new position 
each training session and there are multiple trials per session to examine learning 
(Morris, 1984). This procedure is argued to involve working memory as platform 
location changes between sessions requiring a more short-term memory process that 
involves a temporal component where the subject must remember not only the type of 
stimulus presented but also when the stimulus was presented (Frick et al., 1995). 
One of the earliest studies to examine the effects of chronic MDMA on 
cognition using a working memory Morris water maze task was conducted by 
Robinson, Castaneda and Whishaw (1993). Initially MDMA treated rats were 
significantly impaired at finding a shifting platform during the first trials of each 
session. However they were able to learn the task and there were no deficits on 
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memory tests conducted 24 hours later. Therefore MDMA treatment significantly 
impaired the ability to acquire an efficient search strategy when presented with a new 
spatial problem (Robinson et al., 1993). This impairment was temporary as by the 
fourth session performance did not differ from controls. Hence binge MDMA exposure 
did not produce long lasting spatial memory deficits. 
Researchers have examined the developmental effects of MDMA by 
administering chronic regimes of MDMA to adolescent rats and examining their 
ability to acquire maze tasks in adulthood. Broening, Morford, Inmand-Wood, 
Fukumura and Vorhees (2001) administered a regime of MDMA to young rats for a 
period of ten days. When tested in adulthood they were impaired on acquisition, 
reversal and probe trials in the Morris water maze. However there were no significant 
impairments in performance on a cued version of the task. Williams et al. (2003) also 
administered a chronic regime of MDMA to adolescent rats and tested them in 
adulthood. They showed impairments on all measures of performance (latency, path 
length and cumulative distance) namely acquisition, reversal and reduced platform 
(where the size of the platform is made smaller) Morris water maze tasks. Also during 
acquisition probe trials MDMA treated rats were significantly impaired while 
performance on a cued version of the task was unaffected. Using a standard Morris 
water maze task Vorhees et al. (2004) found chronic MDMA treated rats were 
significantly impaired on task acquisition and probe trials but no impairments in cued 
maze or working memory Morris water maze performance.  
To assess whether memory deficits seen after MDMA exposure during 
adolescence produce long-term effects Skelton, Williams and Vorhees (2006) 
administered a chronic regime of MDMA (from P11 - P20) and then assessed 
cognition in both adolescent rats (P30 – P40) and older rats (P180 to P360). During 
acquisition, reversal and a reduced platform phase of the Morris water maze both 
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MDMA treated groups took significantly longer and travelled a greater distance than 
controls. Both MDMA groups were also significantly impaired during probe trials of 
the Morris water maze spending less time in the target quadrant suggesting MDMA 
exposure produced long-term impairments. More recently Skelton et al. (2009) found 
adolescent rats treated with a chronic regime of MDMA were significantly impaired 
during acquisition and subsequent probe trials of a Morris water maze task. Reversal 
phase and shifted/reduced platform performance was also impaired in MDMA treated 
rats. Therefore chronic MDMA exposure in adolescence produces long lasting 
impairments in reference memory and cognitive flexibility in adulthood, however cued 
learning and working memory appear unaffected. 
Also using a Morris water maze Sprague, Preston, Leifheit and Woodside 
(2003) examined the effects of binge MDMA on memory performance. During 
acquisition there were no significant differences between MDMA treated rats and 
controls. However, during probe trials the MDMA treated rats showed a significant 
impairment in the recall of spatial information indicated by worse proximity scores and 
less time spent in the correct quadrant of the maze during probe trials (Sprague et al., 
2003). In addition Able et al. (2006) found a binge treatment of MDMA impaired 
performance on probe trials but did not significantly impair acquisition of a Morris 
water maze task. More recently Skelton et al. (2008) compared a short-term binge 
regime of MDMA with an intermittent regime designed to better model human use. 
Neither MDMA treatments impaired acquisition, reversal or probe trials on a Morris 
water maze task. However during a shifted-reduced phase both MDMA groups 
produced significantly longer paths to reach the platform than controls and there were 
no differences between the two MDMA treated groups. Therefore there is also 
evidence that short-term binge courses of MDMA impair reference memory processes. 
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It should be noted that the Morris water maze has a potential confound as it 
uses latency (time to find the platform) as a measure of memory performance. 
However, Mechan et al. (2002) found that chronic MDMA exposure reduced anxiety 
in rats using a variety of tests. The Morris water maze uses the aversive stimulus of 
being placed in water to motivate the escape behaviour of rats. Therefore when 
MDMA is administered it may be that the rats are able to remember where the 
platform is but they simply do not swim as fast because after MDMA exposure they 
find the water maze less aversive and are less motivated to escape. Thus the rats 
produce slower swimming times which are taken as evidence of a memory deficit. 
Another common maze used is the Cincinnati water maze (multiple T-maze) 
that assesses spatial memory and path integration (Skelton et al., 2008). It is comprised 
of acrylic T-mazes that are filled with water. Rats are placed in the start position and 
are required to swim to the end of the maze where they can escape. Broening et al. 
(2001) administered a repeated regime of MDMA to young rats for a period of ten 
days and found that when tested in adulthood they produced significantly more errors 
in the Cincinnati maze. Williams et al. (2003) and Skelton et al. (2009) also 
administered a chronic regime to rats and found MDMA exposure significantly 
impaired Cincinnati water maze performance. 
To assess whether MDMA exposure during adolescence produces long-term 
effects Skelton et al. (2006) administered a chronic regime of MDMA and then 
assessed cognition in both adolescent rats and older rats. In the Cincinnati maze the 
younger rats produced significantly longer latencies and more errors than saline 
controls. However older rats did not show significant impairments suggesting path 
integration deficits were temporary.  
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Utilising a binge regime of MDMA Able et al. (2003) found MDMA treated 
subjects produced significantly more errors than controls. Skelton et al. (2008) 
compared the previously used binge MDMA regime from Able et al. (2006) with a 
new one that was designed to better modeled human use. Both MDMA treated groups 
produced significantly more errors and significantly longer latencies than saline 
controls on the Cincinnati water maze but there were no significant differences 
between the two MDMA groups. In conclusion MDMA exposure appears to impair 
spatial memory and path integration processes. 
The Barnes maze consists of a circular platform that is mounted on a rotatable 
stand (Vorhees et al., 2004). Around the circumference of the platform are 30 holes. 
Underneath one of them is a goal box that the rat can enter to avoid aversive stimuli 
(Vorhees et al., 2004). The goal box is not visible from the surface of the maze and 
therefore the rats have to learn which hole contains the goal box from extra maze cues. 
Vorhees et al. (2004) examined the effects of a chronic treatment of MDMA on 
cognition using a Barnes maze and found no significant differences between MDMA 
treated rats and controls. However this finding was possibly confounded as 
performance on this task was poor overall (Vorhees, et al., 2004).  
 In conclusion there seems ample evidence that chronic and binge MDMA 
exposure produces memory impairments as assessed using various maze tasks. In 
particular chronic MDMA treatment seems to produce reference memory impairments 
in the Morris water maze while leaving working memory and cued learning intact. It 
would also appear that often these deficits in reference memory are long lasting as the 
impairments are often present when reversal phases of the maze are utilised.  
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Other types of cognitive tasks 
 Not all studies have found evidence of MDMA treatment impairing 
performance on cognitive or learning tasks. Li, Marek, Vosmer and Seiden (1988) 
trained rats on a differential-rate-of-low-reinforcement (DRL) 72 seconds task. In this 
task a response made after 72 seconds produced reinforcement but a response made 
before 72 seconds had elapsed was not reinforced and the timer was restarted. There 
was no significant effect of a binge regime of MDMA on performance. When 
subsequent challenges of acute MDMA were administered performance was impaired. 
Therefore Li et al. (1988) found evidence that acute MDMA exposure disrupted 
performance but a binge regime did not produce a noticeable long-term deficits. 
In addition Byrne et al. (2000) used a DRL lever pressing acquisition task to 
assess the effects of chronic MDMA treatment in rats. There was a significant decrease 
in 5-HT and 5-HIAA levels in several brain regions but no significant differences 
between MDMA and saline treated rats on measures of task acquisition. Therefore 
Byrne et al. (2000) found binge MDMA exposure did not impair learning. However in 
the condition with the longest inter-response delay 25% of the MDMA treated subjects 
failed to acquire the task suggesting some degree of learning impairment. 
 Using a repeated acquisition task that involved learning novel lever pressing 
sequences, Winsauer et al. (2002) examined the effects of binge MDMA exposure on 
cognition. Squirrel monkeys were assessed on the task before and after two binge 
regimes of MDMA. No significant differences between baseline and performance after 
dose 1 and dose 2 of MDMA were found. Therefore Winsauer et al. (2002) found 
binge MDMA exposure did not affect serial learning. 
 Finally Moyano, Del Rio and Frechilla (2005) examined the acute and binge 
effects of MDMA on a passive avoidance task. A week later 5-HT levels were reduced 
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but no effect on the avoidance task was found. However when later challenged with 
acute doses of MDMA performance was significantly disrupted indicative of drug 
sensitisation. Therefore, once again acute MDMA administration appeared to disrupt 
memory performance but binge exposure produced no discernable long-term effects on 
memory consolidation (Moyano et al., 2005). 
 In conclusion there appears ample evidence that acute MDMA administration 
can disrupt performance on a range of cognitive tasks. However there is also evidence 
that binge regimes of MDMA produce no long-term effects on an array of learning and 
cognitive tasks. However, it should be noted that binge MDMA administration does 
seem to alter behaviour when performance is later challenged with acute doses of 
MDMA which may be indicative of some underlying impairment. 
Conclusion 
Although not all studies have found significant impairments in memory 
function on an array of tasks, there is some evidence to suggest that chronic and binge 
regimes of MDMA produce specific memory impairments. Seemingly one of the most 
pronounced effects of chronic and binge MDMA exposure can be seen in maze tasks. 
Perhaps one of the most interesting findings is that using the Morris water maze both 
binge and chronic MDMA administration appears to impair reference memory while 
leaving working memory and cued learning processes intact. However, to date there 
has not been any research conducted on adolescent or adult rats using the radial arm 
maze. In fact the only study that seems to have used this apparatus in chronic MDMA 
research was conducted on rats that were prenatally treated with a chronic regime of 
MDMA (Thompson et al., 2009). The MDMA treatment produced no effect on maze 
performance in the offspring of these rats when tested in adulthood. Therefore it was 
 166 
found that MDMA exposure during pregnancy did not affect the radial arm maze 
performance of offspring later in life. However, this finding does not answer whether 
MDMA exposure would affect radial maze performance in rats who are directly 
administered the drug rather than being exposed via their pregnant mothers. 
The partially baited radial arm maze paradigm is a particularly useful paradigm 
as it enables both reference and working memory processes to be examined 
simultaneously. By using this paradigm the previous research examining the binge and 
chronic effects of MDMA on Morris water maze performance can be extended by 
allowing working and reference memory processes to be investigated using the same 
procedure. Therefore the second part of the current thesis will administer binge 
regimes of MDMA to rats to examine the drugs effects on performance in a partially 
baited radial maze procedure.  
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General Binge MDMA Method 
Apparatus/Materials 
The radial arm maze and other apparatus used in the binge section of the thesis 
was the same as that used in the previous studies of this thesis (see Figure 2 in the 
General Acute MDMA Method section for diagram of the radial maze and details of 
other materials used).  
Procedure 
Pretraining: The procedure for this phase was the same as that used in the 
acute studies (see General Acute MDMA Method section for details).  
Training: The basic training procedure used was the same as that used in the 
acute studies (see General Acute MDMA Method section for details).  
Pharmacological Procedure: The binge studies used a between-subjects 
experimental design. Rats were randomly divided into an experimental binge group 
and a saline control group. Experimental rats received a binge regime of MDMA that 
consisted of 4 injections of 10 mg/kg MDMA that were administered two hourly over 
the period of one day. The control group received 4 injections of 0.9% saline that were 
also administered two hourly. After the drugs were administered in the binge studies, 
rats were then given the training procedure outlined above. Again all drugs were given 
via i. p. injection. 
Statistical Analyses: All inferential statistics were calculated using an alpha 
level of 0.05. All p-values are given to two decimal places. 
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Study 3: Binge Effects of MDMA on Radial Arm Maze Acquisition 
Previous research that has examined the effects of chronic and binge regimes of 
MDMA on cognitive processes has produced mixed results (see Chronic MDMA 
Introduction for a review). More specifically in terms of learning processes the effect 
of chronic and binge MDMA exposure on the ability to learn or acquire tasks has also 
resulted in conflicting findings depending on the type of cognitive task utilised. For 
example the administration of binge regimes of MDMA has failed to produce deficits 
in acquiring tasks involving learning to respond on DRL schedules (Li et al., 1988), 
lever pressing (Byrne et al., 2000), lever sequence pressing (Winsauer et al., 2002), 
and passive avoidance (Moyano et al., 2005).  
While MDMA exposure failed to produce learning deficits in the above 
cognitive tasks there is research that has found the chronic and binge MDMA exposure 
impairs the learning of various maze tasks. However some of these studies have only 
produced evidence of transient memory deficits. For example Robinson et al. (1993) 
found initially MDMA treated rats were significantly impaired at finding the shifting 
platform in a Morris water maze task during the first couple of trials each session. 
However by the end of training they were able to learn the task and were performing at 
a similar level to controls.  
The finding that binge MDMA exposure may produce transient effects has also 
been found in physiological studies. For example Scanzello, Hatzidimitriou, Martello, 
Katz and Ricaurte (1993) examined the effect of a chronic regime of MDMA (4 x 10 
mg/kg) on serotonergic neurotoxicity in rats. Two weeks after drug exposure there 
were significant reductions in 5-HT markers. However after sixteen weeks there was 
 169 
evidence of recovery in some brain regions and by thirty weeks there was almost full 
recovery. Even when using larger doses of MDMA there has been evidence of 
recovery. For example Sabol, Lew, Richards, Vosmer and Seiden (1996) administered 
a binge regime of MDMA to rats (8 x 20 mg/kg) and then measured brain 5-HT 
concentration. A significant reduction in 5-HT levels was found two weeks after drug 
exposure but by sixteen weeks there was some initial evidence of recovery that 
increased up to 52 weeks later. In addition there has been evidence of behavioural 
recovery of function occurring twelve weeks after MDMA exposure in tasks assessing 
locomotor activity (Brennan & Schenk, 2006). Therefore one explanation for the 
apparent transient behavioural effects seen in some of the studies that have examined 
the binge effects of MDMA on cognition may be the result of physiological recovery  
There has also been some evidence that chronic MDMA exposure has produced 
more long-term cognitive deficits which remain several weeks after drug exposure. For 
example Broening et al. (2001) found MDMA treated rats were significantly impaired 
on a Morris water maze and a Cincinnati maze task and these impairments were still 
evident more than 50 days post drug treatment. Similarly chronic and binge MDMA 
exposure produced long lasting impairments in sequential or path integration and 
reference memory as assessed using the Cincinnati and Morris water mazes (Williams 
et al., 2003; Able et al., 2006; Skelton et al., 2008; Skelton et al., 2009). Whereas 
Sprague et al. (2003) found MDMA-treated rats were significantly impaired in their 
ability to recall spatial information during Morris water probe trials. Vorhees et al. 
(2004) found several reference memory measures of Morris water maze performance 
were significantly impaired more than forty days after MDMA administration 
indicating a long-term cognitive impairment. Finally Skelton et al. (2006) found 
MDMA treated rats showed reference memory impairments in the Morris water maze 
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when tested 160 and even 340 days after drug treatment indicating a notable long-term 
cognitive deficit. 
Therefore chronic and binge MDMA exposure can produce deficits in the 
ability to acquire various cognitive tasks. Specifically it impairs maze performance in 
particular reference memory and path integration processes seem more susceptible to 
the effects of MDMA administration. However cued learning and working memory 
tasks appear to be unaffected. Therefore one possible explanation for the conflicting 
task acquisition findings is that chronic and binge MDMA exposure is more likely to 
impair tasks that have a high reference memory component to them. Thus the finding 
that MDMA exposure has not produced impairments in the acquisition of some 
operant based tasks could be that these tasks do not involve reference memory 
processes to the same extent as Morris and Cincinnati water maze procedures. 
However, it should be noted that in many of these maze studies the order in 
which the tasks are conducted may produce a potential confound. The majority of the 
studies that have examined the effects of MDMA exposure on maze performance have 
started testing with the standard Morris water maze and Cincinnati maze tasks and 
generally test cued learning and working memory later. As there is evidence that the 
effects of binge MDMA regimes may produce transient effects it is possible that the 
reason cued learning and working memory processes seem unaffected by MDMA 
exposure may be that by the time these tasks are conducted subjects may have began to 
experience recovery of function from the effects of the drug regime.  
Also when using the Morris water maze to test for reference and working 
memory it requires different procedures that need to conducted during different times 
as this apparatus does not allow for the simultaneous assessment of working and 
reference memory processes. Therefore this introduces potential confounds in trying to 
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ascertain which cognitive processes are affected by chronic and binge regimes of 
MDMA. Hence the partially baited radial arm maze may provide an invaluable 
opportunity to examine the effects of MDMA exposure on both working and reference 
memory processes concurrently. 
Drug Tolerance or Sensitisation 
 Drug tolerance occurs when a subject becomes progressively less responsive to 
a drug and requires more of the drug to have the original effect (Parrott, 2005). Ecstasy 
users have reported having to increase the amount of the drug they take to experience 
the positive effects of the drug (Parrott, 2001). For example while first time users 
generally take one tablet of Ecstasy, regular users often take two to three tablets and 
there are reports of long-term users taking up to 25 tablets (Parrott, 2005). These 
findings indicate Ecstasy users become tolerant to the effects of the drug. Tolerance is 
an important component in DSM-IV criteria for drug dependence and abuse (Cottler et 
al., 2001) and therefore examining whether repeated MDMA exposure produces drug 
tolerance is worthy of further research. However, animal literature that has examined 
the effects of MDMA exposure has mixed findings with some studies reporting 
repeated administration of the drug results in drug tolerance while others report drug 
sensitisation occurs. In contrast to drug tolerance, drug sensitisation occurs when there 
is a progressive increase in the responsiveness to a drug with repeated administration 
of the original dose (Ramos, Goni-Allo & Aguirre, 2005). While there are numerous 
underlying neurochemical causes as to why drug tolerance and drug sensitisation 
occur, the focus of this thesis is on the behavioural effects of MDMA. Therefore we 
will investigate whether behavioural drug tolerance or sensitisation occurs following 
repeated MDMA exposure. 
 172 
Within animal research there is evidence of behavioural tolerance whereby 
animals that have been previously exposed to MDMA are less affected when re-
exposed to the drug compared to subjects that did not experience pre-exposure 
(Shankaran & Gudelsky, 1999; Piper, Vu, Safain, Oliver & Meyer, 2006; Brennan & 
Schenk, 2006). Evidence of behavioural tolerance resulting from repeated exposure to 
MDMA has also been found in more complex tasks that assess cognitive functioning 
(LeSage et al., 1993; Marston et al., 1999). Other studies have also produced evidence 
of behavioural tolerance developing to MDMA such as Frederick et al. (1995), 
Frederick & Paule (1997) and Frederick et al. (1998). In these studies repeated 
exposure to MDMA resulted in a lessening of the initial impairments seen on a large 
battery of cognitive tasks indicating that performance was less affected as drug 
administration continued. 
In contrast there have also been reports of repeated MDMA exposure 
producing behavioural sensitisation within the animal literature (Spanos & Yamamoto, 
1989; Kalivas, Duffy & White, 1998; Modi, Yang, Swann & Dafny, 2006). In addition 
there is evidence that behavioural sensitisation can occur after repeated MDMA 
administration in tasks that investigate cognitive functioning (Li et al., 1989; Moyano 
et al., 2005). 
Therefore in the final phase of the current study, to try and clarify whether 
MDMA exposure produces behavioural tolerance or sensitisation, both the binge 
MDMA treated and saline control rats were subsequently administered acute doses of 
MDMA (4.0 mg/kg) to examine what effect this would have on their performance once 
they had acquired the task. Specifically, this study investigated whether the binge 
treated rats would show evidence of tolerance which would be present if their 
performance in the maze task was less impaired than those of the saline controls 
treated with acute MDMA. Alternatively evidence of sensitivity to the acute effects of 
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MDMA would be indicated by greater impairment in the binge treated rats compared 
to the saline controls after acute MDMA administration. 
The reasons why such conflicting findings as to whether repeated MDMA 
exposure results in tolerance or sensitisation are unclear. However Brennan and 
Schenk (2006) offer one possible explanation that involves the regime of MDMA the 
subjects are exposed to. It has been suggested that repeatedly administering low doses 
of MDMA may result in sensitisation developing to the effects of MDMA while 
tolerance may develop following the administration of large chronic or binge doses 
(Brennan & Schenk, 2006). 
The Current Investigation 
Previous studies concerning MDMA's effects on learning using animal subjects 
have produced mixed results. Previous research has produced evidence that acute and 
chronic or binge MDMA exposure may affect reference memory more than working 
memory (Harper et al., 2005; Harper et al., 2006; Kay et al, 2009; Broening et al., 
2001; Williams et al., 2003; Sprague et al., 2003; Vorhees, 2004; Skelton et al., 2006; 
Able et al., 2006; Skelton et al., 2008; Skelton et al., 2009). However, to date no study 
has used the partially baited radial arm maze paradigm to study the effect of binge 
MDMA exposure performance of adult rats acquiring this procedure. This paradigm is 
advantageous in that it can differentiate between working memory and reference 
memory impairments. Therefore, the partially baited radial arm maze task enables the 
assessment of an issue not specifically examined in studies utilising tasks that focus 
only on working memory or are unable to assess working and reference memory 
simultaneously using the same procedure. 
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The first part of the current study investigated the effects of a previously used 
binge (4 x 10 mg/kg) MDMA treatment (Scanzello et al., 1993; Brennan & Schenk, 
2006) on the acquisition of the partially baited radial arm maze paradigm. Rats were 
administered a binge regime of MDMA and their ability to learn or acquire the radial 
arm maze task was compared against control rats that received saline. Therefore the 
current study hypothesises that the MDMA treated rats would show impaired learning 
compared to saline controls and specifically this impairment would be the result of a 
reference memory deficit. 
The second part of the current study investigated the effects of re-administering 
the binge regime of MDMA to the rats. This phase was conducted due to research 
(Robinson et al., 1993) that suggests MDMA may produce transient effects on 
memory. Due to a period of approximately eight to ten weeks between the initial drug 
administration and the commencement of radial maze training in the initial phase of 
the study, there is the possibility that any transient cognitive deficits would not be 
evident. Therefore the rats in the experimental MDMA group were re-treated with the 
same regime of MDMA used in the first phase to examine whether further exposure 
would produce a deficit in performance in the radial arm maze task after acquisition 
had occurred. It was hypothesised that further MDMA exposure would result in a 
deficit in performance. Specifically it is hypothesised that the MDMA treated rats will 
be less accurate than the saline controls and that they will produce more reference 
memory errors than working memory errors. 
Finally the last part of the current study examined whether repeated MDMA 
exposure would produce evidence of drug tolerance or sensitisation. After the first two 
phases of the study had been completed all rats were challenged with an acute dose of 
MDMA to examine what effect this would have on rats that had already learnt the task 
and had already been exposed to repeated binge regimes of MDMA. As previous 
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research (Brennan & Schenk, 2006) suggests pre-treatment with chronic/binge regimes 
of MDMA may produce tolerance to the effects of MDMA, it was hypothesised that 
repeated MDMA exposure would result in drug tolerance. This behavioural tolerance 
would be revealed by the rats that were previously treated with a binge regime of 
MDMA would be less impaired than the control rats when the subsequent acute 
MDMA treatments were administered. 
 
Method 
Subjects 
The subjects were twenty white male Sprague-Dawley rats that were 
approximately five months old at the beginning of the current study. The rats were 
housed individually. To reduce the number of animals used within the laboratory the 
current rats were not experimentally naïve as they had previously participated in a 
study examining the effects of binge MDMA on anxiety that used an emergence test. 
However they had never received training in a maze or operant procedure previous to 
the current investigation.  
The rats were kept at 85-90% (between 237 and 382 grams) of their free 
feeding body weight and began training in the current study five days after reaching 
this weight. They had continuous access to water and were kept on a 12:12-hour 
dark:light cycle and were run during the light phase of this cycle. 
Apparatus/Materials 
The maze and reinforcers used were the same as those stated in the general 
method section. Drugs used were saline 0.9 % and MDMA 10 mg/kg, which were 
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prepared on the day of use by dissolving to the required dose in 0.9 % saline solution. 
During the tolerance phase of the experiment MDMA 4.0 mg/kg was used and it was 
also dissolved to the required dose in 0.9 % saline solution. 
Procedure 
The study used a between-subjects experimental design where one group of rats 
received binge doses of MDMA and the other received saline. Rats were assigned to 
the experimental and control group (10 rats in each group). Rats in the experimental 
binge group received injections of 10 mg/kg of MDMA while control rats were given 
0.9 % saline. Each rat was given four injections at two hour intervals. Unfortunately 
one of the rats in the experimental group died after receiving only a few sessions of 
training and so this rat‟s data are excluded from all analyses. Therefore, there were 
only nine rats in the binge group, compared to ten in the saline control group.  
Each rat was assigned a set of four reinforced arms and four non-reinforced arms 
within the maze. The binge and control rats had the same sets of reinforced and non-
reinforced arms, so that the first rat in both groups had the same reinforced arms so 
that there were matched pairs of rats. This was done to control for difficulty of the task 
in case some sets of maze arms were easier to learn that others. Training was 
conducted in the same way as outlined in the General Acute MDMA Method section 
with the habituation sessions commencing approximately eight weeks after being 
given either the binge regime of MDMA or saline control.  
Acquisition: During the acquisition phase each rat was only given one session 
(consisting of three trials) in a day. Rats were run in numerical order within their 
experimental groups, starting with rat one and finishing with rat ten. Each group of rats 
were given five sessions of training per week. In the first phase of the experiment rats 
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had to reach a criterion of a group average of at least 85% accuracy for five 
consecutive days before they had been considered to have achieved acquisition. This 
took twenty three training sessions after which time the second phase of the 
experiment began. 
Re-dosing: This phase examined what effect additional exposure to binge doses 
of MDMA would have on performance in a task that had already been acquired. 
Therefore during the second phase the injections were repeated where the experimental 
group again received MDMA (4 x 10mg/kg) and the control group were administered 
saline (0.9%). As in the previous phase, each rat received four injections in total with a 
two hour period between injections. Unfortunately two of the rats that received the 
binge doses of MDMA died during this procedure leaving seven rats in the 
experimental group and ten in the control group. No rats were run during the day of 
injections and they were also given an additional rest day after this. Maze running 
commenced after this rest day and rats were run using the same procedure as in the 
previous phase of this study. This phase continued for another twenty three sessions as 
by this time performance had stabilised. 
Acute Effects: Finally in the third and last phase of the experiment we 
conducted a study to examine the effects of acute administration of MDMA on both 
the experimental and control groups. This phase began immediately following the 
second phase of the study. All drugs were administered via an intraperitoneal injection 
twenty minutes before running. Rats were run in batches where the first four rats were 
injected and then twenty minutes after the first rat was injected all four rats were run. 
Once this batch had completed running the maze the second batch of three was run 
until all the rats were finished. This study began with all rats receiving an injection of 
0.9 % saline and they were then run in the maze as usual. This was followed by three 
sessions of running without any drugs being administered. Finally on the last day of 
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the study all rats received an injection of 4.0 mg/kg of MDMA and were then run in 
the maze as usual.  
 
Results 
Acquisition and Re-dosing 
In all figures error bars show standard error of the mean. Daily percent correct 
figures were calculated by averaging across the three daily trials to obtain an average 
level of performance for the session for an individual. Group means were then 
calculated for both the experimental binge group and the saline control group. This 
was done for each daily session for both initial acquisition and the re-dosing phase and 
these data are shown in Figure 11.  
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Figure 11: Average percent correct across all rats in the binge and control groups for 
each session of acquisition training and then for sessions after re-dosing. 
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Figure 11 shows that during the acquisition phase accuracy increased for both 
groups across training sessions and there was no visible difference between the binge 
and control groups in the accuracy and speed in which they learnt the radial maze task. 
This was confirmed by a two-way mixed ANOVA that found no interaction, F (22, 
374) = 1.07, p > 0.05 (p = 0.38) and no main effect for group, F (1, 17) = 1.24, p > 
0.05 (p = 0.28). However there was a main effect for training session, F (22, 374) = 
50.02, p < 0.05 (p = 0.00). 
In addition during the re-dosing phase there was no real difference in accuracy 
between the groups in the first two sessions. However, by the third session the binge 
group‟s accuracy started to decline in comparison to the control group and this trend 
continued until around session fifteen where performance started to improve until it 
reached an equivalent level to the control group. Therefore, the experimental binge 
group did appear to experience some degree of transient impairment during the re-
dosing phase. These effects were confirmed by a two-way mixed ANOVA where 
during the re-dosing phase there was a main effect for session, F (22, 330) = 3.02, p < 
0.05 (p = 0.00) and for group, F (1, 15) = 28.41, p < 0.05 (p = 0.00), but these main 
effects were moderated by a significant interaction between training session and group, 
F (22, 330) = 3.54, p < 0.05 (p = 0.00). 
Average trial completion times (in seconds) for each daily session were 
calculated for each rat and this data was then used to obtain group averages for both 
the binge and controls groups. These data are depicted in Figure 12 and show trial 
completion time decreased for both groups as training continued producing a main 
effect for session, F (22, 374) = 20.15, p < 0.05 (p = 0.00). However during initial 
acquisition there was no noticeable difference between the MDMA treated group and 
the saline control group with no interaction between training sessions and drug 
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treatment group, F (22, 374) = 1.15, p > 0.05 (p = 0.29) and no main effect for group, 
F (1, 17) = 0.14, p > 0.05 (p = 0.71).  
During the re-dosing phase there is an increase in trial completion times for the 
MDMA treated group that lasted approximately eight sessions. Hence MDMA treated 
rats took longer than the controls on average to complete their trials during this period 
which could be indicative of a learning impairment. A two-way mixed ANOVA 
confirmed these effects with main effects for session, F (22, 330) = 5.76, p < 0.05 (p = 
0.00) and group, F (1, 15) = 12.47, p < 0.05 (p = 0.00) that were qualified by a 
significant interaction between session and group, F (22, 330) = 3.73, p < 0.05 (p = 
0.00). 
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Figure 12: Average trial completion times in seconds across all rats in the binge and 
control groups for each session of acquisition training and then for sessions after re-
dosing. 
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Working Vs. Reference Memory Data 
To examine the difference between types of error, the average number of 
working memory errors and reference memory errors made per session for each rat 
was obtained by averaging across the three trials.  These figures were then converted 
into percentage error values in the same way as in the previous studies. Average error 
percentage values were calculated for both the experimental group and the control 
group by averaging across the rats in these groups. This was done for each daily 
session for both the acquisition and re-dosing phases of the study and each error type.  
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Figure 13: Average working memory error percentages across all rats in both the binge 
MDMA and saline control groups during acquisition and re-dosing.  
 
 
For the acquisition data a 2-way repeated measures ANOVA comparing error 
type and training sessions revealed a significant interaction between error type and 
session, F (22, 396) = 36.75, p < 0.05 (p = 0.00). Thus there was a significant 
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difference in the type of errors made over the training sessions. During the re-dosing 
phase there was no significant interaction between error type and session, F (22, 352) = 
0.93, p > 0.05 (p = 0.56) indicating that there was no difference in error type during re-
dosing. These effects were examined further by individually analysing the data for 
working and reference memory errors across training sessions and between groups.  
The data for average working memory errors are presented in Figure 13 and 
show that both groups made few working memory errors during acquisition and there 
appears to be no clear difference in performance between the two groups. However, 
the size of the error bars indicates there was some variability in the data. A two-way 
mixed ANOVA found no significant differences in performance with no significant 
interaction between group and session, F (22, 374) = 0.68, p > 0.05 (p = 0.86) and no 
main effects for session, F (22, 374) = 0.73, p > 0.05 (p = 0.80) or group, F (1, 17) = 
0.09, p > 0.05 (p = 0.77). Therefore MDMA treatment had no significant effect on 
working memory errors when acquiring the partially baited radial maze task. 
Figure 13 also shows that during the re-dosing phase there were very few 
working memory errors made and there was no obvious change in the number of 
working memory errors made across training sessions with no main effect for training 
session, F (22, 330) = 1.38, p > 0.05 (p = 0.12). There was also no noticeable 
difference in performance between the MDMA treated and saline control group with 
no significant interaction between group and training session, F (22, 330) = 0.79, p > 
0.05 (p = 0.74) and no main effects for group, F (1, 15) = 1.37, p > 0.05 (p = 0.26). 
Therefore exposing the rats to another regime of MDMA still had no significant effect 
on working memory performance.  
The data for average reference memory errors are presented in Figure 14 and 
show that during the acquisition phase initially both groups of rats produced quite a 
high number of reference memory errors. However, as training progressed and rats 
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began to acquire the task the number of reference memory errors decreased to a very 
low level producing a main effect for session, F (22, 374) = 56.66, p < 0.05 (p = 0.00). 
There were no obvious differences between the MDMA and saline treated groups in 
Figure 14 and there was no interaction between group and training session, F (22, 374) 
= 1.13, p > 0.05 (p = 0.31) and no main effect for group, F (1, 17) = 1.28, p > 0.05 (p = 
0.27). Therefore binge MDMA exposure produced no significant reference memory 
impairment compared to saline treatment during the training phase. 
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Figure 14: Average reference memory error percentages across all rats in both the 
binge MDMA and saline control groups during acquisition and re-dosing. 
 
Throughout the re-dosing phase of the experiment the number of reference 
memory errors made by the control group still continued to decrease slightly levelling 
out at a very low number of errors. However, the MDMA group during the same 
period began making more reference memory errors and this continued to increase for 
approximately eight sessions when it began to gradually decrease until it levelled out 
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to reach a similar level of performance to the control group. There were main effects 
for session, F (22, 330) = 2.67, p < 0.05 (p = 0.00) and group F (1, 15) = 36.53, p < 
0.05 (p = 0.00), however these main effects were qualified by a significant interaction 
between group and session, F (22, 330) = 4.14, p < 0.05 (p = 0.00). Therefore re-
exposing the rats to MDMA during the re-dosing phase had a disruptive effect on 
reference memory processes across this phase of the study. 
 
Acute Drug Effects 
Percent correct figures were calculated by averaging across the three daily trials 
to obtain an average level of performance for the session for an individual. Group 
averages for both the experimental and control rats were calculated and these data are 
depicted in Figure 15. This figure shows that both groups produced a high level of 
accuracy, as shown by average percent correct values exceeding ninety percent, during 
the acute saline treatment. There was also no obvious difference between groups in 
their level of performance during saline treatment.  
During the acute MDMA session both groups produced lower levels of 
accuracy than those seen during the saline session. Interestingly the binge MDMA 
group produced a higher average percent correct value than the saline control group 
during this session. This suggested that the saline controls were more affected by the 
acute dose of MDMA than the experimental group. These effects were confirmed by a 
two-way mixed ANOVA that revealed a significant interaction between acute drug 
treatment and group, F (1, 15) = 9.58, p < 0.05 (p = 0.00). There were also main effects 
for acute drug treatment, F (1, 15) = 192.18, p < 0.05 (p = 0.00) and group, F (1, 15) = 
6.01, p < 0.05 (p = 0.03). 
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Figure 15: Average percent correct across all rats for both the experimental binge 
group and the saline control group during the acute phase. 
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Figure 16: Average trial completion time in seconds across all rats for both the 
experimental binge group and the control group during the acute tolerance study. 
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Average session trial completion times (in seconds) were calculated for each 
individual rat. These data are depicted in Figure 16 and show both the binge MDMA 
and control groups produced similar low trial completion times during saline 
administration. However, during the MDMA session both groups produced much 
longer trial completion times compared to the saline session. Also the control group 
produced much longer trial completion times than that of the binge MDMA group. 
Again this suggested that saline controls were more affected by the acute dose of 
MDMA than the binge MDMA group. These effects were confirmed with a significant 
interaction between acute drug treatment and group, F (1, 15) = 8.91, p < 0.05 (p = 
0.01). There was also a main effect for acute drug treatment, F (1, 15) = 69.32, p < 
0.05 (p = 0.00) and a main effect for group, F (1, 15) = 7.54, p < 0.05 (p = 0.02).  
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Figure 17: Average error percentage across all rats in both the binge MDMA and 
saline control groups during the acute phase where all rats were administered 0.9 % of 
saline and 4.0 mg/kg of MDMA. RM stands for reference memory and WM stands for 
working memory. 
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The number of working and reference memory errors made per session for each 
rat were calculated and converted into percentage error values. Average error 
percentage values were calculated for both the binge MDMA group and the saline 
control group. These data are depicted in Figure 17 and show that saline administration 
produced very few working memory errors in either group. With acute MDMA 
exposure the number of working memory errors increased for both groups with the 
control group producing slightly more working memory errors than the binge MDMA 
group. However there was no significant interaction between acute drug treatment and 
group, F (1, 15) = 1.17, p > 0.05 (p = 0.30).and no main effect for group, F (1, 15) = 
2.61, p > 0.05 (p = 0.13). A main effect for drug treatment was found, F (1, 15) = 
12.75, p < 0.05 (p = 0.00). From Figure 17 it is clear that this difference is due to acute 
MDMA treatment producing more working memory errors than acute saline treatment. 
Figure 17 also shows that very few reference memory errors were made by 
either group during the saline session. However during the acute MDMA session there 
were a large number of reference memory errors made by both groups but the saline 
control group appeared to make more reference memory errors than the binge MDMA 
group. A two-way mixed ANOVA confirmed this effect with a significant interaction 
between acute drug treatment and group, F (1, 15) = 6.01, p < 0.05 (p = 0.03). There 
was a main effect for acute drug treatment, F (1, 15) = 133.02, p < 0.05 (p = 0.00), but 
no main effect for group, F (1, 15) = 2.62, p > 0.05 (p = 0.13).  
To compare the types of error made a 3-way mixed ANOVA was conducted. 
There was no 3-way interaction between memory type, acute drug treatment and 
group, F (1, 15) = 1.91, p > 0.05 (p = 0.19). Therefore there was no significant 
difference between the types of errors (working and reference) made during drug 
treatment (acute MDMA and acute saline) between the binge MDMA group and the 
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saline controls. There was also no interaction found between memory type and group, 
F (1, 15) = 0.30, p > 0.05 (p = 0.60). Therefore there was no significant difference 
between the number of working and reference memory errors made between the binge 
MDMA and control groups. However there was a significant interaction between 
memory type and acute drug treatment, F (1, 15) = 51.37, p < 0.05 (p = 0.00); 
indicating that there were significantly more reference memory errors made than 
working memory errors during the acute MDMA treatment. There was also a 
significant interaction between acute drug treatment and group, F (1, 15) = 10.08, p < 
0.05 (p = 0.01); suggesting that there was a significant difference in the effects of the 
acute MDMA treatment and acute saline treatment on the two groups where the saline 
controls were more affected by the acute drug treatment. There were main effects for 
memory type, F (1, 15) = 49.84, p < 0.05 (p = 0.00), acute drug treatment, F (1, 15) = 
196.89, p < 0.05 (p = 0.00) and group, F (1, 15) = 6.95, p < 0.05 (p = 0.02).  
Therefore, it would appear that repeated MDMA exposure produces drug 
tolerance as those in binge MDMA group who have already received MDMA 
treatment were not as affected as the saline control group who had not been previously 
exposed to MDMA. Also as in the first half of the thesis it was found that acute 
MDMA administration produced a decrease in accuracy, an increase in the average 
amount of time taken to complete a trial. Also of note acute MDMA administration 
resulted in more reference memory errors than working memory errors, once again 
indicating that MDMA exposure impairs reference memory processes. 
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Discussion 
To recap, the intention of the current study was to examine whether a binge 
regime of MDMA would impair the ability of rats to acquire the partially baited radial 
arm maze task. The administration of a binge regime of MDMA produced no 
significant differences in terms of accuracy and trial completion time compared to 
saline controls during the initial acquisition phase. Therefore binge MDMA exposure 
did not seem to impair learning thus failing to support the hypothesis that the regime of 
MDMA used would disrupt maze acquisition. Of interest rats produced more reference 
memory errors than working memory errors during the initial acquisition phase of the 
task. However, there were no significant differences between the number and type of 
errors made between the two groups suggesting MDMA exposure did not affect error 
production. 
 The current study also investigated whether additional exposure to a binge dose 
of MDMA would impair performance once the task was learnt. During the re-dosing 
phase the binge MDMA treated group showed a significant decrease in accuracy and 
an increase in trial completion time compared to the saline control group. Also during 
this phase the number of working memory errors made was unaffected, however the 
rats in the binge MDMA group produced a significant increase in the number of 
reference memory errors made compared to the saline group. Therefore, during this re-
dosing phase we did find evidence of MDMA exposure producing a cognitive deficit 
supporting the hypothesis that an additional regime of MDMA would impair 
performance and specifically that this impairment would affect reference memory 
processes. 
 Finally we examined whether there would be any difference between the binge 
MDMA treated group and the saline control group when exposed to acute doses of 
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MDMA. During the acute phase of the task when rats received saline there were no 
significant differences found between the binge MDMA treated and control group in 
accuracy, trial completion time or type of error made. However, when rats received the 
acute challenges of MDMA performance was significantly affected in both groups. Of 
note the saline control group showed a greater degree of impairment than the binge 
MDMA group in terms of decreased accuracy and increased trial completion time. 
Both groups produced more reference memory errors than working memory errors 
when administered acute injections of MDMA, however the saline control rats 
produced significantly more reference memory errors than the binge MDMA group. 
This supported the hypothesis that behavioural tolerance would occur with repeated 
MDMA exposure as the rats that had been previously exposed to a binge dose of 
MDMA were less affected by the acute challenges than the saline controls who had not 
experienced previous MDMA exposure. 
 The finding that the initial binge regime of MDMA did not produce learning 
deficits is in agreement with previous research that has utilised various operant based 
tasks and found MDMA exposure did not disrupt acquisition (Li et al., 1988; Byrne et 
al., 2000; Winsauer et al., 2002; Moyano et al., 2005). However this current finding 
does conflict with research that has utilised more similar maze type procedures to the 
current study and have found that binge MDMA regimes do produce learning deficits 
(Robinson et al., 1993; Broening et al., 2001; Willaims et al., 2003; Sprague et al., 
2003; Vorhees et al., 2004; Skelton et al., 2006; Able et al., 2006; Skelton et al., 2008; 
Skelton et al., 2009). 
The fact that an additional regime of MDMA was able to produce a transient 
but significant disruption in performance does concur with previously cited maze 
studies that have found MDMA exposure disrupts performance. More specifically the 
current studies finding that this impairment seems to be a reference memory 
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impairment concurs with previous research that has used the Morris water maze and 
Cincinnati maze procedures (Robinson et al., 1993; Broening et al., 2001; Willaims et 
al., 2003; Sprague et al., 2003; Vorhees et al., 2004; Skelton et al., 2006; Able et al., 
2006; Skelton et al., 2008; Skelton et al., 2009). 
Therefore the current research adds to the previous MDMA literature as it was 
able to show that a binge MDMA regime impaired reference memory processes while 
leaving working memory processes intact in a paradigm that was able to 
simultaneously assess the two processes. However it could be argued that as the deficit 
in learning was produced after acquisition had taken place, it may be dissimilar in 
nature to these previous studies that found deficits during task acquisition which 
suggests MDMA disrupted learning processes.  
There are two main possible reasons for the current study‟s findings that an 
initial regime of MDMA did not result in impairment while administering an 
additional regime did produce evidence of albeit a transient but significant deficit in 
performance. The first explanation is that the initial regime of MDMA was simply not 
sufficient to produce an effect on cognitive performance. Previous doses of chronic 
and binge MDMA used have often involved higher doses and also administered them 
over a period of several days. For example Robinson et al. (1993) administered twice 
as many of injections of 10mg/kg of MDMA than the current study while Able et al. 
(2006) and Skelton et al. (2008) used four injections of 15mg/kg in a day. In addition 
Williams et al. (2003) and Skelton et al. (2006) administered their regime of MDMA 
(2 x 20mg/kg per day) for a period of ten days. Therefore there is the possibility that 
the regime used in the current study (4 x 10 mg/kg for 1 day) was insufficient to 
produce cognitive impairment. 
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The second possibly more plausible explanation for these finding could be due 
to the eight to ten week gap between MDMA exposure and the beginning of training in 
the radial arm maze. Previous research (Robinson et al., 1993; Brennan & Schenk, 
2006) has shown that while MDMA may produce behavioural effects they may only 
be temporary. In addition, research examining the neurochemical effects of MDMA 
has shown evidence of recovery after MDMA exposure (Scanzello et al., 1993; Sabol 
et al., 1996). Therefore it is possible that we did not find an initial deficit in learning 
the radial maze task as during the time period between drug administration and training 
the rats experienced some recovery of function from the effects of the drug regime 
used. 
The finding that when challenged with an acute dose of MDMA the rats that 
had previously been administered a large binge dose of MDMA were less impaired 
than saline controls concurs with several studies that have also found evidence of 
behavioural tolerance developing with repeated MDMA exposure (Shankaran & 
Gudelsky, 1999; Piper et al., 2006; Brennan & Schenk, 2006; LeSage et al., 1993; 
Marston et al., 1999; Frederick et al., 1995; Frederick & Paule, 1997; Frederick et al., 
1998). However this finding conflicts with several studies that have found evidence of 
behavioural sensitisation occurring after repeated MDMA exposure (Spanos & 
Yamamoto, 1998; Kalivas et al., 2006; Modi et al., 2006; Li et al., 1989; Moyano et 
al., 2005).  
Brennan and Schenk (2006) offer the explanation that this may be due to the 
type of MDMA regime used where repeated smaller acute doses may result in 
sensitisation whereas larger chronic or binge regimes may result in behavioural 
tolerance. Due to the size of the regime used in the current study which previous 
studies have found it produces significant effects on 5-HT levels to justify its use in 
binge MDMA studies (Scanzello et al., 1993). Therefore the regime used in the current 
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study may explain this finding as the dosage used may have been sufficiently large and 
brief enough to produce behavioural tolerance rather than sensitisation. 
 The nature of the deficit produced in the current study involved reference 
memory processes. However, it should be noted that both the binge MDMA treated 
and saline control groups produced more reference memory errors than working 
memory errors overall. Intuitively this makes sense as while subjects are learning the 
task they do not know which arms produce reinforcement and hence are likely to often 
enter arms that do not contain reinforcement. The subjects did not make many working 
memory errors at any stage during the initial and re-dosing phases of the study and 
hence appeared quickly able to learn not to re-enter the arms of the maze within a trial. 
However this may relate to the rats natural tendency to not repeat arms but instead 
alternate arm entries (Chrobak & Napier, 1992). Thus this finding replicates the results 
from first half of the current thesis that found MDMA administration affected 
reference memory processes more than working memory processes. In fact the finding 
that the reference memory deficit was not present until the rats had acquired the task is 
very similar to the results from the acute studies in the first half of the current thesis. 
Therefore it could be argued MDMA exposure did not disrupt learning processes but 
more likely memory processes as it disrupted information that had already been 
retained. As in the first half of the thesis this deficit could be due to a long-term 
memory impairment or a disruption in the rules of the task. 
A limitation of the current study was the potential confound produced by the 
eight to ten week gap between administering the binge regime of MDMA and 
commencing maze training. Due to the evidence that an additional regime of MDMA 
was able to significantly disrupt performance in the current study the next experiment 
in the thesis aimed to examine what would happen to the ability to acquire the maze if 
the gap between receiving the same regime of MDMA and training was much smaller.  
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In conclusion this study found that an initial binge regime of MDMA failed to 
have any significant effect on acquiring the partially baited radial maze task. However, 
when an additional binge regime of MDMA was administered it produced a transient 
but significant decrease in accuracy and an increase in trial completion time compared 
to saline controls. During the re-dosing phase the number of working memory errors 
made did not significantly differ compared to the initial acquisition phase. During the 
re-dosing phase the MDMA treated group produced an increase in the number of 
reference memory errors made compared to the controls. Therefore when there was 
evidence of an impairment it appeared to be due to a deficit in reference memory 
performance. However, it is unclear as to whether the nature of this deficit involves 
learning processes or memory processes due to the deficit occurring after task 
acquisition has taken place. 
During the acute phase of the task when rats received saline there appeared no 
difference in performance between the chronic MDMA and control group. However 
when rats were administered acute challenges of MDMA the control group showed 
greater impairment than the binge MDMA group. In addition during the acute 
challenge of MDMA, both groups produced more reference memory errors than 
working memory errors thus replicating the findings from the first half of this thesis. 
Therefore it would appear that binge MDMA exposure produces behavioural tolerance 
when later challenged with acute exposure to the drug. 
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Study 4: Binge Effects of MDMA on Acquisition and Reversal Learning in the Radial 
Arm Maze. 
Initial acquisition 
The rats in the first binge study of this thesis (Study 3) failed to show 
impairment in the acquisition of the partially baited radial arm maze after being 
exposed to an initial binge regime of MDMA. However these rats were not assessed in 
the radial arm maze until approximately eight to ten weeks after MDMA 
administration. There is physiological and behavioural evidence that the effects of 
binge MDMA treatment in rats are transient and recover over time (Scanzello et al., 
1993; Sabol et al., 1996; Brennan & Schenk, 2006). In addition the findings of the 
previous study in this thesis found a significant impairment in the binge MDMA 
treated rats after they were exposed to an additional regime of MDMA. Thus the 
current study examined whether the reason there was no initial learning impairment 
shown by the MDMA-treated rats was due to the delay between drug exposure and 
training or whether the single binge MDMA regimen used in the previous study was 
not large enough to produce impairment.  
The current study investigated what effect binge MDMA exposure would have 
on maze performance if a much shorter gap occurred between dosing and training. In 
the current experiment a new group of twenty rats was used to examine the effects of 
the previously used binge dose of MDMA on acquisition of the partially baited radial 
arm maze task. Again in this study ten rats were given a binge regime of MDMA while 
ten controls received saline injections. However, in the current study the rats were 
already at 85% of their free feeding body weight and had received the habituation 
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phase of training before the drugs were injected. Maze training then began two days 
after MDMA and saline were administered. 
Drug Tolerance versus Sensitisation 
In Study 4 preliminary evidence of drug tolerance was found as rats that had 
received two binge regimes of MDMA were less affected by a subsequent acute dose 
of MDMA compared to saline controls that had not previously been exposed to 
MDMA. Therefore the current study also attempted to replicate and extend this finding 
by administering acute doses of MDMA and saline to the rats after they had acquired 
the radial arm maze task after only being exposed to a single binge regime of MDMA. 
Reversal Training 
Research examining the effects of binge MDMA exposure on cognition has 
found evidence of long-term learning impairments (Broening et al., 2001; Williams et 
al., 2003; Sprague et al., 2003; Vorhees et al., 2004; Skelton et al., 2006; Able et al., 
2006; Skelton et al., 2008; Skelton et al., 2009). In addition to learning impairments 
there is evidence that MDMA exposure may impede the ability of subjects to adapt 
their behaviour to changing consequences. For example the Wisconsin Card Sorting 
Task (WCST) utilises a constant changing of task rules that is used to accesses 
cognitive flexibility and it has been found that Ecstasy users are impaired on this task 
(von Geusau et al, 2004; Smith et al., 2006). Similarly tasks that assess associative 
learning have been found to be impaired due to perseverative responding in Ecstasy 
users (Montgomery et al., 2005).  
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More recently Dafters (2008) used a modified Stroop task to examine task 
switching in Ecstasy users. In a standard Stroop task participants are presented with 
word stimuli that are the names of colours displayed in different coloured ink and 
participants have to report the colour that the word is presented in (Dafters, 2008). This 
involves having to resist reading the word and subjects tend to be faster when the name 
of the word and the ink match and take longer when they do not (Dafters, 2008). In the 
modified task on random trials the presented word was underlined indicating that in 
this trial participants were required to name the word rather than the ink colour, hence 
requiring a switch in task. Ecstasy users were significantly slower than controls during 
the task switching trials and impairment was correlated with amount of previous 
Ecstasy use. The finding that participants with a history of Ecstasy use are impaired on 
this Stroop switching task has also been found by Lamers, Bechara, Rizzo and 
Ramaekers (2006). 
Within the animal literature there is also evidence that reversal learning is 
impaired after MDMA exposure. For example Verrico, Lynch, Fahey, Fryer, Miller 
and Madras (2008) found MDMA administered both orally and intramuscularly to 
cynomolgus monkeys significantly disrupted performance on a well learnt reversal 
learning task. This was evidence that acute MDMA exposure produced perseverative 
errors indicating MDMA administration can impair the ability to suppress irrelevant 
information and adapt behaviour in the face of changing consequences (Verrico et al., 
2008).  
Possibly more relevant to the current study is that MDMA treated animals have 
trouble adapting their behaviour to changing consequences in studies utilising reversal 
phases in the Morris water maze. In this paradigm once rats have acquired the task and 
learnt the position of the platform it is shifted and the ability of the rats to learn its new 
location is assessed (Morris, 1984). There have been several studies indicating chronic 
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or binge MDMA exposure produces impairments in these tasks. In Williams et al.‟s 
(2003) study once initial Morris water maze acquisition occurred the platform was 
shifted to the opposite quadrant of the pool. Once performance had stabilised during 
this reversal phase the platform was reduced in size and moved again. Rats that 
received a chronic regime of MDMA produced significantly longer latencies, greater 
path lengths and cumulative distance from the platform during both of these reversal 
phases suggesting that MDMA significantly impaired their ability to alter their 
behaviour to changing task demands. More recently Skelton et al. (2006) and Skelton 
et al. (2009) also found that administering a chronic MDMA regime to rats 
significantly impaired their performance during a reversal phase and a reduced 
platform reversal phase.  
However not all studies using Morris water maze reversal phases have found 
such clear MDMA induced impairments. For example Skelton et al. (2008) found 
MDMA treatment did not impair performance during an initial reversal phase but did 
impair performance on an additional reduced platform reversal phase suggesting a task 
switching deficit. Able et al. (2005) found no difference in performance between rats 
exposed to a binge regime of MDMA and those given saline during acquisition of a 
reduced platform reversal phase. However, during probe trials that were conducted 
afterwards where the platform was removed, the MDMA treated rats showed a 
significantly greater average distance from where the platform had been indicating 
some degree of impairment in reversal learning. 
In conclusion there is converging evidence from human Ecstasy studies and 
experimental animal research suggesting MDMA exposure produces deficits in 
changing behaviour when tasks are altered. Therefore in the final phase of the current 
study the ability of the binge MDMA treated and saline control rats to adapt their 
performance to changing consequences was investigated. This was assessed by 
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reversing the rules of the maze task whereby the arms that had initially contained 
reinforcement were changed. Therefore, the arms of the maze that previously had not 
contained reinforcers would now have reinforcers while the arms that previously 
contained reinforcement would now not have reinforcers.  
The Current Investigation 
The present study examined the effect of a binge regime of MDMA on 
acquisition in the partially baited radial arm when training commenced two days after 
drug administration. It was hypothesised that the MDMA treated rats would show 
evidence of learning impairments compared to saline controls and that this impairment 
would be predominantly evident by MDMA treated rats producing more reference 
memory errors than controls. The current study also utilised a reversal phase where the 
reinforced arms of the maze were swapped to assess the effects of a binge MDMA 
regime on a task requiring subjects to alter their behaviour. It was hypothesised that 
MDMA treated rats would be impaired in their ability to adapt their behaviour 
compared to saline controls which would be evident by MDMA treated rats acquiring 
the new task more slowly than controls.  
In between the acquisition and the reversal phases, acute doses of MDMA and 
saline were administered to examine whether behavioural tolerance would be evident 
in rats that were previously exposed to MDMA. Based on the findings from the 
previous study of this thesis it was hypothesised that the previously treated binge 
MDMA rats would be less impaired when administered acute doses of MDMA 
compared to saline controls. 
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Method 
Subjects 
The subjects were twenty white male Sprague-Dawley rats that were 
approximately three to four months old at the beginning of the study. The rats were 
housed individually and were experimentally naïve at the beginning of the study. They 
were kept at 85-90% (between 218 and 324 grams) of their free feeding body weight 
and began habituation training around two weeks after reaching this weight. They had 
continuous access to water and were kept on a 12:12-hour dark:light cycle and were 
run during the light phase of this cycle.  
Apparatus/Materials 
The maze and reinforcers used were the same as those stated in the General 
Acute MDMA Method section. Drugs used were saline 0.9 % and MDMA 10 mg/kg, 
which were prepared on the day of use by dissolving to the required dose in 0.9 % 
saline solution. During the tolerance phase of the experiment MDMA 4.0 mg/kg was 
used and it was also dissolved to the required dose in 0.9 % saline solution. 
Procedure 
 The current study used a between-subjects experimental design where one 
group of rats received binge doses of MDMA and the other received saline. Rats were 
assigned into the experimental and control group (10 rats in each group). Unfortunately 
one of the binge rats died after receiving MDMA and therefore, there were only nine 
rats in the binge group, compared to ten in the saline control group. Again each rat was 
assigned a set of four reinforced arms and four non-reinforced arms within the maze. 
The binge and control rats had the same sets of reinforced and non-reinforced arms, so 
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that the first rat in both groups had the same reinforced arms and so that there were 
matched pairs of rats. This was done to control for difficulty of the task in case some 
sets of maze arms were easier to learn that others.  
Training was conducted in the same way as outlined in the General Binge 
MDMA Method section. However, in this study the rats received the habituation pre-
training before they were given the injections. The day after completing the habituation 
phase, rats were given four injections of either 10 mg/kg of MDMA or 0.9 % saline. 
The following day rats were given a rest day. Training involving assigned reinforcer 
arms began after the rest day (two days after the injections). Unlike the previous study 
rats were not run within their experimental groups but in their matched pairs. This was 
done as it was more convenient in terms of not having to change the arms that needed 
to be baited so often. However, to control for order or odour scenting in the maze the 
running was counterbalanced so that which rat ran first was changed on alternate days 
so one day the binge rat in the pair would run first and the next day the control rat was 
run first. 
Each group of rats was given five sessions of training per week. In the first 
phase of the experiment both groups of rats had to reach a criterion of a group average 
of at least eight five percent accuracy for six consecutive days before they had been 
considered to achieve acquisition. This took twenty four training sessions and occurred 
30 days after drug treatment.  
Two days (32 days post drug treatment) after the first phase was completed the 
second phase began. This second phase examined the effects of acute challenges of 
MDMA after the rats had acquired the radial maze task. During this phase each rat 
from the previous experimental and control groups received all drugs and doses. As 
this study was conducted in between the acquisition and reversal phases of the 
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previous experiment each rat used its original set of four reinforced arms. Maze 
running was identical to that explained in the general method section. Each rat was 
injected i.p. twenty minutes before running. Rats were run in batches as described 
previously. Each drug dose was repeated; therefore two doses of 4 mg/kg MDMA and 
0.9% saline were administered to each rat. Several days were left in between each drug 
treatment to control for carry on effects of the drugs. On these days the rats were 
trained in the maze without being administered drugs.  
To ensure that no residual acute drug effects were present the final phase of the 
experiment began three days after completion of the second phase and hence began 46 
days post drug treatment. During the final phase of the experiment the effect of 
changing the rules of the task was assessed. During this third phase each rat‟s 
previously reinforced maze arms now did not contain obtainable reinforcers and the 
previously non-reinforced arms now contained obtainable reinforcers. Rats continued 
to run as in the first phase of the experiment where they were allowed to enter four 
arms of the maze per trial and received three trials of training per day. As in the first 
phase rats were run in their matched pairs and the order in which the rats within the 
pairing ran was counterbalanced as before. Training continued until a 90% level of 
accuracy for both groups was achieved. During this reversal phase this took eighteen 
training sessions which concluded 70 days post binge drug treatment. 
 
Results 
In all figures error bars show standard error of the mean. Daily percent correct 
figures were calculated by averaging across the three daily trials to obtain an average 
level of performance for the session for each individual rat. Group averages were then 
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calculated to obtain a group mean for each group and acquisition session. These data 
are presented below in Figure 18 and show during initial acquisition both the MDMA 
group and the saline control group began the task with an accuracy level of 
approximately fifty percent (which is above chance in this task) and this gradually 
increased across the sessions until rats were performing consistently above ninety 
percent.  
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Figure 18: Average percent correct per session across all rats in both the binge MDMA 
group and the saline control group for acquisition and reversal training. 
 
 
Although performance of the two groups starts at a similar level for the first 
three sessions, the saline group‟s performance seems to improve at a faster rate than 
the MDMA group. However, by the last two sessions of training the performance of 
the two groups is similar. This suggests the group that received the binge regime of 
MDMA acquired the task slower than the saline control group, but did manage to 
eventually perform at similar levels to the control group. These effects were confirmed 
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by a two-way mixed ANOVA. Main effects for session, F (23, 391) = 104.89, p < 0.05 
(p = 0.00) and group, F (1, 17) = 16.23, p < 0.05 (p = 0.00) were found but were 
moderated by a significant interaction between session and group, F (23, 391) = 2.90, p 
< 0.05 (p = 0.00). 
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Figure 19: Average trial completion time in seconds per session across all rats in the 
binge MDMA and the saline control group for acquisition and reversal training. 
 
 
During the reversal phase of the experiment Figure 18 shows initially both 
groups were very inaccurate producing an average of around 10% correct. Again, this 
gradually increased for both groups over the training sessions with performance on the 
last session reaching around 90% correct. As in the acquisition phase both groups 
produced similar levels of accuracy during the initial training sessions. However, on 
the fifth session the control group‟s performance dramatically increased and continued 
progressing at a faster rate than that of the MDMA treated group. Finally on the last 
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two sessions the two groups performances were similar. This trend suggests the group 
that were administered MDMA acquired the reversal task at a slower rate than that of 
the saline controls. However once again they were eventually able to perform at a 
similar level to the controls by the end of training. Again these effects were 
corroborated with a significant interaction between session and group F (17, 289) 
=4.52, p < 0.05 (p = 0.00). There was also a main effect for session, F (17, 289) 
=184.859, p < 0.05 (p = 0.00), and group, F (1, 17) =31.81, p < 0.05 (p = 0.00). 
Mean trial completion times in seconds for each daily session, were also 
calculated for each rat. Group means were then calculated for the MDMA treated 
group and the control group. These data are depicted in Figure 19 and show that trial 
completion times for both groups during the initial acquisition phase of the experiment 
decreased as training continued which was confirmed by a main effect for session, F 
(23, 391) = 26.02, p < 0.05 (p = 0.00). It also depicts that trial completion times 
between the two groups were similar. A two-way mixed ANOVA revealed a 
significant interaction between group and session, F (23, 391) = 1.69, p < 0.05 (p = 
0.03) and no main effect for group, F (1, 17) = 0.76, p > 0.05 (p = 0.40).  
Despite showing decreases in accuracy during initial learning as seen in Figure 
18 there does not seem to be any obvious effect of changing the task on trial 
completion time as shown in Figure 19. There also does not seem to be any difference 
in trial completion times between the two groups during the reversal phase. Therefore 
although rats become much less accurate during the reversal phase the average time it 
took them to complete a trial did not seem altered apart from maybe a slight increase in 
trial completion time during the first couple of trials. These effects was supported as no 
significant interaction between group and session was found, F (17, 289) = 0.64, p > 
0.05 (p = 0.86). There was also no main effect for group, F (1, 17) = 1.24, p > 0.05 (p 
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= 0.28). The ANOVA revealed a main effect for session, F (17, 289) = 3.78, p < 0.05 
(p = 0.00) but there was no consistent trend in the data over sessions. 
 
Working Vs. Reference Memory Data 
To examine the number and patterns of errors produced, the number of working 
memory and reference memory errors made per session for each rat was recorded. 
These figures were then converted into percentage error values. Average error 
percentage values were calculated for both the binge MDMA group and the saline 
control group by averaging across the rats in these groups. This was done for each 
daily session for both the acquisition and the reversal phases of the study.  
To analyse the error data a 2-way repeated measures ANOVA was conducted 
on the acquisition data comparing error type and training. During the acquisition phase 
a significant interaction was found between error type and session, F (23, 414) = 35.09, 
p < 0.05 (p = 0.00). Therefore there was a significant difference in the type of errors 
made across the training sessions during task acquisition. During the reversal phase a 
significant interaction between error type and session was also found, F (17, 306) = 
95.30, p < 0.05 (p = 0.00). When comparing the working memory data on Figure 20 
and the reference memory data on Figure 21 it is obvious that more reference memory 
errors were made than working memory errors during both acquisition and reversal 
phases of the study. These effects were examined further by individually analysing the 
data for working and reference memory errors across training sessions and between 
groups. 
The data for average working memory errors is presented in Figure 20. This 
figure shows that there were very few working memory errors made during 
 207 
acquisition. The saline control group made more working memory errors than the 
MDMA binge group during the first three training sessions but on subsequent training 
sessions there appears no obviously trend in the data. A 2-way mixed ANOVA 
revealed a significant interaction between session and group, F (23, 391) = 2.46, p < 
0.05 (p = 0.00). This indicated that there was a significant difference between two 
groups in the number of working memory errors made and this was dependent on 
training session. During acquisition there was no main effect for session, F (23, 391) = 
0.92, p > 0.05 (p = 0.58) and no main effect for group, F (1, 17) = 0.01, p > 0.05 (p = 
0.93). 
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Figure 20: Average working memory error percentages across all rats in both the binge 
MDMA and saline control groups during acquisition and reversal training. 
 
 
During the reversal phase of the study both groups made very few working 
memory errors with no clear differences between the two groups. Also the number of 
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working memory errors remained fairly stable across the entire reversal phase. This 
was confirmed by a 2-way mixed ANOVA that found no significant interaction 
between session and group, F (17, 289) = 0.63, p > 0.05 (p = 0.87). There were also no 
main effects for session, F (17, 289) = 0.83, p > 0.05 (p = 0.65) and group, F (1, 17) = 
1.80, p > 0.05 (p = 0.20). 
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Figure 21: Average reference memory error percentages across all rats in both the 
binge MDMA and saline control groups during acquisition and reversal training. 
 
 
 Data depicting reference memory performance are shown in Figure 21 and 
show that both groups made a lot of reference memory errors. During the acquisition 
phase both groups made a large number of reference memory errors at the beginning of 
training and this steadily decreased over the training sessions as the task was acquired. 
By the end of the training session both groups were making similar numbers of 
reference memory errors. During the acquisition phase the saline control rats appeared 
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to reduce the number of reference memory errors made across sessions at a faster rate 
than the binge MDMA treated rats. These effects were corroborated by a 2-way mixed 
ANOVA that found main effects for session, F (23, 391) = 84.91, p < 0.05 (p = 0.00) 
and group, F (1, 17) = 17.84, p < 0.05 (p = 0.00) which were moderated by a 
significant interaction between group and training session, F (23, 391) = 2.20, p < 0.05 
(p = 0.00). 
During the reversal phase both groups made a very high number of reference 
memory errors during the first couple of sessions. The number of reference memory 
errors than steadily decreased as the subjects began to adapt their behaviour to the 
change in the task. However, the control rats were quicker to do this than the MDMA 
treated group as shown by the faster decrease in the number of reference memory 
made by the saline controls. By the end of the reversal phase the MDMA group and 
the saline controls were producing a similar number of reference memory errors where 
both groups were making very few reference memory errors. These effects were 
confirmed by a significant interaction between group and training, F (17, 289) = 4.13, 
p < 0.05 (p = 0.00). During the reversal phase there was also a main effect for session, 
F (17, 289) = 171.76, p < 0.05 (p = 0.00) and a main effect for group, F (1, 17) =29.64, 
p < 0.05 (p = 0.00). 
 
Acute Data: 
Percent correct figures were calculated in the same way as in the previous acute 
drug studies. Group values for the binge MDMA treated rats and saline controls were 
then calculated for each drug session and these values were averaged across the two 
sessions of each acute drug treatment (MDMA and saline). This data is shown in 
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Figure 22 and shows both the binge MDMA group and the saline controls produced a 
very high level of accuracy during acute saline administration. There also appears to be 
no difference in accuracy between the two groups during saline exposure.  
With the acute administration of MDMA both groups showed a marked 
impairment with a large drop in accuracy where the saline control group appears to be 
more affected by the acute administration of MDMA than the binge MDMA group. 
This effect was supported by a 2-way mixed ANOVA with a significant interaction 
between group and drug treatment, F (1, 17) = 9.72, p < 0.05 (p = 0.01). There was 
also a main effect for acute drug treatment, F (1, 17) = 213.33, p < 0.05 (p = 0.00) but 
no main effect for group, F (1, 17) = 3.62, p > 0.05 (p = 0.07). 
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Figure 22: Average percent correct across all rats in both the binge MDMA group and 
the saline control group for the acute doses of saline and MDMA. 
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Average session trial completion times (in seconds) were calculated for each 
individual rat and were used to obtain group averages. These data are depicted in 
Figure 23 and show that both the binge MDMA and saline control groups produced 
similar low trial completion times during the saline sessions. However, during the 
acute MDMA sessions both groups produced much longer trial completion times 
compared to the saline sessions. The saline control group produced only a slightly 
longer average trial completion time than that of the binge MDMA group suggesting 
they were not obviously more affected than the MDMA binge group when 
administered with acute doses of MDMA.  
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Figure 23: Average trial completion time in seconds across all rats in both the binge 
MDMA group and the saline control group for the acute doses of saline and MDMA. 
 
 
This lack of an effect was confirmed by a 2-way mixed ANOVA where no 
significant interaction between acute drug treatment and group was found, F (1, 17) = 
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1.26, p > 0.05 (p = 0.28). There was also no main effect for group, F (1, 17) = 1.38, p > 
0.05 (p = 0.26). There was a main effect for drug treatment, F (1, 17) = 108.65, p < 
0.05 (p = 0.00) and from Figure 23 it is obvious that acute MDMA treatment impaired 
performance more than acute saline treatment. 
Differences between error types were examined by calculating the number of 
working and reference memory errors made per session for each rat. These figures 
were then converted into percentage error values. Average error percentage values 
were calculated for both the binge MDMA group and the saline control group by 
averaging across the rats in these groups and are depicted in Figure 24.  
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Figure 24: Average error percentage of working memory (WM) and reference memory 
(RM) errors across all rats for both the MDMA binge group and the saline control 
group. 
 
 
When examining the working memory error data Figure 24 shows that during 
the saline session very few working memory errors were made by either the binge 
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MDMA group or the saline control group. Also the number of working memory errors 
made during saline treatment did not seem to obviously differ between the two groups. 
With acute exposure to MDMA the number of working memory errors increased 
slightly for both groups and the binge MDMA group produced marginally more 
working memory errors than the control group. These small effects were shown to be 
non significant using a 2-way mixed ANOVA that revealed no interaction between 
acute drug treatment and group, F (1, 17) = 0.13, p > 0.05 (p = 0.72) and no main 
effects for acute drug treatment, F (1, 17) = 4.30, p > 0.05 (p = 0.05) or group, F (1, 
17) = 0.61, p > 0.05 (p = 0.45). 
Figure 24 also shows that very few reference memory errors were made by 
either group during the saline session. During the acute MDMA session there were a 
large number of reference memory errors made by both groups. In addition the saline 
control group appeared to make more reference memory errors than the binge MDMA 
group when administered acute doses of MDMA. These effects were confirmed by a 2-
way mixed ANOVA that produced a significant interaction between acute drug 
treatment and group, F (1, 17) = 19.11, p < 0.05 (p = 0.00). There were also main 
effects for acute drug treatment, F (1, 17) = 294.46, p < 0.05 (p = 0.00) and group, F 
(1, 17) = 6.25, p < 0.05 (p = 0.02).  
To compare error types a 3-way mixed ANOVA was conducted examining 
memory type (working and reference memory errors), acute drug treatment (MDMA 
or saline) and group (binge and control). There was a 3-way interaction between 
memory type, acute drug treatment and group, F (1, 17) = 9.36, p < 0.05 (p = 0.01). 
Thus the type of error made differed significantly depending on the type of acute drug 
administered and whether the subjects had been pre-treated with binge MDMA or 
saline. Referring to Figure 24 this result suggests there were more reference memory 
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errors than working memory errors during acute MDMA administration and this was 
more pronounced in the saline control group. 
There was also an interaction between memory type and group, F (1, 17) = 
4.81, p < 0.05 (p = 0.04). Thus there was a significant difference in the type of errors 
made between the two groups. Examining Figure 24 shows the control group made 
more reference memory errors than the binge group. In addition there was a significant 
interaction between memory type and acute drug treatment, F (1, 17) = 88.42, p < 0.05 
(p = 0.00). Hence there was a significant difference in the type of memory errors made 
during acute MDMA and saline treatments where MDMA treatment produced more 
reference memory than working memory errors. Finally there was a significant 
interaction between acute drug treatment and group, F (1, 17) = 6.90, p < 0.05 (p = 
0.02), indicating a significant difference on the effects of administering acute doses of 
MDMA and saline on group performance. Main effects for memory type, F (1, 17) = 
39.13, p < 0.05 (p = 0.00) and acute drug treatment, F (1, 17) = 169.96, p < 0.05 (p = 
0.00). There was no main effect for group, F (1, 17) = 2.58, p > 0.05 (p = 0.13).  
 
Discussion 
Acquisition and Reversal 
To recap, the aim of this study was to examine if a binge dose of MDMA 
would impair acquisition of the partially baited radial arm maze task if training 
commenced two days after drug administration. During the initial acquisition phase 
both groups of rats learnt the task as accuracy (percent correct) significantly increased 
during training. During this phase the binge MDMA group showed evidence of 
learning impairment compared to controls as they acquired the task at a significantly 
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slower rate. However, they were able to eventually acquire the task and perform at a 
similar level to the saline controls. Throughout the acquisition phase trial completion 
time significantly decreased for both groups of rats as they learnt the task. Of note 
there was no significant difference between the two groups on this variable suggesting 
that the learning impairment produced by MDMA exposure was not the result of a 
motor impairment. 
In terms of the types of error made, during acquisition both groups produced a 
similar low number of working memory errors. During training both groups initially 
produced a high number of reference memory errors and as this phase continued the 
MDMA treated group made significantly more reference memory errors than the 
controls. Again by the end of training performance was similar between the two groups 
with both of them producing a low number of reference memory errors. Therefore 
MDMA exposure produced evidence of a learning impairment and this cognitive 
deficit appeared to involve reference memory processes.  
This finding is consistent with previous literature that has utilised Morris and 
Cincinnati water maze tasks that have found that chronic or binge MDMA exposure 
impairs the acquisition of tasks requiring reference memory processes (Robinson et al., 
1993; Broening et al., 2001; Williams et al., 2003; Sprague et al., 2003; Vorhees et al., 
2004; Skelton et al., 2006; Able et al., 2006; Skelton et al., 2008; Skelton et al., 2009). 
However it does conflict with findings from more operant based tasks that have failed 
to find evidence of learning impairments (Li et al., 1988; Byrne et al., 2000; Winsauer 
et al., 2002; Moyano et al., 2005). Again a possible reason why these chamber-based 
operant tasks failed to show evidence of impairment following MDMA administration 
could be due to the tasks not having a large reference memory component compared to 
the maze tasks that have found evidence of MDMA induced cognitive impairments. 
Another possible explanation for the conflicting findings between operant chamber 
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tasks and maze paradigms is that the latter involves greater spatial memory processes 
which may be more susceptible to the effects of MDMA exposure. 
The findings from the previous study of this thesis that failed to find evidence 
of binge MDMA exposure impairing task acquisition can be addressed using the 
results from the current study. Of note, the finding that the same dose as that used in 
the previous study was able to impair task acquisition suggests the lack of deficit found 
in the previous study was not due to the size of the drug regimen used. An alternative 
explanation for the conflicting findings is due to the delay between drug exposure and 
training. The current study found that a binge regime of MDMA was able to produce a 
learning deficit in the partially baited radial arm maze when only two days had elapsed 
between drug exposure and training. This finding suggests that the failure of the 
previous study to find a learning deficit could be due the long period of time 
(approximately eight to ten weeks) between drug administration and commencement 
of training. In addition the fact that for the first couple of trials the two groups of rat‟s 
performance did not differ can rule out the explanation that any difference seen were 
due to residual acute effects of the drug treatment. Therefore the seemingly most 
plausible explanation for the failure to find evidence of an acquisition impairment 
following MDMA exposure in the previous study is because the large time gap 
between drug exposure and training allowed a degree of recovery of function to occur. 
There is some evidence within the neurochemical literature to support this hypothesis 
as the damage to 5-HT levels produced by the same regime of MDMA as that used in 
the current study has been shown to recover over time (Scanzello et al., 1993). 
However as our study did not assess 5-HT levels during the study we can directly 
provide evidence of physiological recovery from the effects of MDMA exposure. 
The current experiment also examined if a binge dose of MDMA would affect 
the ability of rats to adapt their performance to changing consequences when the rules 
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of the radial arm maze paradigm were reversed. During the reversal phase the saline 
controls learnt the task significantly faster than the MDMA treated group. Thus 
MDMA exposure significantly impaired the ability of the rats to adapt their behaviour 
to a change in task demands. However by the end of training both groups produced a 
similar level of performance indicating that eventually the MDMA group were able to 
acquire the new task. Also in this phase there was no real increase in trial completion 
time for both groups and this did not differ between the two groups. Therefore 
although both groups of rats were initially less accurate during the task change they did 
not take longer to complete trials during this phase of the task. While MDMA 
exposure impaired accuracy it did not significantly affect the amount of time it took to 
complete trials and hence the deficit seen in this phase cannot be explained in terms of 
motor impairments. 
When examining the kind of errors made both groups during the reversal phase 
they produced very few working memory errors and this did not differ significantly 
between the two groups. In contrast the reversal phase produced a large increase in 
reference memory errors for both groups. During this phase the MDMA treated group 
produced significantly more reference memory errors than the saline controls. Hence 
once again the impairment produced by MDMA exposure involved reference memory 
processes. However, it should be noted that while entering non-reinforced arms in this 
phase was counted as a reference memory error the same way as in the previous phase 
the cognitive process they were assessing may be different. This is because reference 
memory errors in the reversal phase meant subjects were failing to alter their behaviour 
rather than remembering previously learnt information about which arms contained 
reinforcement. 
 The finding that binge MDMA exposure produced significant impairments in 
cognitive flexibility is consistent with previous literature (von Geusau et al., 2004; 
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Smith et al., 2006; Montgomery et al., 2005; Dafters, 2008; Lamers et al., 2006) that 
has found that Ecstasy users are impaired at tasks that involve altering their behaviour 
in response to changing task demands. In addition it is consistent with research 
(Williams et al., 2003; Able et al., 2005; Skelton et al., 2006; Skelton et al., 2008; 
Skelton et al., 2009) that has utilised reversal phases in the Morris water maze which 
require subjects to alter their behaviour once the initial task had been acquired. Again 
there is some neurochemical evidence within the literature to further support these 
findings. For example there is evidence that monkeys produce significant perseverative 
impairments on reversal discrimination tasks following experimental 5-HT depletion 
in the prefrontal cortex (Clarke, Dalley, Crofts, Robbins & Roberts, 2004; Clarke, 
Walker, Dalley, Robbins & Roberts, 2007). As the binge regimen of MDMA utilised 
within the current study has been shown to significantly reduce 5-HT levels in multiple 
brain regions including the prefrontal cortex (Scanzello et al., 1993) this may account 
for the finding that MDMA exposure impairs cognitive flexibility. Again as this study 
did not conduct any physiological measures of 5-HT activity it is unknown as to the 
degree of 5-HT depletion subjects in the current study experienced. 
In conclusion rats administered a large binge dose of MDMA took significantly 
longer to learn both the acquisition and reversal task in the partially baited radial arm 
maze compared to saline controls. However, they were able to eventually acquire both 
tasks performing at a similar level to saline controls. In addition when there was 
evidence of impairment it appeared to primarily involve reference memory processes. 
The deficits seen appeared to be relatively long-term as the subjects continued to show 
impairment during the reversal phase of the task which began 46 days after drug 
treatment and did not reach a similar level of performance to controls till around 68 
days post drug treatment. Therefore while performance of the MDMA treated animals 
appeared to be similar to the saline controls by the time acquisition training was 
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finished, the fact they then showed impairment when they were required to alter their 
behaviour suggests they still were suffering from an underlying cognitive impairment. 
Hence one possible reason why some research has failed to show evidence of cognitive 
impairments produced by MDMA exposure is that they have involved tasks where the 
subjects have already received a lot of training on the task. The current study would 
suggest that an impairment would be more visible on tasks that were still being 
acquired and those that required subjects to alter their behaviour. 
There are several potential explanations for the underlying cause of these 
cognitive impairments. The impairments produced by binge MDMA exposure in the 
current study are characterised as learning impairments, hence subjects that received 
MDMA had trouble acquiring the task compared to controls. One possibility for this is 
that MDMA treatment may produce problems in consolidating the information about 
which arms contain reinforcement into long-term memory. Hence they have trouble 
learning the arms of the maze that contain reinforcers as this information takes longer 
to enter and become available in long-term memory. When the task changes and the 
reinforced arms of the maze are reversed, once again the rats have trouble encoding the 
new information about the arms into long-term memory. 
Another possible explanation is that MDMA produces impairments in 
acquiring task rules. Therefore the reason why the subjects that received MDMA were 
slower to acquire the task is that it took them longer to ascertain that there were fixed 
arms that contained reinforcement and those that did not. This explanation would also 
explain the findings from the reversal phase as MDMA administration could have then 
impaired the subjects ability to ascertain that the rules of the task had changed and then 
impaired their ability to acquire the new task rule. Unfortunately the current study does 
not allow us to differentiate between these two possible explanations as to the 
underlying cognitive impairment seen with MDMA exposure. 
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A possible confound in the current study was that the acute drug phase of the 
experiment was run in between the acquisition and reversal phases. There should be no 
residual acute effects of the drug during the reversal phase because of the three day gap 
between the last acute MDMA drug session and the beginning of the reversal phase. 
However, there is the possibility that the acute dose of MDMA may have in some way 
affected performance during the reversal phase of the task. For example, it is unknown 
what effect two additional acute doses of MDMA would have on the rats that had 
already received a binge regime of MDMA. While there is evidence that there is both 
behavioural (Brennan & Schenk, 2006) and neurochemical (Scanzell et al., 1993) 
recovery of function after the binge regime of MDMA used in the current study, it is 
unknown what effect additional low doses of acute MDMA would have on this 
process. Therefore, there is the possibility that these additional acute doses of MDMA 
may have affected performance in the reversal phase. Future studies could replicate 
this experiment by excluding the acute drug treatments between the acquisition and 
reversal phases of the study to examine whether this factor would influence 
performance. 
 
Acute MDMA Effects 
 To reiterate, the aim of this phase of the study was to examine whether rats that 
had already acquired the radial arm maze task and had been exposed to a binge dose of 
MDMA would show evidence of behavioural sensitisation or tolerance when exposed 
to acute administration of MDMA compared to saline controls. During acute saline 
administration both the binge MDMA and control groups produced a high level of 
accuracy and there was no real difference between the groups. However, during acute 
MDMA administration both the binge MDMA and control groups produced a decrease 
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in accuracy. Also, the control group was significantly more impaired than the binge 
MDMA treated group. There were no real differences between the groups in terms of 
trial completion time when saline was administered, but during the acute MDMA 
phase both groups trial completion times increased and there was no significant 
difference between the two groups.  
The control group produced more reference memory errors than the binge 
MDMA group, but the groups produced similar amounts of working memory errors. 
Therefore, we found evidence of behavioural tolerance as the saline controls who had 
not received the binge MDMA regime performed worse when administered acute 
MDMA. The impairment produced by acute MDMA exposure involved reference 
memory processes replicating the acute effects from the first half of the thesis. The 
finding that behavioural tolerance occurred is consistent with previous research 
(Shankaran & Gudelsky, 1999; Piper et al., 2006; Brennan & Schenk, 2006; LeSage et 
al., 1993; Marston et al., 1999; Frederick et al., 1995; Frederick & Paule, 1997; 
Frederick et al., 1998) and the findings from the previous study of this thesis. 
 
Conclusion 
To summarise, the current study found when rats were treated with a binge 
regime of MDMA and began training shortly after drug exposure they took 
significantly longer and had a slower rate of learning compared to saline controls when 
acquiring the partially baited radial arm maze. As subjects were able to eventually 
acquire the task and perform at a similar level to that of the controls it appeared this 
impairment was transient. However, when the rules of the task were changed the 
MDMA treated rats were again significantly slower to adjust their behaviour and learn 
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to perform the new task. Therefore, this learning impairment appeared to be long-term 
in nature as it continued to impair performance up to 68 days post drug treatment. 
Evidence of behavioural tolerance was found as rats who had not experienced previous 
exposure to MDMA were more impaired when administered acute challenges of 
MDMA. Finally, as in the previous study the impairments produced by MDMA 
exposure, both from the binge regime and acute drug treatments, involved reference 
memory processes more than working memory processes. 
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Study 5: Binge and Repeated Acute Effects of MDMA on Radial Maze Acquisition 
The findings from Study 3 and 4 of this thesis found evidence that binge 
MDMA exposure impairs learning in the partially baited radial arm maze. However, 
this impairment may be temporary in that by the end of training both MDMA treated 
and saline treated groups produce a similar level of performance. Recovery of neural 
impairments may underlie behavioural recovery as there is evidence subjects who are 
administered MDMA experience recovery of function. Indeed there is both 
behavioural (Brennan & Schenk, 2006) and neurochemical (Scanzello et al., 1993) 
evidence that the binge regime of MDMA used in these studies is accompanied by 
recovery over time. Therefore the current study examined what effect administering 
repeated acute doses of MDMA to subjects that had been pre-treated with a binge 
regime of MDMA would have on their ability to acquire the radial arm maze. 
Specifically this study investigated if subjects that continued to be exposed to MDMA 
would show recovery of the reference memory impairment seen in Studies 3 and 4 in 
the radial arm maze or whether subjects would remain impaired. 
The majority of previous research that has examined the effects of binge 
MDMA exposure on cognition has utilised drug regimes that consist of large doses (10 
to 20 mg/kg) given one to four times a day over a short period of several days. These 
types of regimes have been found to impair learning in the Morris water maze 
(Sprague et al., 2003; Able et al., 2005). Alternatively chronic regimes of MDMA (5 to 
20 mg/kg) have been repeatedly administered for an extended period to young rats and 
performance on various cognitive tasks has been shown to be impaired when they were 
older (Vorhees et al., 2004; Skelton et al., 2006; Skelton et al., 2009; Broening et al., 
2001; Williams et al., 2003). 
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In contrast there has been some research that has examined the effects of 
MDMA on cognition by administering long-term repeated acute doses of MDMA to 
subjects. For example Frederick et al. (1995) and Frederick and Paule (1997) 
administered ascending doses of MDMA (0.10 to 20 mg/kg) and found that long-term 
repeated exposure to the drug did not significantly alter performance on a previously 
learnt battery of cognitive tasks from baseline levels.  
In addition there have been studies that have administered low acute doses of 
MDMA and then later conducted a chronic study by administering a high dose regime 
of MDMA to subjects. For example LeSage et al. (1993) administered a range of acute 
doses of MDMA (0.32 to 5.6 mg/kg) before administering a chronic regime of MDMA 
(3.2 to 5.6 mg/kg). The acute doses significantly impaired performance on a DMTS 
task; however chronic drug administration did not significantly alter behaviour 
compared to baseline performance. Also Byrne et al. (2000) initially administered rats 
an acute regime of MDMA (0.1 to 5.6 mg/kg) before exposing them to a binge regime 
(4 x 20 mg/kg for 4 days). Neither drug treatment had a significant effect on acquiring 
a DRL lever pressing task. 
More recently, to try and represent human Ecstasy use more effectively, 
Skelton et al. (2008) compared different regimes of MDMA on acquiring the 
Cincinnati and Morris water maze. Rats were administered either 4 injections of 15 
mg/kg administered once a day for a period of 4 weeks (4 lots of MDMA in total) or 4 
injections of 15 mg/kg administered once in a single day (1 lot of MDMA in total). 
Skelton et al. (2008) found MDMA exposure produced deficits on both tasks. 
However, there were no differences in performance between the rats treated once with 
MDMA versus those treated repeatedly.  
 225 
While there have been studies (Li et al., 1989; LeSage et al., 1993; Moyano et 
al., 2005) that have administered acute challenges of MDMA after binge exposure to 
the drug they have done so after the cognitive task being used has been acquired. As 
subjects have already learnt the task this dosing technique has usually been conducted 
to seek evidence of drug tolerance or sensitisation rather than investigating the effect 
of repeated MDMA exposure on learning processes per se. 
Therefore to date there is no previous literature that has examined the effects of 
additional acute doses of MDMA on the acquisition of a task after subjects have 
already been exposed to a binge regime of the drug. Therefore, the current study adds 
to the previous MDMA literature by examining an issue not previously examined. In 
addition the repeated exposure to low doses of MDMA also extends the previous work 
of this thesis on whether behavioural tolerance or sensitisation develops following 
recurring MDMA exposure. 
The Current Study 
The current study utilised three groups of rats. The first group was the 
MDMA/MDMA group that were initially administered a binge regime of MDMA and 
then once week they were given one injection of an acute dose of MDMA (4.0 mg/kg). 
The second group was the Saline/MDMA group that was initially administered 
injections of saline and then once a week during training they were administered an 
acute dose of MDMA (4.0 mg/kg). The final group was the Saline/Saline control group 
that was initially administered injections of saline and during training they were given 
injections of saline once a week.  
It was hypothesised that binge MDMA exposure would impair the acquisition 
of the radial arm maze compared to rats that were administered treatments of saline. 
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Additionally it was hypothesised that rats that were exposed to the acute MDMA 
treatments would show impaired performance compared to rats given acute treatments 
of saline. More specifically due to the previous findings from this thesis it was 
hypothesised that the impairments produced would be the result of reference memory 
errors rather than working memory errors. 
Finally because this study design utilised repeated administrations of acute 
doses of MDMA it also enabled further examination of whether behavioural tolerance 
or sensitisation develops with repeated exposure to the drug. As a result of the findings 
from the Studies 3 and 4 that found evidence of behavioural tolerance it was 
hypothesised that the rats that were pre-treated with the binge regime of MDMA would 
be less impaired than the saline controls when administered subsequent acute doses of 
MDMA. 
 
Method 
Subjects 
The subjects were twenty white male Sprague-Dawley rats that were 
approximately three to four months old at the beginning of the study. The rats were 
housed individually and were experimentally naïve at the beginning of the study. They 
were kept at approximately 85-90% (approximately 250 to 350 grams) of their free 
feeding body weight and began habituation training around one week of reaching this 
weight. They had continuous access to water and were kept on a 12:12-hour dark:light 
cycle and were run during the light phase of this cycle.  
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Apparatus/Materials 
The maze and reinforcers used were the same as those stated in the general 
method section. Drugs used were saline 0.9 % and MDMA 10 mg/kg, which were 
prepared on the day of use by dissolving to the required dose in 0.9 % saline solution. 
During the tolerance phase of the experiment MDMA 4.0 mg/kg was used and it was 
also dissolved to the required dose in 0.9 % saline solution. 
Procedure 
 The study used a mixed design utilising a between-subjects factor (binge 
MDMA versus saline pre-treatment) and a within subjects factor (acute MDMA versus 
acute saline) experimental design where the rats were divided into three groups. The 
first group was labelled the MDMA/MDMA group and at the beginning of the study 
prior to training its members received a binge regime (4 x 10mg/kg) of MDMA and 
then once a week throughout the study they received an acute dose (4 mg/kg) of 
MDMA. There were seven rats in this group. The second group, the Saline/MDMA 
group, was given saline at the beginning of the study and thereafter was administered 
an acute dose (4 mg/kg) of MDMA once a week. There were seven rats in this group. 
Finally the third group was designated the Saline/Saline group which, at the beginning 
of the study received saline and once a week was given subsequent acute injections of 
saline. This group acted as the control group and there were six rats in this group.  
The initial study design consisted of four groups as it involved a MDMA/Saline 
treatment group. However, for practical and ethical reasons the number of groups was 
reduced as the current design used fewer rats. In addition the results from the group of 
rats that were administered a binge regime of MDMA in Study 4 could be used as a 
comparison for the performance of the MDMA/MDMA group.  
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Each rat was assigned a set of four reinforced arms and four non-reinforced arms 
within the maze. The three groups of rats had the same sets of reinforced and non-
reinforced arms, so that the first rat in all groups had the same reinforced arms and so 
on. This was done to control for difficulty of the task in case some sets of maze arms 
were easier to learn that others. Training was conducted in the same way as outlined in 
the general method section. However, in this study the rats received the habituation 
pre-training before binge drug treatments were administered. The day after completing 
the habituation phase, rats were given four injections of either 10 mg/kg of MDMA or 
0.9 % of saline. The following day rats were given a rest day where they were not run 
in the maze.  
Assigned reinforcer arm training began the after the rest day (two days after the 
injections). Rats were run within their matched groups as this was more convenient in 
terms of not having to change reinforcer arms so often. However, to control for order 
or odour scenting in the maze the running was counterbalanced so that which rat ran 
first was changed on every third day so that each rat was not able to solve the task 
simply by following the scent of the other rats. To examine whether repeated MDMA 
exposure would affect performance each group of rats received an acute injection of 
either MDMA (4.0 mg/kg) or saline (0.9%) once a week. These injections were 
administered via an i.p. injection 20 minutes before they were run in the maze.  
 
Results 
Training Data 
In all figures error bars show standard error of the mean. Daily percent correct 
figures were calculated by averaging across the three trials conducted each day to 
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obtain an average for the session for each rat. Group values were then obtained for 
each of the three groups by averaging the session performance across all rats in group. 
These data are presented below in Figure 25 and show that the Saline/Saline control 
group started the task at around an average of 45% which is slightly above chance for 
this paradigm (33% chance level) and continue on at a relatively steady rate until 
sessions 17-18 when they start to plateau at around ninety percent. Therefore, this 
group of rats learnt the task quite quickly achieving a high level of accuracy with not a 
lot of variability. It is also clear from the figure below that on the acute drug 
administration days which occurred during sessions 8, 15, 22, 29, 36 and 43, the 
Saline/Saline control group received acute doses of saline and there was no noticeable 
change in their performance.  
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Figure 25: Average Percent Correct for the three rat groups and the effect of the acute 
drug treatment given once a week on training session 8, 15, 22, 29, 36 and 43. 
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The Saline/MDMA group performed similarly to the Saline/Saline control 
group at the beginning of the study and their data almost directly maps on that of the 
Saline/Saline groups. However when the Saline/MDMA group were administered 
acute doses of MDMA their accuracy dramatically dropped indicating that the drug 
impaired their performance. However, what is interesting is that their performance the 
day after receiving the MDMA does not appear to be affected suggesting that the acute 
doses of MDMA produced very short-term effects on performance. 
Finally if we examine the MDMA/MDMA group it is clear that they are slower 
to learn the task compared to both control groups. They start off at a similar level but 
soon after this group‟s accuracy is well below that of the other two groups and 
continues to increase at a much slower rate. However, by the end of training they do 
produce a similar level of performance compared to the two saline control groups. 
During the acute drug days this group also produced a large drop in performance and 
there appears to be some evidence of this impairment affecting performance the day 
after the acute drug session.  
To analyse the accuracy of the three groups during training the data for the 
acute drug administration days was removed and a 2-way mixed ANOVA was 
conducted. The analysis revealed a significant interaction between training and group, 
F (80, 680) = 6.67, p < 0.05 (p = 0.00) and main effects for training, F (40, 80) = 
117.20, p < 0.05 (p = 0.00) and group, F (1, 17) = 211.41, p < 0.05 (p = 0.00). From 
Figure 25 it is clear that while the three groups initially perform at the same level of 
performance the MDMA/MDMA group was then significantly worse than the two 
saline control groups for majority of the remaining sessions. However all groups 
improved over the training sessions with the MDMA/MDMA group improving at a 
slower rate than the two control groups. 
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Average trial completion times were also calculated for the three groups and 
are depicted in Figure 26. This figure shows that all three groups became quicker at 
completing trials over the first sessions of training. Overall the Saline/Saline control 
group seems to improve slightly faster compared to the two other groups. Also there is 
no obvious effect on performance during the acute drug administration sessions for this 
group. Again performance of the Saline/MDMA group is similar to that of the-
Saline/Saline group, except for a brief period at the beginning of training and during 
the acute drug administration sessions where their trial completion times dramatically 
increase. Finally the MDMA/MDMA group again initially produce a similar level of 
performance to that of the two control groups but approximately half way through the 
training sessions they began to produce slightly slower trial completion times. In 
addition during the acute drug administration sessions their performance also becomes 
impaired as indicated by the large increase in trial completion times.  
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Figure 26: Average trial completion time for the three rat groups and the effect of the 
acute drug treatment given once a week on training session 8, 15, 22, 29, 36 and 43. 
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Trial completion time data for the three groups across the training sessions was 
analysed by removing the data from the acute drug administration sessions. A 2-way 
mixed ANOVA revealed a significant interaction between training and group, F (80, 
680) = 1.44, p < 0.05 (p = 0.01) and a main effect for training, F (40, 80) = 16.16 p < 
0.05 (p = 0.00). There was no main effect for group, F (1, 17) = 1.79, p > 0.05 (p = 
0.20).  
Working Vs Reference Memory Data 
To examine the types of error made within the radial maze average error 
percentages were calculated for the three groups (using the same procedure as previous 
studies). The average percent of working memory errors made by the three groups 
during training are depicted in Figure 27. It clearly shows that few working memory 
errors were made by any of the three groups and that the number of errors did not seem 
to change dramatically over the training period. While there appears to be a very slight 
increase in working memory errors by the MDMA/MDMA group half way through the 
training sessions there does not seem to be a clear overall pattern. Also there is no 
obvious effect of acute drug treatment session seen on the number of working memory 
errors made by any of the three groups.  
To analyse the working memory data for the three groups during training the 
data from the acute drug sessions was removed. A 2-way mixed ANOVA found a 
significant interaction between training and group, F (80, 680) = 1.68, p < 0.05 (p = 
0.00). However no main effect of training was found, F (40, 80) = 1.11, p > 0.05 (p = 
0.31) and no main effect of group, F (1, 17) = 3.47, p > 0.05 (p = 0.05).  
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Figure 27: Average working memory errors for the three rat groups and the effect of 
the acute drug treatment given once a week on training session 8, 15, 22, 29, 36 and 
43. 
 
The data for the average reference memory percentage errors for the three 
groups during training data is shown in Figure 28. This figure clearly shows that 
during training more reference memory errors were made than working memory 
errors. At the beginning of training all three groups made a large number of reference 
memory errors. During the early training sessions the number of reference memory 
errors rapidly decreases in the two saline control groups. Therefore it appears the 
Saline/MDMA and Saline/Saline groups show a faster rate of learning than the 
MDMA/MDMA group. Gradually the number of reference memory errors decreases 
for all groups as they acquire the task and eventually the MDMA/MDMA group are 
able to achieve a similar level of performance to the control groups. 
In Figure 28 the effects of the acute drug sessions are also quite evident. The 
Saline/MDMA group and the MDMA/MDMA groups both make more reference 
memory errors when administered acute doses of MDMA. While the number of 
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reference memory errors made between the MDMA/MDMA and the Saline/Saline 
groups appears similar it should be pointed out that the Saline/MDMA group‟s 
performance is more impaired in terms of how many reference memory errors they 
made during acute drug treatment in relation to how many they made the day before.  
Again the interesting finding that the MDMA/MDMA group are more affected 
than the Saline/MDMA group on the days following acute drug treatment is evident in 
terms of the number of reference memory errors made in the sessions immediately 
after drug exposure days. The Saline/MDMA group are quite impaired on the day of 
acute drug administration as evidenced by a large increase in the number of reference 
memory errors made. However, this deficit is short lived with performance returning to 
baseline levels the day immediately after acute drug administration. In contrast, 
although MDMA/MDMA group also show an increase in the number of reference 
memory error made during the drug administration sessions their performance does not 
immediately return to baseline levels but instead remains slightly impaired on the days 
following the acute injections of MDMA.  
To analyse the reference memory data for the three groups during training the 
data from the acute drug sessions was removed and a 2-way mixed ANOVA was 
conducted. Significant main effects for training, F (40, 80) = 125.57, p < 0.05 (p = 
0.00) and group, F (1, 17) = 198.61, p < 0.05 (p = 0.00) were found but these were 
moderated by a significant interaction between training and group, F (80, 680) = 7.70, 
p < 0.05 (p = 0.00). From Figure 28 it is clear that while initially all three groups 
produced a similar number of reference memory errors the MDMA/MDMA group 
produced significantly more reference memory errors than the two saline control 
groups for the majority of the remaining sessions. However all groups improved over 
the sessions with the MDMA/MDMA group improving at a slower rate than the other 
two groups. 
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Figure 28: Average reference memory errors for the three rat groups and the effect of 
the acute drug treatment given once a week on training session 8, 15, 22, 29, 36 and 
43. 
 
 
 In conclusion repeated MDMA administration impaired acquisition of the 
radial arm maze in the group of rats that were pre-treated with a binge regime of 
MDMA. In addition all groups made more reference memory errors than working 
memory errors during task acquisition; however the MDMA/MDMA made 
significantly more than the other groups. Replicating the findings from the first two 
studies of the current thesis it was found that acute MDMA administration impaired 
accuracy, increased trial completion times and produced more reference memory errors 
than working memory errors. 
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Acute Drug Treatment Percent Correct Data 
To examine the effects of the acute drug treatments and to find further evidence 
of behavioural tolerance or sensitisation the average relative change in performance 
was calculated. This involved dividing performance on the day of acute drug treatment 
by the performance of the day before (baseline). This was conducted to provide an 
indication of the relative change between what subjects were like before and during the 
drug sessions. This analysis enabled the subjects starting point to be taken into account 
when examining the impairment produced by drug exposure. If the average relative 
change was a value larger than one it meant the rats performance improved on the drug 
day compared to the day before. Finally if the value was less than one it meant the 
subjects were impaired and the smaller this value the greater the impairment. These 
data are presented in Figure 29.  
The Saline/Saline controls produced values of around one and above as 
administering saline did not alter performance. The Saline/MDMA group‟s 
performance changed dramatically when administered MDMA. Finally it is evident 
that performance of the MDMA/MDMA group did not drop dramatically during the 
first drug treatments but their performance gradually got worse as the acute drug 
sessions continued.  
When comparing the performance of the MDMA/MDMA to the 
Saline/MDMA groups it would appear that initially there may be evidence of 
behavioural tolerance as the Saline/MDMA group‟s performance shows more of a 
dramatic decrease. Therefore during the first couple of sessions it would appear that 
rats that had previously been exposed to MDMA were less impaired when 
administered subsequent acute doses of the drug. However, by the end of the study this 
pattern dissipates. So there maybe some initial evidence of behavioural tolerance that 
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progressively declines as the performance of the MDMA/MDMA group becomes 
gradually more impaired and hence becoming similar to that of the Saline/MDMA 
group.  
Possible explanations for this effect may be due to continued training, repeated 
exposure to acute MDMA or simply as a product of recovery of function at a neuro-
chemical level. However a more likely interpretation is that the initial evidence for 
behavioural tolerance during the first few trials is produced by a floor effect. This is 
due to the fact that the MDMA/MDMA group is performing at such a low level of 
accuracy that when the acute doses of MDMA are administered performance does not 
decrease dramatically because performance cannot show any further impairment. 
Hence in the current study there is no convincing evidence of behavioural tolerance. 
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Figure 29: Average relative change from the day before acute drug treatment and the 
day of acute drug treatment. 
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A 3-way mixed ANOVA was used to analyse the percent correct data from the 
day before drug treatment with performance on the day of acute drug treatment across 
all six drug sessions and between the three groups. A significant 3-way interaction was 
found, F (10, 85) = 2.11, p < 0.05 (p = 0.03). Therefore there was a significant 
difference in accuracy for the day before drug treatment versus the day of drug 
administration and this changed with repeated drug exposure and depended on group. 
Clearly when examining Figure 25 in the previous section, this effect is driven by both 
the MDMA/MDMA group and the Saline/MDMA group whose performance 
significantly decreases during the day of drug treatment compared to the Saline/Saline 
control group and the fact that this difference gets larger as subjects acquire the task 
and their performance the day before treatment improves hence producing a larger 
drop in performance when MDMA is administered. 
In addition a 3-way mixed ANOVA was also used to analyse the data from the 
day after drug treatment with performance on the day of acute drug treatment across all 
six drug sessions and between the three different groups. An interaction was found, F 
(10, 85) = 2.06, p < 0.05 (p = 0.04), indicating a significant difference in accuracy 
between performance on the day of drug treatments versus the day after treatment 
which depended on repeated drug exposure and drug treatment on group. Again when 
examining Figure 25 it can be seen that this effect is driven by the MDMA/MDMA 
group and the Saline/MDMA group whose performance differs from the day of acute 
drug exposure and the day after. While the Saline/MDMA group‟s performance is 
impaired on drug exposure days performance on the day after drug exposure resumes 
to baseline levels. However, the MDMA/MDMA group is impaired on drug days but 
also appears to remain impaired to a degree on the day after drug exposure as 
performance does not return to baseline levels. 
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To further examine these effects the average effect of acute drug treatment was 
calculated by collapsing across the six drug treatment sessions. This data is presented 
in Figure 30 and shows that the MDMA/MDMA group produced an overall lower 
level of accuracy compared to the two other groups. It is also evident that performance 
during MDMA administration produced a similar level of performance for both the 
MDMA/MDMA and the Saline/MDMA groups. This figure also shows that during the 
day after drug treatment there is a residual drug effect for the MDMA/MDMA where 
performance remains impaired. In contrast the Saline/MDMA group‟s performance 
does not show any residual effect with performance returning to levels similar to that 
seen the day before drug treatment. In addition it is clear that for the Saline/Saline 
group had a very high level of performance and during the drug administration days 
where this group received saline their performance did not change. 
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Figure 30: Average percent correct for the day before, the day of drug treatment and 
the day after treatment for the three drug groups collapsed across the six acute drug 
sessions. 
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A one-way repeated measures ANOVA was conducted for each of the three 
drug treatment groups comparing performance on the day before, the day of and the 
day after acute drug administration. For the Saline/Saline group no effect was found, F 
(2, 10) = 0.10, p > 0.05 (p = 0.91), indicating there was no significant difference in 
performance between the day before, the day of or the day after acute drug treatment. 
For the Saline/MDMA group there was an effect of day, F (2, 12) = 279.53, p < 
0.05 (p = 0.00), suggesting a difference in accuracy between the day before, the day of 
and the day after drug administration. Paired sample t-tests were conducted to examine 
where this difference occurred. Rats in this group were significantly less accurate on 
the day of acute drug treatment compared to the day before (t (6)=16.93, p < 0.05) (p = 
0.00). Subjects were also significantly less accurate on the day of drug exposure 
compared to the day after (t (6)=-27.58, p < 0.05) (p = 0.00). Finally there was no 
significant difference between performance on the day before and the day after drug 
treatment (t (6)=0.39, p > 0.05) (p = 0.71). Therefore the Saline/MDMA group‟s 
performance returned to baseline levels the day after drug exposure and no residual 
drug effects were evident. 
Finally when analysing the performance of the MDMA/MDMA group an effect 
of day was produced, F (2, 12) = 49.66, p < 0.05 (p = 0.00). Therefore there was a 
significant difference in accuracy between the day before, the day of and the day after 
acute drug exposure. Subjects were significantly less accurate on the days they were 
given acute doses of MDMA compared to the day before (t (6) = 9.87, p < 0.05) (p = 
0.00). Again subjects were significantly less accurate on the days they were 
administered acute MDMA compared to the day after (t (6) = -6.06, p < 0.05) (p = 
0.00). Finally rats in the MDMA/MDMA group were significantly less accurate the 
day after acute MDMA administration compared to the day before drug treatment (t (6) 
=-3.65, p < 0.05) (p = 0.01). This suggests that this group experienced a significant 
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residual drug effect where the acute doses of MDMA continued to impair performance 
the day after drug exposure. 
 
Acute Reference Memory Data 
A 3-way mixed ANOVA was used to analyse the day before versus the day of 
drug treatment for reference memory errors. There was no significant interaction 
between repeated acute drug exposure with performance the day before versus the day 
of acute drug treatment and group, F (10, 85) = 1.86, p > 0.05 (p = 0.06). Therefore 
there were no significant differences in the number of reference memory errors made 
with repeated administrations of MDMA and saline during the day before treatments 
versus the day of drug treatments and between the three drug treatment groups. 
However, there was an interaction between the performance on the day before acute 
drug treatment versus the day of acute drug treatment with group, F (2, 17) = 144.85, p 
< 0.05 (p = 0.00). Therefore there was a significant difference between the three drug 
treatment groups in the number of reference memory errors made the day before versus 
the day of drug treatment. 
The reference memory data for the day after drug treatment versus the day of 
drug treatment was also analysed using a 3-way repeated measures ANOVA and found 
there was a significant interaction between repeated acute drug exposure with 
performance the day after versus the day of acute drug treatment and group, F (10, 85) 
= 3.03, p < 0.05 (p = 0.00). Therefore there was a significant difference in the number 
of reference memory errors made with repeated administrations of MDMA and saline 
during the day after treatments versus the day of drug treatments and between the three 
drug treatment groups. In addition there was an interaction between the performance 
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on the day after acute drug treatment versus the day of acute drug treatment with 
group, F (2, 17) = 123.48, p < 0.05 (p = 0.00). Hence there was a significant difference 
between the three drug treatment groups in the number of reference memory errors 
made the day after versus the day of drug treatment. 
Therefore to further examine this trend the average effect of acute drug 
treatment was calculated by collapsing across the six drug treatment sessions. This data 
is presented in Figure 31 and shows that overall the MDMA/MDMA group produced 
more reference memory errors than the other two groups. It is also clear that for the 
day before and the day after there is no obvious difference in the number of reference 
memory errors produced by the MDMA/MDMA and the Saline/MDMA groups. 
However on the day of drug exposure both the Saline/MDMA and the 
MDMA/MDMA groups produce a large number of reference memory errors clearly 
indicating impairment with acute drug exposure. 
In addition Figure 31 shows there is some evidence of a residual drug effect for 
the MDMA/MDMA where the number of reference memory errors does not return to 
baseline levels on the day after drug administration. In contrast the Saline/MDMA 
group‟s performance does not show any residual effect with performance returning to 
baseline levels. It is also evident that the Saline/Saline group produced very few 
reference memory errors overall and on the drug administration days where this group 
received saline their performance was not noticeably altered. 
A one-way repeated measures ANOVA was conducted for each of the three 
drug treatment groups comparing the amount of reference memory errors on the day 
before, the day of and the day after acute drug administration. For the Saline/Saline 
group no effect was found, F (2, 10) = 2.44, p > 0.05 (p = 0.14), indicating there was 
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no significant difference in performance between the day before, the day of or the day 
after acute drug treatment.  
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Figure 31: Average reference memory error percentage for the day before, the day of 
drug treatment and the day after treatment for the three drug groups collapsed across 
the six acute drug sessions. 
 
 
 For the Saline/MDMA group there was an effect of day, F (2, 12) = 822.52, p < 
0.05 (p = 0.00), suggesting a difference in the number of reference memory errors 
between the day before, the day of and the day after drug administration. Therefore 
paired sample t-tests were conducted to examine where this difference occurred. Rats 
in this group produced significantly more reference memory errors on the day of acute 
drug treatment compared to the day before (t (6) = -30.00, p < 0.05) (p = 0.00). 
Subjects also produced significantly more reference memory errors on the day of drug 
exposure compared to the day after (t (6) = -45.418, p < 0.05) (p = 0.00). However 
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there was no significant difference in the amount of reference memory errors on the 
day before and the day after drug treatment (t (6) = -1.18, p > 0.05) (p = 0.28). 
Therefore the Saline/MDMA group‟s performance returned to baseline levels the day 
after drug exposure and no residual drug effects were produced. 
 When analysing the reference memory data for the MDMA/MDMA group an 
effect of day was also found, F (2, 12) = 47.32, p < 0.05 (p = 0.00). Hence there was a 
significant difference in the number of reference memory errors made between the day 
before, the day of and the day after acute drug exposure. Subjects produced 
significantly more reference memory errors on the day of drug treatment compared to 
the day before (t (6) = -8.72, p < 0.05) (p = 0.00). Also subjects produced significantly 
more reference memory errors on the days they were administered acute MDMA 
compared to the day after (t (6) = 4.57, p < 0.05) (p = 0.00). In addition the rats in the 
MDMA/MDMA group produced significantly more reference memory errors the day 
after acute MDMA administration compared to the day before drug treatment (t (6) = -
9.05, p < 0.05) (p = 0.00). Therefore the MDMA/MDMA group produced evidence of 
a residual drug effect where acute doses of MDMA continued to impair performance 
the day after drug exposure. 
 
Acute Working Memory Data 
A 3-way mixed ANOVA was used to analyse the working memory data from 
the day before drug treatment with performance on the day of acute drug treatment 
across all six drug sessions and between the three groups. No significant interaction 
was found between repeated acute drug exposure, performance the day before versus 
the day of acute drug treatment and group, F (10, 85) = 0.80, p > 0.05 (p = 0.63). 
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Therefore there were no significant differences in the number of working memory 
errors made with repeated administrations of MDMA and saline during the day before 
treatments versus the day of drug treatments and between the three drug treatment 
groups. 
 However, a 3-way mixed ANOVA was also used to analyse the working 
memory. There was a significant interaction between repeated acute drug exposure 
with performance the day after versus the day of acute drug treatment and group, F 
(10, 85) = 2.27, p < 0.05 (p = 0.02). Therefore there was a significant difference in the 
number of working memory errors made that was dependent on repeated drug 
exposure, performance on the day after versus the day of acute drug treatment and 
chronic drug treatment group.  
However it is obvious from the lack of a clear pattern in Figure 29 that there is 
no consistent change in the amount of working memory errors made across the training 
sessions for any group. This is supported by the non-significant 3-way interaction 
between day before versus day of drug treatment, repeated drug exposure and group. 
The only exception to support that lack of an effect for working memory was the 3-
way interaction found between day after versus day of drug treatment, repeated drug 
exposure and group which just reached significance. 
 
Acute Trial Completion Time Data 
There was no interaction between repeated acute drug exposure with 
performance the day before versus the day of acute drug treatment and group, F (10, 
85) = 0.80, p > 0.05 (p = 0.63). Therefore there were no significant differences in the 
average amount of time to complete trials with repeated drug administration, the 
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difference in performance compared to the day before and the day of drug 
administration and drug group as can be seen in Figure 26. 
In addition there was no interaction between repeated acute drug exposure with 
performance the day after versus the day of acute drug treatment and group, F (10, 85) 
= 1.37, p > 0.05 (p = 0.21). Therefore there were no significant differences in the 
average amount of time to complete trials with repeated drug administration, the 
difference in performance compared to the day after and the day of drug administration 
and drug treatment group. 
 
Discussion 
 To reiterate, the aim of the current study was to examine the effects of repeated 
acute MDMA exposure on acquisition of the partially baited radial maze. It was found 
that acute administration of MDMA following binge MDMA exposure impaired task 
acquisition. Hence the hypothesis that the binge regime of MDMA would significantly 
impair acquisition of the radial maze was supported. In addition when comparing the 
findings from this study with those of Study 4, that utilised the same chronic regime of 
MDMA and the same gap between drug exposure and the commencement of training 
as the current study, it was found that the subsequent MDMA exposure may have 
additionally impaired task acquisition. In the current study it took 47 sessions for the 
group that received binge MDMA treatment to perform at a similar level of 
performance to the groups that were administered saline regimes. However, in Study 4 
this took only 22 sessions to occur. Therefore it would appear receiving a binge regime 
of MDMA and then receiving multiple acute doses of the drug impairs learning 
processes more so than receiving the binge MDMA regime alone. 
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Also consistent with our hypothesis, acute administration of MDMA also 
significantly impaired accuracy. Of interest it seems that administering acute doses of 
MDMA to the pre-treated binge rats produced longer lasting effects on performance. 
The rats that were initially pre-treated with saline and then administered acute doses of 
MDMA were impaired on the day of drug exposure but by the following day their 
performance recovered to baseline levels. However for the rats that were pre-treated 
with a binge regime of MDMA and then given acute doses of MDMA once a week 
their performance was impaired during the drug testing session. However in addition 
there were residual effects whereby their performance remained significantly impaired 
the day after acute exposure. 
 During acute drug treatment sessions there was some initial indication of 
behavioural tolerance in that the saline control rats at first appeared more disrupted by 
the acute doses of MDMA than the binge MDMA treated rats. However this effect 
seemed to dissipate as training continued suggesting it may have been due to a floor 
effect whereby the binge MDMA treated rats could not show such a large degree of 
impairment initially as their performance was so poor. Therefore contrary to the 
findings from Study 3 and 4 the current study did not find compelling evidence of 
behavioural tolerance with repeated MDMA exposure hence our hypothesis that 
behavioural tolerance would occur was not supported. 
 Binge MDMA exposure appeared to have little effect on the amount of time it 
took rats to complete trials. There were no significant differences found between the 
rats that received the binge regime of MDMA and those that received saline during 
acquisition of the task. Therefore it is unlikely that the impairments found in the 
MDMA/MDMA group were not due to motor impairments caused by binge exposure 
to MDMA. However, performance during acute MDMA administration produced 
noticeable increases in trial completion time which is consistent with the findings from 
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Study 1 and 2 of the current thesis. However, it should be noted that with acute 
MDMA exposure there were no obvious differences in trial completion time between 
the group of rats that were administered the binge regime of MDMA and those given 
saline. 
 Binge MDMA exposure also did not appear to obviously impair working 
memory processes and on the whole very few working memory errors were made by 
any group. In addition acute MDMA exposure did not produce a marked increase in 
working memory errors in any group. Therefore it seems that the impairments found in 
this study were not due to an MDMA induced deficit in working memory processes. 
Therefore the deficits produced by MDMA exposure were primarily the result of a 
reference memory impairment. Whereby during acquisition the group that were 
administered the binge regime of MDMA produced significantly more reference 
memory errors than those administered saline. In addition during acute MDMA 
exposure more reference memory errors were made than working memory errors. 
Therefore supporting our hypothesis it was found that both binge and acute 
administration of MDMA produced deficits in reference memory processes more so 
than working memory processes. Again this finding concurs with the previous studies 
of the current thesis. 
 While this study failed to find persuasive evidence of behavioural tolerance it 
should be pointed out that there are differences between the current and previous 
studies of this thesis. In Studies 3 and 4 behavioural tolerance was assessed by 
administering the acute doses of MDMA after the task had been acquired. As 
behavioural tolerance was found it suggests that previous binge MDMA exposure 
produced a protective factor in that performance was less impaired than those who had 
not received the previous MDMA exposure when acute doses of MDMA were 
administered. However in the current study the acute doses of MDMA were 
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administered while learning of the task was still occurring. Therefore it would appear 
that acute administration of MDMA during task acquisition is more disruptive while 
learning is still taking place. Therefore this may indicate that learning processes are 
more disrupted by MDMA exposure compared to memory processes that are used once 
the task has been acquired.  
In addition it may be that administering repeated acute doses of MDMA may 
disrupt the development of behavioural tolerance. It has been argued that repeated low 
doses of acute MDMA results in behavioural sensitisation while large doses of MDMA 
results in the development of tolerance (Brennan & Schenk, 2006). Therefore as this 
study utilised both it may have inhibited the development of behavioural tolerance 
with sensitisation processes from the acute doses of MDMA and tolerance processes 
from the binge MDMA exposure effectively cancelling each other out. Future research 
could examine this phenomenon further by manipulating the exposure of MDMA in 
different doses and regimes to examine which conditions produce behavioural 
tolerance or sensitisation.  
 Due to the novelty in design of the current study the findings are difficult to 
compare with previous research as no studies to date have administered repeated acute 
doses of MDMA after initial binge exposure while subjects are still learning a 
cognitive task. Thus the findings of the current study add something new to the 
existing literature on the effects of MDMA on cognition. In particular it would appear 
that additional exposure to MDMA, while still acquiring a cognitive task, seems to 
impair learning. This is a novel finding as previous research tends to administer large 
regimes of MDMA before training and if subsequent MDMA exposure occurs it does 
so after the task is acquired. Thus while previous work has been able to examine 
whether drug tolerance or sensitisation occurs it has not been able to examine what 
effect repeated MDMA exposure has on actual learning processes during task 
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acquisition. In addition the current study adds to the previous literature as it was able 
to concurrently assess working and reference memory processes. It was found that 
reference memory processes in particular seem to be impaired while working memory 
processes seemed largely unaffected which augments previous work (Broening et al., 
2001; Williams et al., 2003; Sprague et al., 2003; Vorhees, 2004; Skelton et al., 2006; 
Able et al., 2006; Skelton et al., 2008; Skelton et al., 2009) using Morris water maze 
tasks that have had to assess these processes separately.  
 In conclusion it was found that rats that were administered a binge regime of 
MDMA and then given acute doses of MDMA once a week were significantly 
impaired at acquiring the radial arm maze task compared to rats that did not receive the 
regime of MDMA. Also this impairment involved reference memory processes as 
opposed to working memory processes and did not seem to affect trial completion 
time. Repeated acute administration of MDMA did not result in behavioural tolerance 
due to a potential floor effect. Also the MDMA/MDMA group experienced a 
significant residual drug effect from the acute doses of MDMA as they remained 
impaired the day after drug administration. Therefore this study suggests that learning 
processes may be more disrupted by repeated MDMA exposure than memory 
processes. This study indicates that repeated MDMA exposure may inhibit the 
recovery of function seen with binge MDMA exposure in Study 4 as subjects took 
longer to acquire the task when administered additional acute injections of MDMA. 
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Binge MDMA Discussion 
Recap of Main Findings 
In Study 3 a binge regime of MDMA (4 x 10 mg/kg) was administered to rats 
and eight to ten weeks later their ability to acquire the partially baited radial arm maze 
was compared against saline controls. No significant difference on any measure of 
performance was found between the two groups ability to learn the task. To examine 
whether further drug exposure would have any effect on performance once the task has 
been acquired, another binge regime of MDMA was administered to the previously 
treated MDMA rats. This resulted in a significant but transient impairment in 
performance. In the last phase of the study an acute dose of MDMA and saline were 
administered to examine whether behavioural tolerance or sensitisation would occur. 
Evidence of behavioural tolerance was found as the binge MDMA treated rats were 
significantly less impaired when administered acute MDMA than the saline controls. 
 The next study examined whether the lack of an effect produced by the initial 
exposure to MDMA in Study 3 was due to the time period between drug 
administration and training or due to the amount of MDMA administered. Therefore in 
Study 4 the previously used binge regime of MDMA was administered to rats three 
days before training began in the maze. The MDMA treated group were significantly 
slower in acquiring the task compared to the saline controls. However, the MDMA 
treated rats were able to eventually perform at a similar level to the controls suggesting 
MDMA exposure impaired their rate of learning but did not prevent them from 
acquiring the task. The rules of the task were then reversed to examine the permanence 
of the cognitive impairment and to investigate the effect of MDMA treatment on the 
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ability to adapt behaviour to changing consequences. The MDMA treated rats took 
significantly longer to learn the new task compared to saline controls. Therefore binge 
MDMA exposure significantly impaired the ability of subjects to alter their behaviour 
when faced with a change in task demands. By the end of training they were able to 
perform at a similar level to the control group showing they could eventually learn to 
alter their behaviour. The finding that MDMA treated rats that appeared to have 
recovered from the effects of the drug in the first phase of the study went on to show 
impairment when the rules of the task were reversed indicates that the learning 
impairments produced by MDMA may be long-term in nature. This study also 
examined the effects of acute administration of MDMA and saline on rats that had 
previously been treated with a binge MDMA regime of saline. As in the previous study 
evidence of behavioural tolerance was found.  
 The final study of the current thesis examined the effects of repeated MDMA 
exposure on task acquisition in the partially baited radial maze. Rats that were exposed 
to a binge regime of MDMA and then administered repeated acute doses of MDMA 
were impaired in acquiring the radial arm maze compared to rats that were pre-treated 
with saline. In addition administering repeated acute doses of MDMA to rats that had 
already received a binge regime of MDMA further impaired their ability to acquire the 
task taking approximately 47 sessions to perform at a similar level to saline controls. 
This is more than double the number of training sessions compared to the results from 
Study 4 that used the same task, breed of rat and regime of MDMA. Performance was 
significantly impaired during sessions that acute doses of MDMA were administered. 
However there was no convincing evidence of behavioural tolerance with repeated 
MDMA administration. Of interest the group that received the binge regime of 
MDMA were impaired on the day of acute MDMA exposure and the day after whereas 
saline controls were not. Thus this group produced evidence of a residual drug effect.  
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 In conclusion the findings from Studies 3, 4 and 5 that examined the effect of 
binge MDMA exposure on cognitive performance all produced some form of an 
impairment in accuracy in the partially baited radial maze. In addition in all three 
studies these impairments were the result of MDMA exposure producing more 
reference memory errors than working memory errors. This suggests that binge 
MDMA administration affects reference memory processes more so than working 
memory processes. Binge MDMA exposure generally failed to produce an effect on 
trial completion time. Thus the impairments found with drug exposure cannot be 
explained in terms of motor impairments caused by drug exposure. Also supporting the 
findings from Study 1 and 2 in the first half of this thesis it was found that acute 
MDMA exposure impaired accuracy in the radial arm maze as well as increasing trial 
completion times. Acute MDMA exposure produced more reference memory errors 
than working memory errors. 
Comparison to Previous Chronic/Binge MDMA Literature 
 Unlike the findings of the current thesis most studies (LeSage et al., 1993; 
Taffe et al., 2001; Frederick et al., 1995; Frederick & Paule, 1997) that have examined 
the effects of chronic and binge MDMA exposure on cognition by utilising DMTS and 
DNMTS tasks have failed to show that the drug significantly affects performance from 
baseline levels. However it should be noted that in these studies the cognitive task had 
already been acquired and while performance was affected during drug administration 
there were no long-term deficits. Hence chronic or binge MDMA exposure does not 
seem to affect performance on an already acquired task. In addition the results from 
this thesis indicate that reference memory processes are more affected by binge 
MDMA exposure than working memory processes. While DMTS and DNMTS tasks 
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involve a reference memory component they are primarily used to assess working 
memory processes (Harper et al., 2005). Therefore these tasks may not involve a large 
enough reference memory component to produce impairment following chronic or 
binge MDMA administration. 
In contrast to the findings of the current thesis Winsauer et al. (2002) also 
failed to find evidence of binge MDMA exposure impairing performance on a 
cognitive task. A repeated acquisition task was used where each session subjects had to 
learn a sequence of lever presses to gain reinforcement. While this task is used to 
assess learning as the lever sequences change each session, subjects were pre-trained 
before drug exposure. Hence they had acquired the general rules of the task before 
MDMA was administered. Therefore a possible reason why Winsauer et al. (2002) 
failed to find an effect with binge MDMA exposure may be similar to the DMTS task 
findings whereby as subjects have had experience with the task their performance is 
harder to disrupt with drug exposure compared to tasks that subjects are still learning.  
Similarly Moyano et al. (2005) found that a binge regime of MDMA did not 
significantly alter performance from controls on a passive avoidance task when tested 
seven days after drug exposure. However, when later challenged with an acute dose of 
MDMA the previously MDMA treated animals were significantly impaired compared 
to controls. Therefore although the initial regime of MDMA did not appear to impair 
performance the finding that these rats were later more sensitive to the effects of the 
drug may suggest an underlying impairment. Also as previously mentioned a potential 
flaw in passive avoidance paradigm is that they rely solely on motor function to assess 
memory which can be problematic as any drug can produce general effects that may 
result in changes in motor ability. 
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While the findings from object recognition tasks (Morley et al., 2001; Piper & 
Meyer, 2004; Piper et al., 2005) concur with those of the current thesis as both have 
found evidence of MDMA exposure producing significant impairments in 
performance, it should be noted that these tasks are quite different to the one utilised in 
the current thesis. Object recognition tasks do not involve learning per se as often these 
studies use only one trial. Instead they examine the natural disposition of rats to 
explore a novel object over a familiar one (Ennaceur & Delacour, 1988). Therefore 
these tasks are quite unique in comparison to other cognitive tasks. They are used to 
assess memory as when faced with a familiar object and a novel object the subject is 
inferred to remember the old object if it spends more time exploring the novel object 
(Ennaceur & Delacour, 1988). However they differ from other memory tasks such as 
DMTS type tasks that use lots of trails per session or maze tasks that generally utilise 
multiple training sessions. Hence object recognition tasks may assess different 
cognitive processes than other cognitive tasks. Despite the evidence that they show 
disruption with chronic MDMA exposure which concurs with the findings from the 
current thesis they are difficult to more directly compare with the findings from the 
partially baited radial maze due to their differing task structure.  
There are also a number of studies that have examined the effects of chronic 
MDMA exposure on the ability to acquire various operant based tasks. For example Li 
et al. (1988) and Byrne et al. (2000) investigated acquisition of a DRL task. Neither 
study found significant evidence of binge MDMA exposure disrupting acquisition of 
these tasks. However it could be argued that these are not complex tasks and are not 
used to assess cognitive function as they involve simply learning to press a lever at a 
specific rate and do not require memory processes to the same extent as DMTS or 
maze type tasks. Hence these tasks may not be complex enough to show evidence of 
impairments involving higher cognitive processes.  
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 Perhaps the most relevant research for the purpose of this thesis, in terms of 
similarity of paradigm, are studies that have used other maze tasks. Not all studies that 
have utilised maze based tasks have found evidence of MDMA exposure producing 
cognitive impairments. For example Slikker et al. (1989) and Ricuarte et al. (1993) 
both found no evidence of impairment in acquiring tasks involving various mazes 
following binge and chronic MDMA exposure despite finding evidence of reductions 
in 5-HT levels within the brain. However one major difference between Slikker et al.‟s 
(1989) study and that of the current thesis was the route of drug administration. Slikker 
et al. (1989) administered MDMA via oral gavage whereas the current thesis used 
intraperitoneal injections. Administering MDMA via injections, either intraperitoneal 
or subcutaneous are a more common method used in MDMA research despite the fact 
that most Ecstasy users take the drug orally (Finnegan et al., 1988). This may be 
important as it is known that the route of administration of a drug can affect absorption 
with oral drug administration potentially having less of an effect than when the drug is 
injected (Finnegan et al., 1988). Also of note in Ricaurte et al.‟s (1993) study 
acquisition training within the T-maze did not actually begin until 7 weeks after drug 
treatment. Therefore these findings are similar to the results from Study 3 that failed to 
find evidence of a learning impairment in the radial arm maze when there was an eight 
to ten week gap between drug exposure and training and this may account for the lack 
of an impairment in performance in Ricaurte et al.‟s (1993) study.  
Nevertheless, there are a number of studies (Robinson et al., 1993; Broening et 
al., 2001; Williams et al., 2003; Sprague et al., 2003; Vorhees et al., 2004; Skelton et 
al., 2006; Able et al., 2006; Skelton et al., 2008; Skelton et al., 2009) that have used 
Morris water maze and Cincinnati water maze procedures and have found convincing 
evidence of cognitive impairments produced by chronic and binge MDMA exposure. 
These results concur with the findings of the current thesis as the studies examined the 
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acquisition of these tasks and found MDMA treated subjects showed deficits in their 
ability to learn the tasks compared to saline controls. Like the findings of the current 
thesis that found MDMA exposure did not affect trial completion time these studies 
also did not find evidence that the impairments were due to motor impairments as 
swimming ability remained unaffected. In addition these studies have found that 
reference memory processes appear to be impaired by MDMA exposure while cued 
learning and working memory processes remain unaffected which is consistent with 
the findings of the current thesis.  
Longevity of MDMA Induced Cognitive Impairments 
There are some studies that suggest that impairments produced by MDMA 
exposure are transient. For example Robinson et al. (1993) found MDMA treated rats 
were initially impaired at acquiring a water maze task but eventually were able to learn 
the task. In addition Vorhees et al. (2004) found the order in which subjects were 
administered cognitive tasks produced different results. The subjects that were 
administered MDMA and then trained on a Morris water maze task first (42 days post 
drug exposure) and then a Barnes maze showed significant impairments in learning the 
Morris water maze whereas those that were trained on the same Morris water maze 
task second (77 days post drug exposure) did not produce significant learning 
impairments. Vorhees et al. (2004) explained this finding suggesting that transfer of 
learning may have occurred between the cognitive tasks. However another explanation 
may be that the deficits produced by MDMA were transient and subjects that did not 
begin training until 77 days after drug treatment may have experienced recovery of 
function. In contrast other studies have found that MDMA induced cognitive deficits 
may be more long-term in nature with cognitive impairments being present 50 days 
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post drug treatment (Williams et al., 2003; Broening et al., 2001). There is also 
evidence of impairments having been found 160 days post drug treatment and even up 
to 340 days after drug exposure (Skelton et al., 2006). 
The findings from the current thesis as to the longevity of cognitive 
impairments produced by the regime of MDMA used are mixed. The finding that 
learning impairments were only found when there was a three day gap between drug 
exposure and training may indicate that these learning impairments were transient. In 
other words as subjects were able to acquire the task towards the end of training it 
might suggest that they no longer were impaired. Therefore it could be argued that the 
only reason any impairment was found in Studies 4 and 5 was due to the short time 
delay between drug exposure and training. Whereas in Study 3 when a longer delay 
(eight to ten weeks) between drug exposure and training occurred there was no 
evidence of a learning impairment. 
In contrast to the findings from Study 3 numerous other maze studies have 
found evidence of cognitive impairments produced by MDMA exposure with large 
delays between drug exposure and training. One possible important difference between 
the studies in the current thesis and previous maze research is the amount of time 
between drug administration and the commencement of training. The majority of 
studies that have used the Morris water maze and Cincinnati maze tasks have 
conducted developmental studies in that they have examined the effect of 
administering large chronic regimes of MDMA to young rats and then investigated 
what affect this has on learning when they are older. Hence they leave a large amount 
of time between drug exposure and training. A possible explanation for the conflicting 
findings was the age of our subjects who were older than those used in the 
developmental studies. The rationale of the development studies is to administer the 
drug at a pivotal developmental stage to examine whether this will produce cognitive 
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deficits later in life (Broening et al., 2001). However this may not be the finding for 
studies that utilise adult rats like those conducted in the current thesis as they are not 
exposed to the drug during this potentially crucial developmental phase where subjects 
may be more vulnerable to the effects of the drug. However an alternative explanation 
is the sheer volume of drug that subjects in the developmental studies are exposed to 
which is much larger than that used in the current thesis. 
Other studies within the MDMA literature have also found evidence of 
cognitive impairments with short time delays between drug exposure and cognitive 
testing. For example Able et al. (2006) used adult rats and maze training commenced 
one week after drug exposure and still found evidence of learning reference memory 
impairments. Similarly Sprague et al. (2003) used adult rats and only had a week long 
gap between drug exposure and testing in the Morris water maze. Sprague et al. (2003) 
also found that the rats administered MDMA produced evidence of reference memory 
impairments which is consistent with the findings of the current thesis. Therefore there 
is evidence within the literature that suggests cognitive impairments can be produced 
by MDMA exposure when there is a relatively small time period between drug 
exposure and cognitive testing which concurs with the findings of Study 4 and 5 of the 
current thesis. Hence when taking this previous research and the current thesis findings 
into account there is converging evidence that chronic or binge MDMA exposure 
produces impairments in acquiring maze tasks. More specifically these impairments 
seem to involve reference memory processes.  
Perhaps the most convincing evidence that the impairments produced by 
MDMA exposure in the current thesis are not short-term is the findings from the 
reversal phase in Study 4. In this experiment MDMA treated subjects were 
significantly slower to acquire the radial maze task compared to saline controls. 
However they were able to eventually perform at a similar level to controls and 
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therefore towards the end of this phase of the experiment there was no evidence of a 
deficit in performance in the MDMA treated animals. After the completion of this 
phase the rules of the task were reversed and the subjects had to adapt their behaviour 
and go to previously non-reinforced maze arms and avoid the previously reinforced 
arms. It was found that MDMA treated animals were significantly worse at this task 
compared to the controls. Therefore even though the evidence of the initial impairment 
was no longer visible there was evidence of a continuing underlying impairment in 
terms of a cognitive flexibility deficit. Therefore the impairments produced by MDMA 
exposure may be long-term in nature but these deficits become less obvious over time. 
This may help explain the conflicting findings within the literature where some studies 
have found evidence of chronic MDMA exposure produced cognitive impairments 
while others have not.  
Type of MDMA Regime Used 
Another important difference between the developmental studies and the 
studies in the current thesis is the amount of MDMA that subjects are exposed to. 
Typically developmental studies expose subjects to a much more MDMA than that 
used in the current thesis. In addition the drug is often administered over a much 
longer period. The most commonly used (Broening et al., 2001; Vorhees et al., 2004; 
Skelton et al., 2006; Williams et al., 2003) chronic regime in the developmental studies 
involves 20 mg/kg given twice a day for ten days. Therefore a possible reason why 
these studies still find evidence of learning impairments after a large time gap between 
drug administration and training is due to the sheer volume of the drug they have been 
exposed to which may impair recovery of function. 
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Indeed the binge regime used in the current thesis (4 x 10 mg/kg for one day) 
generally involves less MDMA than much of the previous work that has examined the 
effects chronic MDMA exposure on cognition. For example Robinson et al. (1993) 
gave double the injections of 10mg/kg of MDMA to that used in the current study and 
both Able et al. (2006) and Skelton et al. (2008) used four injections of 15 mg/kg in a 
day. In addition the developmental type studies mentioned above (Broening et al., 
2001; Vorhees et al., 2004; Skelton et al., 2006; Williams et al., 2003) also involve 
larger amounts of MDMA being administered to subjects.  
While exposing subjects to a smaller amount of MDMA may result in a less 
obvious impairment in performance the regime used in the current study has been 
shown to produce 5-HT damage (Scanzello et al., 1993) and result in significant 
behavioural effects (Brennan & Schenk, 2006). In addition there has been criticism 
that the doses of MDMA previously used in chronic studies are unrealistically large 
compared to human use of the drug (Baumann et al., 2007). Hence the finding that the 
current study was able to show evidence of cognitive deficits while administering a 
smaller regime of MDMA adds to the existing MDMA literature. 
The Underlying Cognitive Processes in the MDMA Induced Impairments 
Within the current thesis, binge MDMA exposure produced deficits that 
affected the ability of subjects to acquire the task producing significantly slower rates 
of learning. Although in the second phase of Study 3 a deficit was found when the task 
had been acquired this was only produced when an additional regime of MDMA was 
administered. Therefore the current thesis found binge MDMA exposure produced 
deficits that could be predominantly characterised as learning impairments. 
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The findings from studies that have used Morris and Cincinnati water mazes 
along with the results from the current thesis suggests that chronic and binge MDMA 
exposure can affect cognitive performance. In particular it appears to be learning 
processes that are more vulnerable to disruption by drug exposure as studies that have 
examined the acquisition of a task tend to more likely to produce impairments than 
those that have pre-trained subjects to perform a task and then administered the drug. 
A possible explanation for this comes from research that has examined the effects of 5-
HT lesioning on cognitive performance. For example Cassaday, Norman, Shilliam, 
Vincent and Marsden (2003) conducted a study that examined the acquisition of two 
maze tasks and found that subjects in the experimentally 5-HT depleted group were 
significantly impaired at acquiring the tasks compared to controls. However once the 
tasks were learnt their performance did not differ from controls. Therefore Cassaday et 
al. (2003) argued that damage to the 5-HT system produced impairments in acquiring 
tasks but did not seem to affect performance once the tasks had been acquired. This 
finding indicates that learning processes may be more easily disrupted than memory 
processes by 5-HT damage and hence may contribute to the current findings which 
used a regime of MDMA that has been shown to produce 5-HT damage (Scanzello et 
al., 1993). However it should be noted that the current thesis did not carry out any 
physiological measure of 5-HT levels and hence it is unknown whether or to what 
degree subjects experienced damage to 5-HT levels within the brain. 
 In particular it appears that reference memory processes seem to be impaired 
following binge MDMA exposure. There are a number of possible explanations for 
what is underlying this MDMA induced deficit in reference memory. One possible 
reason for the impairment in reference memory is that binge MDMA exposure impairs 
the subjects‟ ability to encode or input information into long-term memory. Therefore 
the subjects that have been exposed to MDMA have trouble consolidating the 
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information about which arms contain reinforcement and hence make a large number 
of reference memory errors. However subjects do seem to readily learn not to repeat 
arm visits and hence do not make a large number of working memory errors, thus it 
appears MDMA exposure does not seem to impair working memory processes. 
 Another possible explanation for the reference memory deficit is that binge 
MDMA exposure produced a deficit in acquiring task rules. Therefore subjects have 
difficulty in ascertaining that the task requires them to learn that there are four arms of 
the maze that contain reinforcement and four arms that do not. In addition they must 
learn that this rule does not change between trials or training sessions. Therefore while 
they do not tend to repeat arm entries due to a natural predisposition to alternative arm 
entries (Chrobak & Napier, 1992) they do tend to produce a large number of reference 
memory errors by continuing to visit arms that do not contain reinforcers. 
 A less cognitive explanation for the behaviour produced by the subjects 
exposed to MDMA is that the drug simply impairs their ability to utilise extra-maze 
cues which are generally used to solve radial maze tasks (Liao et al., 2002). However, 
this explanation would seem unlikely as the visual distortions that are reported with 
Ecstasy use that could explain these visual impairments are associated with acute use. 
In other words Ecstasy users only tend to experience visual hallucinations while under 
the influence of the drug (Peroutka et al., 1988) which has been linked to the increase 
in 5-HT activity produced by acute MDMA administration (Liechti & Vollenweider, 
2000). This makes it unlikely to be a factor in the current thesis as the regime of 
MDMA used has been shown to produce a decrease or depletion in 5-HT activity 
(Scanzello et al., 1993). 
During training there was no particular evidence that MDMA exposure affected 
trial completion time. Therefore there did not seem to be any major differences 
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between MDMA treated rats and controls in terms of how long it took them to 
complete trials within the radial maze. Hence it seems unlikely that the impairments 
found after MDMA exposure were the result of drug induced motor impairments. This 
finding is consistent with the previous research that has found that MDMA has 
produced reference memory impairments in maze paradigms without affecting 
swimming ability as assessed by straight channel swimming tasks (Broening et al., 
2001; Vorhees et al., 2003; Williams et al., 2003; Able et al., 2006; Skelton et al., 
2006; Skelton et al., 2009) which are used to assess motor impairments after drug 
exposure. Therefore it would appear unlikely that reference memory deficits can be 
explained in terms of the drug impairing motor ability. 
Tolerance and Sensitisation 
The findings from the first two studies that examined binge MDMA exposure 
in the radial maze both found evidence of drug tolerance. This was evident in that rats 
who were exposed to binge MDMA regimes were less impaired when later exposed to 
acute doses of MDMA compared to saline controls that has not had previous MDMA 
exposure. This is consistent with a number of studies such as LeSage et al. (1993), 
Marston et al. (1999), Frederick et al. (1995), Frederick and Paule (1997) and 
Frederick et al. (1988) that found the effects of MDMA on cognitive performance 
lessened with repeated exposure.  
 However the findings from the final study of this thesis are more complicated 
in that while there was initial evidence of drug tolerance this effect seemed to dissipate 
as training continued. Therefore it could be argued that this effect was not driven by 
drug tolerance but by a floor effect. This occurred as initially acute exposure did not 
appear to affect the binge MDMA treated rats as performance was so poor that the 
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addition of further MDMA exposure did not seem to disrupt performance to a notable 
extent. As training continued as the performance of this group improved the acute 
doses of MDMA appeared to have more of an effect on performance as accuracy was 
able to decrease more due to the more accurate level of performance. In fact it 
appeared that in the final study there may be evidence that acute MDMA exposure had 
more of an effect on the pre-exposed MDMA group as there was a residual effect of 
the drug on performance on the days after acute drug administration. 
The finding from Study 5 that repeated MDMA exposure while subjects were 
still learning the task did not produce behavioural tolerance may indicate that learning 
processes (what subjects use while acquiring the task) are more easily disrupted than 
memory processes (what subjects use once they have acquired the task) with MDMA 
administration. In addition the finding that previous binge MDMA exposure produced 
residual drug effects may also support this suggestion as performance seems to be 
more disrupted during acquisition with repeated MDMA exposure.  
Future Study 
As the findings from the second part of this thesis suggest that learning 
processes (task acquisition) is significantly affected by MDMA exposure, it might be 
interesting for future research to examine the effects of binge MDMA exposure on 
acquiring a DMTS task. This is due to the finding that the previous research (LeSage et 
al., 1993; Taffe et al., 2001; Frederick et al., 1995; Frederick & Paule, 1997) that has 
examined the effects of pre-training subjects on DMTS and DNMTS type tasks and 
then exposing them to a chronic and binge MDMA regimes have generally failed to 
find evidence of cognitive impairments. In addition to replicate and extend the findings 
from Study 4 from this thesis once the DMTS task has been acquired it could be 
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interesting to then switch the rules of the task to a DNMTS task. This would allow the 
longevity of any impairment found to be examined and also assess cognitive 
flexibility. This study would allow not only acquisition to be studied but also whether 
any impairment would be found in the ability of subjects to change their behaviour 
following a change in the requirements of the task which could further support the 
findings from the current thesis. In addition conducting this research might clarify 
whether the reason DMTS type tasks fail to produce impairments following MDMA 
exposure is due to their ability to greater assess working memory rather than reference 
memory processes or whether the lack of an effect is due to the fact subjects are tested 
after the tasks have been acquired.  
 To further extend the results of the current thesis it may be beneficial to 
replicate the findings using another cognitive task that allows the simultaneous 
assessment of reference and working memory processes. For example the holeboard 
task (see Acute MDMA Discussion or van der Staay et al., 1999 for detail on 
procedure) also assesses spatial memory and allows simultaneous investigation of both 
working and reference memory processes. A future study could administer the same 
binge regime of MDMA used in the current study and examine whether acquisition of 
this task is impaired and whether reference memory processes were more impaired 
than working memory processes. In addition this study could further examine the 
effects of MDMA on cognitive flexibility through altering the rules of the task by 
switching which holes contain reinforcement and examine how MDMA treated 
subjects alter their behaviour to this change.  
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Conclusion 
In summary the current thesis found binge MDMA exposure resulted in 
significant impairments in acquiring the partially baited radial arm maze but only if 
there was a small delay between drug exposure and training. While the learning 
impairment may have appeared transient and amenable to behavioural recovery it 
should be noted that when the rules of the task were reversed subjects again showed a 
significant learning impairment. Hence the MDMA induced impairment may be long-
term in nature and primarily involve reference memory processes leaving working 
memory processes intact. In addition the impairments found seem unlikely to be 
explained in terms of motor impairments due to a lack of an effect on the time taken to 
complete trials. Possible explanations for the cognitive impairment found may be the 
result of a deficit in encoding information into long-term memory or an impairment in 
acquiring task rules. Unfortunately the current thesis is unable to differentiate between 
these potential explanations and further research will be needed to determine the nature 
of the MDMA induced reference memory impairment. 
In addition this section of the current thesis replicated the first half of the thesis 
whereby acute administration of MDMA impaired accuracy, increased trial completion 
times and resulted in more reference memory errors than working memory errors. 
Mixed evidence of behavioural tolerance was found whereby Study 3 and 4 produced 
evidence of behavioural tolerance to acute challenges of MDMA after the task had 
been acquired. However in Study 5 due to a possible floor effect no convincing 
evidence of behavioural tolerance was produced. The findings from this half of the 
thesis suggest that binge MDMA exposure may affect learning processes more so than 
memory processes. This is because when compared to previous research it would seem 
that the drug disrupts performance while subjects are acquiring cognitive tasks as 
opposed to producing impairments once the tasks have been learnt. 
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In conclusion the second half of the current thesis that examined the effects of a 
binge regime of MDMA added to the existing literature by utilising a smaller, and 
possibly more realistic, regime of MDMA than those used in previous research and 
also utilised a paradigm not used within the MDMA literature that allowed 
simultaneous assessment of working and reference memory processes. In addition it 
allowed the assessment of cognitive flexibility by changing the rules of the task which 
may contribute to the issue of the longevity of MDMA induced cognitive impairments. 
Finally in Study 5 the effects of repeated acute MDMA administration after an initial 
binge regime of MDMA were examined. This manipulation has not been conducted by 
earlier research and produced the interesting finding that it further impaired task 
acquisition and produced residual drug effects. 
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GENERAL DISCUSSION 
Recap of Findings 
 The first half of the thesis not only examined the acute effects of MDMA on 
maze performance but also investigated which neurotransmitter system may be 
responsible for the memory deficits seen with acute MDMA administration in the 
partially baited radial arm maze. Study 1 administered the 5-HT agonist Citalopram 
and the dopamine agonist GBR12909 and an acute dose of MDMA to rats. The 
dopamine agonist produced a pattern of impairments that were more similar to those 
produced by MDMA than Citalopram. Therefore, increased dopamine activity when 
subjects are administered acute doses of MDMA may play more of a role in the 
reference memory impairments in the radial maze. In Study 2 the D1 agonist A63930 
and the D2 agonist Quinpirole were administered to examine which dopamine receptor 
system may be driving the reference memory impairment seen with acute MDMA 
exposure. At the doses used both agonists produced some level of impairment however 
when co-administered they produced a synergistic effect more similar to that seen with 
acute MDMA exposure. Therefore it would appear that not only is it the dopamine 
release that produces the reference memory effect but that both D1 and D2 receptor 
systems are involved. 
The second half of the thesis examined whether binge doses of MDMA would 
impair the ability of rats to acquire the partially baited radial arm maze task. Learning 
was significantly impaired when there was a small delay between drug exposure and 
training. In addition when the rules of the task were reversed subjects again showed a 
significant learning impairment suggesting there may be long-term underlying 
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cognitive impairments not readily visible until the requirements of the task are altered. 
Once again the impairment involved reference memory processes leaving working 
memory processes relatively intact. In addition in the final study (Study 5) subjects 
were exposed to binge doses of MDMA and then once a week administered acute 
doses of MDMA. Task acquisition was significantly impaired with the task taking 
twice as long to acquire than in Study 4 suggesting repeated MDMA exposure further 
impairs learning processes. The second half of the thesis also examined whether drug 
tolerance or sensitisation would occur when subjects were challenged with acute doses 
of MDMA. Study 3 and 4 found evidence of drug tolerance as when subjects had 
acquired the task and were challenged with acute doses of MDMA the subjects who 
had previously been exposed to the binge doses of MDMA were less impaired than 
saline controls. In Study 5 no convincing evidence of tolerance was found possibly due 
to a floor effect in performance while subjects were still acquiring the task. 
 Therefore the current thesis found acute MDMA exposure significantly 
impaired performance in the radial arm maze by affecting reference memory processes 
more than working memory processes. In addition binge exposure to MDMA also 
impairs performance in the radial maze paradigm where learning is significantly 
slower that is the result of an increase in reference memory errors not working memory 
errors. Hence the current research found MDMA exposure in general affects reference 
memory processes more so than working memory processes. 
Defining Reference Memory: Problems Comparing Human and Animal Research 
One complication when trying to interpret the findings on the effects of MDMA 
on memory functioning is that the definitions for different memory processes vary 
between the animal and the human literature. For example working memory in animal 
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research generally refers to remembering a stimulus during a delay (where this 
stimulus is not present) after which time a subject must make a response (Dudchenko, 
2004). It is a memory process that involves temporary information that is only relevant 
for a specific trial (Dudchenko, 2004). Hence it involves remembering short-term 
episodic memory that involves stimuli or events they have just seen or places they 
have just been (Hampton & Schwartz, 2004). For example whether the subject was just 
presented with a red or green light or which arm of a maze it just entered.  
However within human research the definition of working memory is more 
complex. It arose from an earlier construct called short-term memory (Baddeley, 1998) 
that involved a unitary system that temporarily stored information (Baddely, 2000). 
The term working memory now generally refers to Baddely‟s three component model 
that involves the temporary storage and manipulation of information needed to perform 
complex tasks such as learning, memory and comprehension (Baddeley, 2000). More 
generally within the human literature it refers to the ability to temporarily store and 
manipulate information (Howard et al., 2003).  
This type of memory functioning is typically more complex than that referred to 
as working memory within the animal literature and hence could be explaining an 
entirely different set of memory processes. Indeed even Baddeley (2000) has argued 
the term working memory used within animal research involves the storage of 
information over several trials and to some extent may rely on long-term memory 
processes. Hence Baddeley (1998) argued that animal working memory processes 
involve different memory processes than those used in human literature (Baddeley, 
1998).  
To make matters even more complicated the definition of exactly what is 
involved in reference memory remains unclear even within the animal literature. Most 
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papers that examine reference memory define it solely in terms of the apparatus used. 
For example in the partially baited radial maze reference memory is defined as visiting 
an arm that does not contain reinforcement (Olton & Papas, 1979). Whereas in the 
Morris water maze it is defined as the ability of a subject to learn where a platform is 
within a water maze that does not change position from trial to trial (Frick et al., 1995). 
These papers often do not delve into any further explanation or discussion on what the 
reference memory processes involved in these tasks entail. Studies that have tried to 
define reference memory have described reference memory as a long-term, 
(Dudchenko, 2004) trial independent form of memory as the to be remembered 
information remains the same across trials (Olton & Papas, 1979). It has also been 
described as the memory process involved in acquiring task rules, for example running 
to the end of a maze or swimming to a fixed platform (Frick et al., 1995). 
Even within the animal literature there appears to be some debate as to how to 
assess reference memory. For example there appears to be confusion as to whether 
tasks that involve visual discrimination that involve a task rule actually assess 
reference memory or whether it involves more of a memory (having to remember 
information) component. For example Bushnell and Levin (1993) used modified 
DMTS task trials involving visual discrimination that they argued assessed reference 
memory. In these trials subjects had to press the lever in an operant chamber which 
illumined a light source above it. Hence subjects did not have to remember which lever 
to press from trial to trial they only had to remember the general rule that they needed 
to press the lever with the light above it. However it could be argued that this task does 
not really encompass the complexity of reference memory processes as it did not 
involve a memory component. Hence this task was more similar to cued learning type 
tasks. So even though the definition of reference memory is often described as a long-
term general rule that does not change from trial to trial it does seem more complicated 
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in that the subject has to remember something from trial to trial that is not externally 
cued. Therefore reference memory functioning appears to involve more complex 
cognitive processes than simple visual discrimination or cued learning as it appears to 
involve a larger memory component in that subjects are required to remember spatial 
information across trials. 
Another problem when trying to make comparisons between human and animal 
research is that there appears to be no real definition of reference memory in human 
literature. This makes trying to determine what the equivalent memory process in 
human memory functioning difficult. The closest definition for reference memory in 
the human cognitive literature appears to be that of procedural memory which involves 
the gradual acquisition of rules or procedures (Thomas-Ollivier et al., 1999). 
Procedural memory also is defined as the processing system responsible for the 
encoding, storage and retrieval of procedures that can be motor or cognitive and hence 
have been examined using tasks assessing the learning of both motor and cognitive 
tasks (Beaunieux et al., 2006). Unfortunately there is no apparent research that has 
examined the effects of MDMA on this type of human memory functioning. In 
addition procedural memory often tends to refer to basic motor or perceptual learning 
involving tasks such as mirror reading, pursuit rotor tasks and jigsaw puzzles 
(Schmand, Brand & Kuipers, 1992). This is problematic as this type of learning does 
not encompass the type of reference memory referred to in animal studies. More 
recently there has been more focus on cognitive procedural memory which involves 
more complex cognitive rule learning which uses problem solving tasks (Schmand et 
al., 1992).  
Hence cognitive procedural memory is similar to human working memory and 
executive functioning as it assesses the ability of subjects to learn cognitive task rules. 
For example disc transfer tasks like the Tower of Hanoi and Tower of London are used 
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to assess executive functioning and cognitive procedural memory (Schmand et al., 
1992; Beaunieux et al., 2006). These tasks involve three poles that have a varying 
number of disks placed on them (Schmand et al., 1992). In general the task involves 
having to move the disks from the first pole to the last pole as quickly as possible and 
in as few moves as possible by only moving one disk at a time and not placing a bigger 
disk on top of a smaller one (Schmand et al., 1992). These tasks have been argued to 
assess executive functioning over the initial trials and assess cognitive procedural 
learning when they are administered over several sessions (Beaunieux et al., 2006). 
Fox et al. (2001) found Ecstasy users were impaired on the Tower of London task. 
However only twelve trials were given during this study and therefore executive 
functioning alone may have been measured as opposed to cognitive procedural 
memory. It would be interesting for future studies to examine whether Ecstasy users 
are impaired on these types of tasks when they are administered over repeated 
sessions.  
The current thesis found strong evidence that MDMA exposure affects reference 
memory processes as measured by the partially baited radial maze paradigm. But it is 
difficult to claim with certainty what processes Ecstasy users may show corresponding 
impairments in due to the discrepancies between the definitions and types of memory 
processes used in animal and human cognitive literature. 
The Underlying Cognitive Impairments of the Reference Memory Effect 
One aim of this discussion is to try to find an underlying cognitive impairment 
that will tie the findings of the two parts of the thesis together. This is not an easy ask 
considering the acute and binge regimes used produce very different physiological 
responses. The findings from the first half of this thesis that involved acute MDMA 
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administration suggest that the reference memory impairments produced by MDMA 
exposure are the result of the release of dopamine. However, the findings from the 
second half of the thesis suggest that the reference memory impairments found are the 
result of a decrease in 5-HT activity as the regime we used has been shown to reduce 
5-HT levels (Scanzello et al., 1993). 
One of the most clear and replicated findings from the current thesis is that 
MDMA exposure (whether acute of binge) appears to affect reference memory more 
than working memory processes as measured by the partially baited radial maze. One 
difficulty in interpreting these findings is in trying to ascertain what exactly reference 
memory is and what the underlying cognitive processes are that produce the pattern of 
errors that has been found in the partially baited radial arm maze. Reference memory 
errors involve subjects going to arms of the maze that do not contain reinforcers rather 
than repeating arm visits within a trial (working memory error). Thus the question 
remains as to why MDMA produces this particular pattern of behaviour within the 
maze. 
One possible explanation that has been given within this thesis is that MDMA 
exposure may produce long-term memory impairments. With acute MDMA studies 
(where they task has been acquired) the drug may impair the ability to retrieve 
information from long-term memory about which arms contain reinforcement and 
hence rats visit arms that do not contain reinforcers. During the binge studies while 
rats are still acquiring the task the drug may impair the ability of subjects to encode the 
information about which arms contain reinforcement into long-term memory. They do 
not tend to make working memory errors as this form of memory is left intact and they 
do not repeat arm entries within a trial. Therefore the rats can remember where they 
have been in a trial (avoiding working memory errors) but are unable to retain their 
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memory of where they have obtained reinforcers across trials (producing reference 
memory errors). 
An alternative explanation is that MDMA exposure produces impairments in 
acquiring or using task rules. In acute studies when MDMA is administered subjects 
may become confused as to what they are meant to be doing. They are able to 
remember where they have been and hence do not repeat arm entries into already 
visited arms but they have difficulty ascertaining that there are arms of the maze that 
contain reinforcers and those that do not. In addition during the binge studies where 
subjects have already acquired the task the subjects may also become confused as to 
the rules of the task after MDMA exposure. Hence while learning the task subjects 
have difficulty ascertaining that the maze arms that contain reinforcers do not change 
from trial to trial. Subjects may not make working memory errors as when drugs are 
administered and performance is disrupted they fall back on their naturally occurring 
behaviour which is going to novel arms (not repeated arms). Rats have an innate 
disposition for preferring novelty or to alternate (not go back and revisit arms). 
Unfortunately neither of these explanations are easily disentangled from one another. 
Also when learning long-term unchanging rules it would be difficult not to involve 
long-term memory so these two explanations may be unable to be differentiated. 
In addition, in the Acute Interim Discussion it was argued that the reference 
memory impairment seen with acute MDMA exposure was unlikely to be the result of 
perseveration. This was because if rats were going to perseverate they would be more 
likely to produce more working memory errors than reference memory errors as they 
would repeatedly visit arms. However the MDMA induced reference memory 
impairment seen with acute drug exposure may be able to be explained via 
perseveration if instead of thinking in terms of individual or single arm entries being 
the response rather subjects solve the task by producing a sequence of arm visits. 
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Instead of each arm visit being a response, all four arm visits (in a particular sequence) 
are the response. Indeed once subjects had acquired the task they tended to stick to a 
fixed arm entry pattern whereby they would enter the reinforced arms of the maze in a 
specific order. Perseveration may occur not by repeatedly visiting a particular arm but 
by repeating a particular arm entry pattern consisting of a set of arm entries. Hence 
subjects learn the correct arms of the maze as a sequence and they repeat it from trial 
to trial. When they are given MDMA if they make a mistake early on in the sequence 
they do not self-correct and continue with their fixed sequence despite it not producing 
reinforcement. They continue to produce a fixed behaviour (set of arm entry patterns) 
despite it not being effective and show a preservative pattern of behaviour. This pattern 
of responding would result in reference memory errors but not working memory errors 
as subjects would not repeat arm entries but instead mistakenly go to unbaited arms of 
the maze. 
The impairments found in the binge studies could also be explained by subjects 
producing a perseverative pattern of responding. During habituation trials at the 
beginning of all studies all arms of the maze are baited and the rat is allowed to explore 
the maze. This was done to ensure that the rats would visit all arms of the maze and not 
adapt any biases where they might avoid certain arms of the maze. However rats may 
tend to adopt a strategy where they visit all arms of the maze by simply learning to go 
to consecutive arms. This pattern of responding would produce very few or no working 
memory errors as they would simply keep going to the next arm of the maze until they 
had consumed all reinforcers at which point they were removed from the maze. When 
actual maze training began only four arms of the maze are baited, however some rats 
may continue to adopt this strategy. Specifically when they are only allowed four arm 
entries they may enter four consecutive arms of the maze before being removed and 
then when placed back in the maze for the next trial they visit the other four arms of 
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the maze. Hence they adopt a particular strategy to solve the task before they learn that 
some arms contain reinforcement while others do not. As MDMA exposure may result 
in perseveration the rats that were exposed to MDMA may continue to adopt this 
strategy where they try to visit all arms of the maze instead of trying to ascertain which 
arms of the maze contain reinforcers. Thus they produce more reference memory 
errors and take significantly longer to learn the partially baited maze task than controls. 
 Unfortunately the data collected from these experiments does not easily lend 
itself to these arm entry pattern analyses. This could be an interesting area of research 
to explore in future studies where an experimental design that examined arm entry 
patterns and sequence learning could be established. Indeed it has been shown that 
tasks involving lever pressing sequences have been impaired with acute MDMA 
exposure (Frederick & Paule, 1997) with subjects showing a perseverative pattern of 
responding. However Winsauer et al. (2002) failed to find a difference in performance 
before and after chronic MDMA treatment in a repeated acquisition lever pressing task 
suggesting MDMA exposure did not affect this form of learning. It should be noted 
that Winsauer et al. (2002) gave subjects experience with the task before drug 
exposure and hence performance may have been harder to disrupt. This pattern of 
responding could also be used to explain some of the patterns of impairment found 
with MDMA administration in the existing literature. For example the finding that rats 
are affected by the previous trial type in DMTS tasks (Harper et al., 2005; Harper et 
al., 2006) may suggest a perseverative impairment rather than proactive interference. 
Harper et al. (2005; 2006) found if a rat that had been administered acute MDMA 
pressed on the left lever in a trial it was then more likely to continue responding on the 
left lever thus suggesting a perseverative pattern of behaviour. Indeed perseveration is 
a pattern of responding that has been found in Ecstasy users (von Geusau et al., 2004; 
Smith et al., 2006; Montgomery et al., 2005; Dafters, 2008; Verrico et al., 2008). 
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Therefore a possible explanation for the impairments seen with MDMA exposure may 
be the result of MDMA administration producing perseveration. 
Tolerance/Sensitisation 
The findings from Study 3 and 4 both found evidence that subjects that had 
been administered binge regimes of MDMA were less impaired than saline controls 
when later challenged with acute doses of MDMA. Hence these studies provided 
evidence that repeated MDMA exposure resulted in behavioural tolerance where 
subsequent exposure to MDMA has less of an effect on performance. This is a 
consistent finding within the animal literature that has found that the effects of MDMA 
reduce with repeated exposure (LeSage et al., 1993; Marston et al., 1999; Frederick et 
al., 1995; Frederick & Paule, 1997; Frederick et al., 1988). In addition there is 
evidence within the human literature that Ecstasy users report tolerance developing 
with repeated drug exposure (Parrot, 2001; Cottler et al., 2001; Parrot, 2005).  
 In Study 3 and 4 subjects had acquired the task before they were challenged 
with acute drug exposure. However in Study 5 subjects were repeatedly challenged 
with acute drug exposure while they were still acquiring the radial maze task. In Study 
5 convincing evidence of drug tolerance was not found as there were no obvious 
differences between saline and binge MDMA treated animal‟s performance when they 
were challenged with acute doses of MDMA. One possible explanation for this finding 
is that the performance of the binge treated MDMA group was so poor that is was 
unable to show evidence of impairment with acute MDMA administration. Hence this 
finding may be due to a floor effect.  
Another possible explanation is that while subjects are still acquiring the task 
they are more susceptible to the disruptive effects of MDMA exposure suggesting 
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learning processes are more affected by MDMA exposure than memory processes 
which would be more required once task acquisition occurred. Of interest acute 
MDMA exposure seemed to have more of an effect on the binge treated group as there 
was evidence of residual drug effects the day after acute drug administration which 
was not present in the saline treated group.  
Implications for Human Ecstasy Users  
 As stated earlier in this chapter due to the lack of research examining reference 
memory processes per se within the human literature, it is difficult to extend the 
current findings of this thesis to human Ecstasy users. However, when taking the 
findings from the first half of the current thesis that examined the acute effects of 
MDMA on cognitive performance it could be speculated that while under the influence 
of Ecstasy people may experience difficulties in performing previously well learnt 
cognitive tasks. It has been reported that when acute doses of Ecstasy were 
administered to healthy volunteers they reported difficulty in concentrating, decision 
making and general disturbances in thinking (Vollenweider et al., 2002) indicating that 
the drug could affect the ability of users to perform cognitive tasks. 
In addition within the second half of the thesis that examined binge regimes of 
MDMA on task acquisition it was found that subjects who were exposed to MDMA 
showed slower rates of learning than controls. Hence Ecstasy users may show slower 
rates of learning on cognitive tasks. Again there is some evidence of this within the 
literature showing Ecstasy users are impaired at acquiring cognitive tasks compared to 
controls. For example Fox et al. (2001) found Ecstasy users required significantly 
more trials to perform at a similar level to controls on a task that assessed verbal 
learning. Verbal learning has also been found to be impaired in Ecstasy users in other 
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studies (Reneman et al., 2001; Gouzoulis-Mayfrank et al., 2000; McCardle et al., 
2004). McCardle et al. (2004) suggested the impairment in verbal learning was the 
result of Ecstasy users having deficits in encoding information into long-term memory 
which would be consistent with the findings of the current thesis. In addition Ecstasy 
users have also been found to show associative learning impairments requiring 
significantly more trials to acquire an associating learning task (Montgomery et al., 
2005) which is also consistent with the findings of the current thesis.  
Similarly due to the findings in Study 4 where subjects who were exposed to 
MDMA took longer to change their behaviour when the rules of the task were altered 
may suggest that Ecstasy users may show impairments in cognitive flexibility. 
Consistent with this finding Ecstasy users have produced impairments in tasks that 
assess the ability to change performance in the face of changing consequences (von 
Geusau et al., 2004; Smith et al., 2006; Montgomery et al., 2005; Dafters, 2008; 
Lamers et al., 2006). 
Future Research 
 Trying to differentiate between the explanations for what is the underlying 
cause of the reference memory impairments would be beneficial. In particular future 
research examining the perseveration explanation of the reference memory 
impairments could be useful. Hence a future study could examine the sequence of arm 
visits with acute drug administration. For acquisition studies using binge regimes of 
MDMA it could be interesting to examine whether starting maze training with only 
four arms of the maze being baited (excluding the habituation phase where all arms are 
baited) would affect the rate of learning in MDMA treated animals. In addition it 
would be helpful to try and replicate the findings of the current thesis by using another 
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paradigm that allows working and reference memory processes to be examined 
simultaneously. Therefore the holeboard task could be a useful paradigm to further 
study the effects of MDMA on working and reference memory processes. Finally in 
order to ascertain whether previous studies have failed to find evidence of binge or 
chronic regimes affected DMTS performance future study could examine the effects of 
binge regimes of MDMA on acquiring the DMTS task. This is because previous 
studies have trained subjects on the tasks before drug administration and have not 
examined the effect of the drug on DMTS acquisition. 
 
Conclusion 
In summary the current thesis found both acute and binge MDMA exposure 
produced impairments in the partially baited radial arm maze. Reference memory 
processes were more adversely affected than working memory processes. Also there 
was some evidence of behavioural tolerance occurring when binge regimes of MDMA 
were administered and subjects were challenged with acute doses of MDMA after the 
task had been acquired. However no clear evidence of tolerance was found with 
prolonged repeated MDMA exposure while task acquisition was occurring suggesting 
MDMA exposure may disrupt learning processes.  
Of note, the findings from the current thesis are interesting in that working 
memory processes are usually described as more prone to interference whereas 
reference memory processes are considered to be harder to disrupt (Olton & Papas, 
1979). By using the partially baited radial arm maze that allows the simultaneous 
differentiation between working and reference memory the current thesis found 
exposure to MDMA predominantly disrupted reference memory processes leaving 
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working memory relatively intact. Hence this is a relatively novel finding that shows 
the drug disrupted a memory process that is generally thought to be more robust than 
working memory and therefore adds an interesting counterintuitive finding to the 
existing MDMA literature. 
In conclusion the current thesis examined the effects of acute and binge 
regimes of MDMA on a paradigm not previously used within the existing MDMA 
literature that allowed simultaneous assessment of working and reference memory 
processes. In addition it examined cognitive flexibility by altering the rules of the 
cognitive task which is not commonly performed in the existing literature. This thesis 
also examined the effects of repeated MDMA exposure which is also not commonly 
performed within the MDMA literature and is important as it more closely mirrors 
human Ecstasy use. While the current thesis consistently produced the finding that 
MDMA exposure resulted in more reference memory errors than working memory 
errors it still remains unclear as to why these pattern of responding emerged. Further 
research is needed to try and differentiate what underlying cognitive impairments 
produced the MDMA induced reference memory impairments in the radial arm maze. 
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